Axon pathology in mouse models of Huntington's disease by Marangoni, Martina
AXON PATHOLOGY IN MOUSE MODELS
OF HUNTINGTON’S DISEASE
Martina Marangoni, MSc.
Thesis submitted to the University of Nottingham
For the degree of Doctor of Philosophy
MAY 2014
1Declaration
This dissertation is the result of my own work and includes nothing which is the
outcome of work done in collaboration except where specifically stated in the text.
The work presented here is not substantially the same as any I have submitted for a
degree or diploma or other qualification at any other University.
2Abstract
AXON PATHOLOGY IN MOUSE MODELS OF HUNTINGTON’S DISEASE
Martina Marangoni
Axon or synapse dysfunction parallels or precedes symptom onset in many
neurodegenerative disorders. In some of these conditions, not only do axon and
synapse loss determine the course of pathology, but protection of those neuronal
compartments is mandatory to alleviate the disease. Whether this is also the case in
Huntington’s disease (HD), a devastating neurodegenerative disorder characterised by
progressive deterioration of both physical and mental abilities and inevitable early
death, remains unclear. Present therapeutic strategies do not address protection of
axons and synapses, which may help explain why there is no effective treatment
currently in use. Moreover, an accurate characterisation of the development of axon
pathology relative to neuronal loss and to the deposition of mutant-Huntingtin
(mHTT) aggregates, neuropathological hallmark of HD, is lacking.
In the present thesis I have carried out a detailed study aiming to investigate axon
degeneration in the R6/2 transgenic (Tg) and the HdhQ140 knock-in (KI) mice, two
HD models, and to assess whether this occurs early in and contributes to the course of
pathology. I tested the hypothesis that axon degeneration precedes or at least parallels
degeneration of other neuronal compartments in these mice. To characterise axon
pathology and its spatio-temporal relationship to aggregate formation, neuronal loss
and symptom onset, I crossed R6/2 and HdhQ140 mice with YFP-H transgenic mice
that express the yellow fluorescent protein (YFP) in a subset of neurons. Neuronal
pathways labelled by YFP in this model include some reported to be affected in HD.
In these mice individual fluorescent neurons can be tracked over long distance and
axons can be traced back to their cell bodies.
Using a powerful axon imaging method that was developed and successfully applied
to study Alzheimer’s disease, I was able to place axon degeneration accurately in the
sequence of pathological events and develop methods to quantify it as readout for
future therapeutic studies from our group and elsewhere.
I found that the morphology of axons was strikingly abnormal in some brain areas in
HdhQ140 homozygous mice (HdhQ140/Q140) where large axonal swellings were
3detected at 6 months and at 12 months of age in stria terminalis and striatum. In these
mice, the number of axonal swellings increased age-dependently and was significantly
higher than that found in wild-type littermates. However, I did not detect degeneration
in cell bodies, dendrites or synapses suggesting that axon pathology is the main
feature of the disease in this model.
To better characterise the KI model, I also performed a battery of behavioural tests to
assess motor and cognitive impairment during disease progression. I used tests of
locomotor activity, motor coordination and balance and sensorimotor gating to
measure motor function and tests of spatial working memory and anxiety-like
behaviour to assess cognitive and behavioural symptoms, respectively. A longitudinal
study from 1 to 12 months was carried out to detect pathological changes from early
stage and relate them to swelling formation. In all tests, I found a strong reduction in
locomotor activity in HdhQ140 mice compared to the controls although balance and
coordination seemed not to be impaired as rotarod performance was unaltered.
Alterations were also detected in prepulse inhibition, suggesting sensorimotor defects
occur in these mice, while no abnormal cognitive or psychiatric behaviour was
detected in the time-frame of the study. Behavioural symptoms, as well as abnormal
morphological changes found in axons, worsened with time and major impairments
were found at the latest time-point, 12 months of age.
Finally, I asked whether alterations in the NAD biosynthetic pathway could underline
the signs of axon pathology detected in HdhQ140 homozygous mice, as it has recently
emerged that this pathway regulates axon survival and axon and synapse degeneration
in many neurodegenerative disorders. To this purpose, I looked at possible alterations
in the level of nucleotides (NMN, NAD) and in the activity of key enzymes in this
pathway (NMNAT, NAMPT). I also tested the hypothesis that mHTT interacts with
NMNAT enzymes and with the Wallerian degeneration slow protein (WLDs), an
NMNAT fusion protein, and interferes/impairs their normal function. As WLDs delays
axon degeneration in acute and neurodegeneration models, future works may address
beneficial role of WLDs in HD/WldS crossed mice. Despite no detected alterations in
nucleotide levels or enzymatic activity in the KI mice compared to the controls,
colocalisation was found between mHTT and WLDs and between mHTT and
NMNAT2, an important axon survival factor, suggesting a possible interaction
between these proteins which could play a role in HD neurodegeneration.
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Above all, don’t fear difficult moments.
The best comes from them
Rita Levi-Montalcini
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CHAPTER 1
Introduction
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1.1 Huntington’s disease
Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative
disease caused by a cytosine adenine guanine (CAG) triplet expansion in the coding
region of the IT15 (interesting transcript 15) gene which results in an abnormal poly-
glutamine (polyQ) stretch in the Huntingtin protein (HTT). It is also known as
Huntington’s chorea from the Greek word chorea (dance) as HD patients writhe,
twist, and turn in a constant, uncontrollable dance-like motion. It is characterised by a
triad of symptoms including motor dysfunction, cognitive impairment and psychiatric
abnormalities which dramatically affect the social and economic life of the patients
and their families as it interrupts a person's ability to live an independent life.
Symptoms typically appear in middle age, although they can appear earlier (juvenile
HD) or later, and progress to inevitable death within 15-20 years from onset (Bates,
2001). HD occurs in various geographic and ethnic populations worldwide with
prevalence estimated at 5-10/100,000 in Caucasian population and the diagnosis is
based on a neurological evaluation with the manifestation of motor symptoms together
with a positive genetic test for the HD CAG expansion or a confirmed family history
of HD. Fewer than 5% of individuals at risk for the disease choose to actually pursue
predictive genetic testing which is not without consequences (Laccone et al., 1999);
psychological distress and suicide cases increase following a positive result (Almqvist
et al., 1999, Almqvist et al., 2003).
The first accurate description of the disease was made in 1872, by a 22 year old
American physician working in New York, George Huntington, in a paper called On
Chorea: “And now I wish to draw your attention more particularly to a form of the
disease which exists, so far as I know, almost exclusively on the east end of Long
Island. It is peculiar in itself and seems to obey certain fixed laws” (Fig. 1). It took
over a century though to clarify the genetic nature of HD. In 1983, the HD locus was
mapped on chromosome 4p16.3 using RFLP (restriction fragment length
polymorphism) genetic markers (Gusella et al., 1983) and only 10 years later,
scientists from all over the world joined together into The Huntington Disease
Collaborative Research Group and reported the discovery of the gene responsible for
HD and its associated mutation (HDCRG, 1993).
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Fig. 1
George Huntington and his original paper on Chorea.
1.2 Genetics and neuropathology
HD is one of at least nine inherited neurodegenerative diseases caused by an expanded
CAG triplet encoding an abnormal polyQ expansion in disease proteins.
Spinocerebellar ataxias (SCA) 1, 2, 3, 6, 7 and 17, spinobulbar muscular atrophy
(SBMA or Kenedy’s disease) and dentatorubralpallidoluysian atrophy (DRPLA) are
among the others. Despite different function and cellular localization, all polyQ
expanded proteins share the common tendency to aggregate and form inclusion bodies
whose role is still not fully understood.
The normal IT15 gene contains from 9 to 35 CAG repeats, while in HD affected
individuals the number rises above 40 and up to 100. Subjects with CAG repeat
number ranging between 36 and 39 show incomplete penetrance and may or may not
develop the signs and symptoms of the disease. An inverse relationship exists between
CAG length and age of onset: patients with a large number of repeats tend to develop
symptoms at an earlier age and juvenile HD, which appears in childhood or
adolescence, is normally associated to repeat length of 60 or greater (Brinkman et al.,
1997, Duyao et al., 1993). Moreover, while repeats in the normal range are stably
inherited, abnormal repeats are unstable and can increase in length due to meiotic
instability during development, resulting in earlier onset disease in later generations.
This phenomenon is known as “genetic anticipation” (Ranen et al., 1995). Meiotic
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instability may occur in both maternal and paternal transmission but the risk of
expansion is enhanced during spermatogenesis. It has been suggested that expansion
of the repeat tract can occur during mitotic divisions in the germ-line due to
replication slippage, a commonly observed replication error which occurs at the
repetitive sequences when the new strand mispairs with the template strand. The
larger number of mitotic divisions in male spermatogenesis compared to the ones in
oogenesis could explain the higher risk of anticipation when the disease gene is
inherited from the father (Pearson, 2003).
Pathological changes in HD are brain specific. On external post-mortem examination
80% of HD human brains show atrophy of frontal lobes (Halliday et al., 1998) (Fig. 2)
and macroscopic analysis reveals extended atrophy of the striatum although cortex,
substantia nigra, hippocampus, cerebellum, hypothalamus, and thalamus are also
severely compromised (Spargo et al., 1993, Macdonald et al., 1997, Kremer et al.,
1991, Heinsen et al., 1999).
Fig. 2
Atrophy of HD brain. Normal brain (right) and Huntington’s disease patient brain (left). From
Harvard Brain Tissue resource centre.
In 1985, Jean Paul Vonsattel introduced the first grading system to describe the
severity of HD degeneration in post-mortem brain specimens, according to the degree
of macroscopic and microscopic neuropathological striatal variations. 5 grades (0-4)
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were described in ascending order of severity: grade-0 brain is a brain apparently
indistinguishable from the normal one, with no discernible neurological abnormalities;
grade-1 to 4 brains show progressively more severe atrophy, neuronal loss and
astrogliosis in the striatum (Vonsattel et al., 1985). Later studies described in more
detail the differential degeneration of striatal neurons (Ferrante et al., 1985, Ferrante et
al., 1987, Ferrante et al., 1986) and revealed that within the striatal neuronal
subpopulations, projection neurons rather than interneurons are most affected (Albin
et al., 1990b, Ferrante et al., 1987, DiFiglia, 1990) and among these, those termed
??????? ?????? ?????? ???????? ????????? ????? ???? ??????????????? ????? ???????
neurons that represent about 90% of all neurons in the striatum and are divided in D1
MSSNs, which express substance P, dynorphin and D1 dopaminergic receptors; and
D2 MSSNs which express enkephalin and D2 dopaminergic receptors. Both types take
part in the basal ganglia neuronal circuits formed by the striatal projections to the
globus pallidus (GP) and substantia nigra (STN) that in turn project to the
ventrolateral nucleus of the thalamus, ultimately controlling the activity of cortical
areas important for motor function (Albin et al., 1989) (Fig. 3). In particular, D1
neurons are part of the direct pathway which receives excitatory inputs (E) from the
cortex and makes inhibitory connections (I) with the globus pallidus pars interna (GPi)
and STN. These make inhibitory connections with the thalamus which sends
excitatory connections back to the cortex, stimulating its activity (+):
D2 neurons are instead part of the indirect pathway. This sends inhibitory projections
to the globus pallidus pars externa (GPe) which makes inhibitory connections with the
subthalamic nucleus which in turn sends excitatory connections to the GPi and this
ultimately results in inhibition of the cortex (-):
In HD, neurons of the indirect pathway are affected first and without the normal
inhibitory influence on the thalamus that is provided by the indirect pathway, thalamic
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neurons can fire inappropriately, causing the motor cortex to execute motor programs
with no control resulting in increased movement, chorea (Reiner et al., 1988; Albin et
al., 1992). At later stage of the disease, both subpopulations are affected and this
results in a rigid bradykinetic state (Albin et al., 1989).
Fig. 3
Schematic representation of the cortical inputs to striatal neurons and the major projections of
striatal MSSN. From (Li and Conforti, 2013). The direct and indirect loops of the basal ganglia are
represented on different parts of the brain, for clarity. The location of intranuclear and extranuclear
mHTT aggregates, of dystrophic neurites and of fibre loss is also represented. Str =corpus striatum,
Thal=thalamus, STN=subthalamic nucleus, GPi=globus pallidus (internal segment), GPe=globus
pallidus (external segment), SNpc =substantia nigra (pars compacta), SNpr = substantia nigra (pars
reticulata).
Microscopically, HD brains present nuclear (NIIs) and cytoplasmic (neuropil)
inclusions of mutant Huntingtin (mHTT) as the mutated protein is more prone to be
cleaved and form aggregates than normal HTT, and this is a specific hallmark of the
disease. Whether the nuclear inclusions are toxic is still controversial. Inclusion
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formation can be linked to disease progression but so far no correlation with neuronal
degeneration has been fully documented (Gutekunst et al., 1999, Slow et al., 2005).
On the other hand, it has been proposed that nuclear aggregates may form as an
attempt of the cell to degrade or inactivate the toxic soluble mHTT (Saudou et al.,
1998, Arrasate et al., 2004).
1.3 Models of Huntington’s disease
Modelling HD in non-human organisms is fundamental to understand the mechanisms
underlying pathology, to identify therapeutic targets and to validate the efficacy and
safety of potential drugs in preclinical trials. Before the discovery of the gene
responsible for HD, the disease was induced in animals by injection of neurotoxins
such as kainic acid (KA) and other glutamate agonists or mitochondrial toxins such as
malonate and 3-nitropropionic acid (3-NPA). These toxins were injected directly into
the striatum and were able to induce selective degeneration of striatal neurons
(McGeer and McGeer, 1976, Beal et al., 1986, Beal et al., 1991) and in some cases
behavioural changes similar to HD. However, they could not reproduce the
pathophysiological mechanisms induced by the mutant gene and for this reason could
be of limited use in developing and testing treatments for the disease. Moreover, the
acute nature of these lesions was sharply contrasting the slow progression of HD
which in patients takes decades to manifest. Soon after the discovery of the IT15 gene
and its mutation in HD, several genetic animal models became available, allowing a
more precise reproduction of the human pathology. Models included invertebrates
such as Caenorhabditis elegans and Drosophila melanogaster, and small and large
mammals such as mice, rats and monkeys. Models differed in the expression of either
truncated or full-length HTT; in the length of the CAG repeat inserted; in the
expression of the mutant gene which could be a transgene or a knock-in into the
endogenous Hdh locus; and in the use of cDNA or genomic DNA containing all the
introns and regulatory sequences which influence the level of expression of the gene.
Invertebrate models
Although phylogenetically very distant from mammals, simpler organisms such as
worms and flies have been demonstrated to be useful models to study the genetics and
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the mechanisms of cellular processes. The main advantage of these models is that they
have rapid generation time and reproduce the pathological phenotypes in a very short
period of time. Successful transgenic nematode and fly models have been generated
expressing truncated N-terminal fragments of human mHTT in targeted neurons
(Parker et al., 2001, Gunawardena et al., 2003, Marsh and Thompson, 2006). C.
elegans does not contain a HTT homologue or other polyQ proteins however it
expresses homologues of HTT-interactors and these can interact with the inserted HTT
transgene. Thus, this model can represent a useful tool to study protein-protein
interactions. Several transgenic worms expressing a HTT fragment with 57 to 171
aminoacids in sensory neurons were generated and showed age-dependent increase
defects in sensory neurons and axonal abnormalities preceding cell loss (Faber et al.,
1999, Parker et al., 2001, Li and Le, 2013).
In Drosophila, expression of full-length or N-terminal fragments of 65 to 548
aminoacids of the human HTT was driven by a UAS/GAL4 system in the
photoreceptor neurons of the eye. In the fly, integrity of photoreceptor cells of the eye
and motor function are used as a readout to identify genetic modifiers of
neurotoxicity. Similarly to humans, fly models exhibit a polyQ length dependency,
late onset neuronal degeneration, and motor abnormalities (Jackson et al., 1998,
Krench and Littleton, 2013).
Rodent models
Rodents are the most commonly used animals to model HD and they recapitulate
many aspects of the human disease. Mouse models are the most exploited and among
them, the following sub-categories are found (Table 1):
? Truncated HTT Transgenic models: these models were generated by insertion
of N-terminal fragments of the human HTT gene into the mouse genome. The
first transgenic (Tg) mouse line, termed R6, was generated by introducing in
the mouse genome a fragment of 1.9 Kb including the promoter and exon1 of
IT15 gene carrying an expanded CAG repeat. Several lines (R6/1, R6/2, R6/5
and R6/0) differing in the CAG repeat length, ranging from 115 to 150, were
characterised (Mangiarini et al., 1996). Among these, R6/2 mice (145 CAG)
represent one of the most commonly used model for the study of HD since
several of the characteristics specific of the pathology are modelled in these
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mice. Brain atrophy has been detected as early as 5 weeks, weight loss by 8
weeks, mHTT inclusions by 3.5 weeks (Davies et al., 1997) and first signs of
behavioural deficits from 5-6 weeks of age (Carter et al., 1999). Another N-
terminal transgenic mouse is the N171-82Q line which expresses a 171 amino
acid mHTT N-terminal fragment with 82 glutamines under the regulation of
the mouse prion protein promoter vector (Schilling et al., 1999). In general, Tg
N-terminal fragment mice exhibit a rapid onset of symptoms including motor,
cognitive and behavioural deficits. They also exhibit neuropathological
changes and shortened life-span and for this reason they are a popular choice
for therapeutic trials. In these mice however, the exogenous HTT fragment
inserts randomly, in multiple copies, in the mouse genome and can interact
with the activity of other genes not related to HD. Also, the transgene
expression above physiological concentrations and driven by artificial
promoters may lead to a phenotype that does not correctly mimic the disease.
Moreover, striatal neuronal loss widely reported in HD patients is minimal in
these mice and appears evident only at a very late stage of the disease, after the
appearance of behavioural symptoms (Mangiarini et al., 1996, Davies et al.,
1997, Turmaine et al., 2000);
? Full-Length HTT Transgenic models: these models were created using yeast
artificial chromosome (YAC) and bacterial artificial chromosome (BAC)
technology. They provide better insights into the events and factors
determining the selective cell vulnerability typical of HD, since the expanded
polyQ stretch is expressed in the context of the entire HTT protein. YAC-72
mice were created in 1999 by cloning the entire HD gene with 72 CAG repeats
in the Yeast Artificial Chromosome (YAC), under the control of the
endogenous promoter (Hodgson et al., 1999). These mice showed typical HD
behavioural phenotype and significant neuronal loss but mHTT aggregates
were rarely detected and, despite levels of mHTT expression were higher than
in R6/2 mice, motor symptoms appeared late and with slow progression;
? Knock-In models: they are considered the most genetically accurate model for
HD. These mice carry the mutation in the appropriate genomic and protein
context and at a physiological concentration. They were generated by gene
targeting of the endogenous mouse homolog of human IT15 gene (Hdh) on
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chromosome 5 of the mouse genome with insertion of either a chimeric IT15–
Hdh exon1 containing an expanded CAG repeat or an expanded CAG repeat
into the endogenous mouse gene. Initial results were disappointing as the first
knock-in (KI) mice generated, with 70-80 CAG repeats (HdhQ70-80), had
normal life-span and did not show the classical HD motor deficits (Shelbourne
et al., 1999) but further studies on mice with larger repeats revealed subtle
behavioural abnormalities at an early age (Menalled et al., 2000). Even in
those mice tough, behavioural deficits are not as pronounced as the ones seen
in transgenic mice and they usually take longer to develop. Mice with 94 and
140 CAG repeats (Hdh94-140) show abnormal behaviour characterised by
hyperactivity at around 2 months of age followed by hypoactivity at 4 months
(Menalled and Chesselet, 2002). In HdhQ140 mice, diffuse nuclear staining
and micro-aggregates of mHTT are detected in the striatum at around 6
months of age, a relatively early phase of the disease (Wheeler et al., 2000, Lin
et al., 2001), while nuclear inclusions are detected only around 10–18 months;
no cell death is reported in these mouse models although the striatal volume is
decreased (Hickey et al., 2008) (Fig. 5).
Hdh gene knock-out in mice revealed the important role of normal HTT in embryonic
development as the complete inactivation of the gene was embryonically lethal by
embryonic day 8.5 (Duyao et al., 1995, Nasir et al., 1995, Zeitlin et al., 1995, White et
al., 1997) while conditional knock-out of HTT in brain and testes resulted in neuronal
dysfunctions (Dragatsis et al., 2000).
Large animal models
Large animal models offer some distinct advantages over rodent models, including a
larger brain, more easily used for imaging and intracerebral therapy, longer lifespan,
and a more human-like neuro-architecture. Primates in particular, are genetically more
similar to humans, have similar lifespan, metabolism, and physiology and for these
reasons probably better models for monitoring disease progression and the
effectiveness of experimental drugs. On the other hand, they are more expensive, take
longer time to develop pathology and raise more ethical concerns than non-primate
models.
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The use of primates as model of HD was very limited before 2008 and disease was
replicated by acute lesions of basal ganglia by quinolinic acid (QA) or 3-
nitroproprionic acid (3-NPA) (Brouillet et al., 1999). These early models manifested
chorea similar to human HD but had the limitations of the neurotoxin model
previously discussed. In 2008, the first transgenic non-human primate HD model was
generated by injecting rhesus monkey eggs with lentiviral vectors expressing exon 1
of the human HTT gene with 84 CAG repeats and the GFP protein under the control of
the human poly-ubiquitin promoter, and then fertilized and introduced into surrogate
mothers. The transgenic monkeys exhibited similar features to human HD, including
extended nuclear and neuropil mHTT aggregate inclusions and motor defects such as
chorea and dystonia, although the rapid progression of the disease made them survive
for no longer than 6 months (Yang et al., 2008). Other large HD models included a
transgenic sheep and a transgenic miniature pig. The pig model like the monkey
expressed only a fragment of human HTT including the CAG repeat expansion while
the sheep was obtained by microinjecting the full-length human HTT cDNA with the
expanded triplet under the control of the human HTT promoter (Jacobsen et al., 2010,
Yang et al., 2010).
Cellular models
Several cellular systems are also available, with constitutive or inducible expression of
wild-type or mHTT. They represent a good system to study some of the molecular
mechanisms underlying the disease. Non neuronal cells such as the human embryonic
kidney (HEK) 293 cells, transiently transfected with wild-type and mHTT, have been
used as a model to study the effect of the polyQ extension on aggregate formation and
localisation (Martindale et al., 1998). Also primary neurons have been used to
investigate the role of normal HTT and the mechanisms of polyQ toxicity (Saudou et
al., 1998, Moulder et al., 1999); and embryonic stem cells from knock-out mice
(Metzler et al., 1999, Metzler et al., 2000). Several neuronal-like cellular systems with
stable expression of HTT have been developed. Among these, the pheochromocytoma
12 cells (PC12) are widely utilised and their properties are well known (Greene and
Tischler, 1976). PC12 cells differentiate into neuronal-like cells in the presence of
neuronal growth factor (NGF). Engineered PC12 systems expressing the N-terminal
portion of mHTT show intranuclear polyQ aggregate formation, cellular defects and
altered gene expression. They also present abnormal morphology and neurite
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development, and they are more susceptible to apoptotic stimulation (Li et al., 1999b,
Wyttenbach et al., 2001). Human HD cell models based on induced pluripotent stem
(iPS)-cell technology have been recently generated (Park et al., 2008) and
characterised (Zhang et al., 2010, HDiPSCConsortium, 2012). They represent a novel
method to generate pluripotent stem cells bypassing the ethical issues related to the
use of human embryonic stem (ES) cells (Hanley et al., 2010) and also provide a valid
HD cellular model to be used for drug screening and understanding the molecular
mechanisms leading to pathology.
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Table 1
Genetic mouse models of HD. From (Heng et al., 2008).
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1.4 Huntingtin protein structure and potential function
Huntingtin is a large protein of around 3150 amino acids (350 kDa), highly conserved
among vertebrates (Baxendale et al., 1995, Tartari et al., 2008) and with no sequence
homology with any other protein. It is expressed ubiquitously with highest levels in
neurons of the central nervous system (Vonsattel and DiFiglia, 1998, DiFiglia et al.,
1995), particularly in cortical pyramidal neurons in layers III and V that project to the
striatum (Fusco et al., 1999). Inside the cell, it localises in different compartments
such as nucleus (Kegel et al., 2002), cell body, neurites and synapses and associates
with a number of organelles including Golgi (Strehlow et al., 2007), endoplasmic
reticulum, mitochondria (Panov et al., 2002) and vesicles (DiFiglia et al., 1995). Its
ubiquitous distribution and subcellular localisation make it difficult to understand the
function, which at present is still not fully clarified.
HTT is a multi-domain protein (Fig. 4) with a polymorphic glutamine/proline (Q/P)-
rich domain at the N terminus. The polyQ tract starts at amino acid 18 and it is
immediately followed by two proline-rich domains (polyP) containing 11 and 10
prolines. Numerous proteins with Q/P-rich domains are involved in transcriptional
regulation (Gerber et al., 1994), suggesting a similar function for this domain in HTT.
Downstream of the polyQ domain there are HEAT (Huntingtin, Elongator factor3,
PR65/A regulatory subunit of PP2A, and Tor1) repeats which are sequences of ?40
amino acids organised in 3 main clusters. The function of HEAT repeats is still
unclear, although they seem to play a role in protein-protein interaction and are found
in a variety of proteins involved in intracellular transport and chromosomal
segregation (Andrade and Bork, 1995, Takano and Gusella, 2002), suggesting a
similar function in HTT.
Other regions of interest in the HTT sequence are an export signal (NES) at the C-
terminus and a nuclear localisation signal (NLS) at the N-terminus, that suggest that
HTT might have a role in transporting molecules from the nucleus to the cytoplasm.
In support of this, it has been shown that the 17 amino acids preceding the polyQ
region interacts with the nuclear pore protein TPR (translocated promoter region) and
allows HTT to shuttle to and from the nucleus (Cornett et al., 2005); and alterations in
this amino acid sequence increases HTT nuclear accumulation of (Xia et al., 2003).
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HTT contains also consensus cleavage sites for proteolytic enzymes such as caspase-3
and 7 at amino acids 513 and 552, caspase-6 at amino acid 586, caspase-2 at amino
acid 552 (Hermel et al., 2004, Wellington et al., 2002, Wellington et al., 2000) and
calpain (Gafni and Ellerby, 2002). Both wild-type and mHTT are cleaved by caspases
into fragments but the mutant form is more susceptible to the cut and its fragments are
more likely to aggregate into the inclusions found in cytoplasm and nucleus (Lunkes
et al., 2002). The importance of cleavage in wild-type HTT is still unclear however,
some lines of evidence show that modifications in the activity of caspase and calpain
reduce the proteolysis and the toxic effect of the mutant protein, ultimately delaying
disease progression (Wellington et al., 2002, Gafni and Ellerby, 2002, Ona et al.,
1999, Graham et al., 2006).
HTT N-terminal region is subjected to post-translational modifications (Wang et al.,
2010). Ubiquitination occurs at lysines (K) 6, 9, and 15 at the N-terminus and directs
HTT to the proteasome for degradation (Kalchman et al., 1996). In the presence of
mHTT the ubiquitin/proteasome system is impaired and causes accumulation of HTT
fragments and inclusion formation. The same lysines can be also sumoylated and this
modification reduces HTT accumulation and promotes repression of nuclear
transcription (Steffan et al., 2004). Phosphorylation occurs at serine 421 by the protein
kinase B (PKB or Akt) and at serine 434, 1181 and 1201 by the cyclin-dependent
kinase 5 (CDK5) (Anne et al., 2007). Phosphorylation by Akt has been shown to be
neuroprotective by reducing the pro-apoptotic activity of mHTT (Humbert et al.,
2002), while phosphorylation by CDK5 reduces the cleavage of HTT by caspases at
residue 513, diminishing aggregate formation and toxicity (Luo et al., 2005).
Palmitoylation is carried out by the HTT partner Huntingtin-Interacting Protein 14
(HIP14), a palmitoyl acyl transferase (PAT) that binds to HTT and palmitoylates it at
cysteine 241. This is important for vesicle trafficking and function and evidence
showed that it is crucial for its normal trafficking to the Golgi (Yanai et al., 2006). In
the presence of mutant HTT, reduced interaction between HTT and HIP14 and
consequently reduced palmitoylation, increases aggregation and toxicity (Yanai et al.,
2006, Singaraja et al., 2002).
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Fig. 4
Schematic representation of the AA sequence of Huntingtin protein. From (Cattaneo et al., 2005).
(Q)n = polyglutamine tract; (P)n = polyproline tract; red squares = three main clusters of HEAT
repeats; arrows = caspase cleavage sites and their amino acid positions; blue arrowheads = calpain
cleavage sites and their amino acid position. NES = nuclear export signal; red and blue circles = post-
translational modifications: ubiquitination (UBI) and/or sumoylation (SUMO) (red), and
phosphorylation at serine 421 and serine 434 (blue). The glutamic acid (Glu)-, serine (Ser)- and
proline (Pro)-rich regions are indicated (serine-rich regions encircled in green).
Given the large size and the complexity of its structure, it is not surprising that wild-
type HTT interacts with a great variety of partners, in this way influencing a number
of biological functions; and that these are lost or aberrantly carried out by mutant HTT
in disease.
1.5 Mechanisms of pathogenesis: loss of function vs gain of function
Given the large number of functions, HTT is a very important protein and its loss or
reduced activity alters fundamental biological processes. In HD, it is now accepted
that it is the combination of loss of function of HTT and toxic gain of function of
mHTT to trigger neuropathology (Zuccato et al., 2010).
Normal Huntingtin function
Several studies have tried to identify the exact function of HTT linked to HD
symptomatology. Despite a specific role has not been found, these studies have
demonstrated the importance of wild-type HTT both in development and in adulthood
in mammals (Cattaneo et al., 2005):
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? Role in embryogenesis: HTT is important for embryonic development. Its
complete inactivation in knock-out mice (Hdh-/-) is lethal before gastrulation
and formation of the nervous system (Duyao et al., 1995, Nasir et al., 1995,
Zeitlin et al., 1995) while conditional knock-out in forebrain and testes results
in progressive degenerative neuronal phenotype and sterility, suggesting that
the protein is required for neuronal function and survival in the brain
(Dragatsis et al., 2000). Expression of mHTT in knock-out mice rescued from
embryonic lethality (Leavitt et al., 2001, Van Raamsdonk et al., 2005a) and
humans homozygous for HTT mutation develop normally (Wexler et al.,
1987), suggesting that mHTT can compensate for the absence of normal HTT
during development. After gastrulation in mice, reduction in HTT level below
50% causes defects in the epiblast, structure that gives rise to the neural tube,
and malformations in cortex and striatum (White et al., 1997), indicating that
HTT participates in the formation of the CNS. Moreover, HTT plays a role in
neuronal survival; experiments on chimeras created by injection of Hdh-/-
embryonic stem cells into the blastocyst showed cell degeneration specific to
the striatum, cortex and thalamus, supporting the idea that in these areas HTT
synthesis is required for neuronal development and differentiation (Reiner et
al., 2003);
? Anti-apoptotic role: In vitro experiments on conditionally immortalized
striatum-derived cells demonstrated that overexpression of wild-type HTT is
neuroprotective in cells exposed to various apoptotic stimuli (Rigamonti et al.,
2000, Rigamonti et al., 2001); in vivo, mice with null mutations of HTT in
neurons showed apoptotic cells in the hippocampus, cortex, and striatum
which led to neurological abnormalities and progressive degeneration
(Dragatsis et al., 2000). The mechanisms of HTT protection from apoptotic
cell death have been partially elucidated. Wild-type HTT directly inhibits the
proteolitic action of caspases such as caspase 3 and 9 or inhibits the formation
of the pro-apoptotic complex constituted by the huntingtin interacting protein
1 (HIP1) and its interacting partner HIP-1 protein interactor (HIPPI), which
controls the activation of caspase 8 (Rigamonti et al., 2000, Rigamonti et al.,
2001). Moreover, HTT is a substrate for the kinase Akt which is involved in
activating survival pathways and blocks cell death (Rangone et al., 2004,
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Humbert et al., 2002), thus HTT might act as a survival factor in the
phosphoinositide 3-kinase (IP3K)/Akt signaling pathway and contribute to
stimulate the expression of survival genes such as Bcl-xL or brain derived
neurotrophic factor (BDNF) and repress pro-apoptotic genes such as BAX or
Bcl-2 (Harjes and Wanker, 2003);
? Role in controlling BDNF production: HTT stimulates cortical production of
brain derived neurotrophic factor (BDNF), a neurotrophin important for
survival of striatal neurons. In vitro and in vivo studies showed that wild-type
HTT, and not the mutated form, stimulates cortical BDNF production by
regulating its gene transcription (Zuccato et al., 2001). In particular, HTT
enhances transcription from BDNF promoter II which contains the silencing
sequence repressor element-1 (RE1) recognised by the repressor element-1
transcription factor (REST), a transcriptional repressor of BDNF transcription.
HTT binds to REST and sequesters it in the cytoplasm thus inhibiting its
translocation into the nucleus and its activity (Zuccato et al., 2003). The
binding of HTT to REST occurs indirectly through the formation of a complex
with HAP1 and REST-interacting LIM domain protein (RILP), a protein that
directly binds REST and promotes its nuclear translocation (Shimojo, 2008);
? Role in axonal transport: HTT is associated with vesicles (DiFiglia et al.,
1995, Block-Galarza et al., 1997) and enhances both anterograde and
retrograde transport of vesicles containing neurotransmitters, neurotrophic
factors such as BDNF and organelles, through binding to the microtubules. In
support of this role, studies in Drosophila showed that reduction of HTT
disrupts axonal transport and causes degeneration in the eye (Gunawardena et
al., 2003). In primary cortical neurons, wild-type HTT was shown to stimulate
BDNF vesicular trafficking and this effect was attenuated by reducing its
levels by RNAi (Gauthier et al., 2004). Other in vitro and in vivo studies also
implicated HTT in fast axonal transport (FAT) of mitochondria in mammals:
in primary striatal neurons taken from mice expressing only one copy of the
wild-type allele or knock-down expressing <50% of normal HTT,
mitochondria were progressively immobilized (Trushina et al., 2004). HTT
associates with microtubules by direct binding with dynein intermediate chain
(Caviston et al., 2007) and indirect binding with huntingtin-associated protein-
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1 (HAP1) which in turn interacts with the p150(Glued) subunit of dynactin and
kinesin (Engelender et al., 1997, Li et al., 1998, Gauthier et al., 2004, McGuire
et al., 2006);
? Role in synaptic activity: HTT interacts with cytoskeletal and synaptic vesicles
proteins essential for exo- and endocytosis at the synaptic terminals controlling
synaptic activity in neurons (Smith et al., 2005). Direct binding of HTT with
the Src homology 3 (SH3) domains of the postsynaptic density protein 95
(PSD-95) controls its binding to N-methyl-D-aspartate (NMDA) and kainate
glutamate receptors and ultimately glutamate release; overexpression of HTT
has been reported to attenuate neuronal toxicity induced by NMDA receptors
and mHTT (Sun et al., 2001).
All the above mentioned roles reveal the importance and beneficial effects of wild-
type HTT in the mature brain and several lines of evidence showed its loss in HD
contributes to neuropathology. Both in humans and mouse models, a more severe
phenotype was found in homozygotes for the HD mutations compared with
heterozygotes with the same CAG expansion (Reddy et al., 1998, Squitieri et al.,
2003). In YAC128 mice lacking expression of wild-type HTT (YAC128-/-) but
expressing the same amount of mHTT as normal YAC128 mice (YAC128+/+),
performance in the rotarod test of motor coordination was disrupted and testicular
atrophy and degeneration were markedly worsened (Van Raamsdonk et al., 2005a).
Moreover, an in vivo study on YAC transgenic mice showed direct evidence of a role
of wild-type HTT in decreasing HTT cellular toxicity. In these mice, increased
apoptosis in male testes in the presence of mHTT and absence of the wild-type form
was rescued by increasing endogenous HTT levels (Leavitt et al., 2001). All these data
suggested that elimination of wild-type HTT expression results in the exacerbation of
behavioural deficits and survival although the absence of more severe striatal
abnormalities indicated that the striatal phenotype is dependent primarily on mHTT
toxicity.
The role of mutant Huntingtin in neurodegeneration
The exact mechanism of neurotoxicity induced by mHTT has not been yet clarified
however, a number of biological processes have been demonstrated to be influenced
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by the mutant protein and several theories have been proposed to explain its toxic role
(Zuccato et al., 2010) (Fig. 5):
? Transcriptional dysregulation: microarray studies revealed alterations of gene
expression in cellular and mouse models of HD at an early stage of HD, before
symptom onset, suggesting that transcriptional dysregulation is an important
causative factor in the disease. Altered mRNAs were those associated with
transcriptional processes, neurotransmitter receptors, synaptic transmission,
cytoskeletal and structural proteins, intracellular signaling, and calcium
homeostasis, all affected in HD (Sipione et al., 2002, Luthi-Carter et al., 2000,
Luthi-Carter et al., 2002, Chan et al., 2002). Both HTT and mHTT directly
bind to several transcriptional regulators such as specificity protein 1 (Sp1),
TATA-box-binding protein-associated factor II, 130kDa(TAFII130), cAMP-
response–element binding protein (CREB) and repressor element 1-silencing
transcription factor/neuron-restrictive silencing factor (REST/NRSF) (Buckley
et al., 2010) thus regulating expression of a number of genes. Aberrant
protein–protein interaction of mHTT with the transcriptional machinery either
by direct interaction with genomic DNA or by modification of chromatin such
as histone modification, is accounted for the dysregulation. Indeed, mHTT
aberrantly binds to specific transcription factor proteins forming an inactive
transcriptional complex that functions essentially as a repressor or forms
complexes with co-repressor proteins and therefore aberrantly de-represses
transcription of normally silent genes (Cha, 2000). Moreover, mHTT
sequesters transcription factors through aberrant interactions, depleting the
levels of required factors within the cell (Cha, 2007, Kumar et al., 2014). For
instance, mHTT abnormal binding to REST leads to the translocation of the
latter into the nucleus where it acts by inhibiting BDNF transcription and
production (Zuccato et al., 2003, Shimojo, 2008);
? Excitotoxicity: alterations in the glutamatergic neurotransmission have been
found in HD brains. In the cortex of HD patients, over-activation of glutamate
receptors is triggered by an increased release of glutamate from cortical
afferents and by a reduced uptake by glial cells where mHTT is also expressed.
Loss of striatal glutamate N-Methyl-D-aspartate (NMDA) receptor binding
sites is also observed in early symptomatic HD patients and even in pre-
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symptomatic stages as well as changes in their subunit composition which
alters the function (Albin et al., 1990b, DiFiglia, 1990, Dure et al., 1991,
London et al., 1981, Young et al., 1988). Moreover, hypersensitivity of
NMDAR on striatal projection neurons leading to impaired synaptic plasticity
(Fan and Raymond, 2007), linked to altered intracellular Ca2+ homeostasis and
mitochondrial dysfunction as downstream consequences, is believed to
contribute to neuropathology (DiFiglia, 1990, Beal et al., 1986, Coyle and
Schwarcz, 1976). mHTT aberrant interaction with the post synaptic density 95
(PSD95), a scaffolding protein at the excitatory postsynaptic density, results in
the sensitization of NMDA receptors and promotes neuronal apoptosis induced
by glutamate (Sun et al., 2001); mHTT also induces phosphorylation of
NMDAR subunits and contributes to over-activation of NMDAR (Song et al.,
2003). Finally, mHTT alters NMDAR trafficking destabilizing the complex
HTT-HIP1 responsible for NMDAR endocytosis (Metzler et al., 2007).
Moreover, mHTT binds the C-terminus of the inositol 1,4,5-triphosphate
receptor 1 (InsP3R1) on the endoplasmic reticulum and makes the receptors
more sensitive to IP3, leading to increased calcium release from InsP3R1
(Tang et al., 2003). Recent studies demonstrated that the consequences of
NMDAR activity are determined by the subcellular location of the receptor:
synaptic NMDAR transmission drives neuroprotective gene transcription
(Kohr, 2006), whereas extrasynaptic NMDAR activation promotes cell death.
Extrasynaptic receptors are increased in HD mouse striatum and this is
believed to contribute to neuropathology, as pharmacological block of
extrasynaptic NMDARs with the selective antagonist memantine reversed
motor learning deficits observed in mice (Milnerwood et al., 2010, Zhou et al.,
2013);
? Aggregate toxicity: mHTT is more likely to be cleaved by caspases than wild-
type HTT. The cleavage of mHTT releases N-terminal toxic fragments that
easily aggregate and accumulate in the nucleus leading to activation of other
proteolytic enzymes responsible for cell death (Davies et al., 1997, DiFiglia et
al., 1997, Kim et al., 2001, Lunkes et al., 2002, Wellington et al., 2002). The
toxicity of nuclear aggregates is based on the evidence that inclusion formation
in cultured cells leads to cell death (Hackam et al., 1998, Ho et al., 2001).
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Studies report that mHTT aggregates accumulate in the nucleus and sequester
transcriptional regulators of important neuron survival genes (Cha, 2007,
Nucifora et al., 2003). In contrast, some studies support the idea of a non-
pathogenic role of these aggregates which would be an attempt to reduce the
soluble more toxic fraction of the mutated protein (Kuemmerle et al., 1999,
Saudou et al., 1998). In addition to nuclear inclusions, the presence of mHTT
aggregates is found in neuronal processes and axonal terminals where they are
correlated with disease progression and axonal degeneration in HD mice (Li et
al., 1999a, Li et al., 2001). Extranuclear or neuropil aggregates are reported to
impair axonal transport, synaptic vesicle recycling and receptor endocytosis by
aberrantly interacting with proteins involved in these processes or physically
impairing axonal transport (Gunawardena et al., 2003, Li et al., 2001, Li and
Conforti, 2013);
? Autophagy: in the presence of mHTT aggregates, the inhibitor of the
mammalian Target Of Rapamycin (mTOR), an activator of autophagy, is
sequestered into the aggregates and clearance of the aggregates is enhanced
(Ravikumar et al., 2004). This suggests a positive role of mHTT aggregates. A
recent study showed that HTT and HAP1 are regulators of autophagosome
transport in neurons and that in the presence of mHTT, abnormal transport
leads to inefficient autophagosome maturation and results in defective
clearance of both mHTT aggregates contributing to neurodegeneration and cell
death in HD (Wong and Holzbaur, 2014);
? Mitochondrial dysfunction: mHTT perturbs mitochondrial function by altering
transcription of nuclear-encoded mitochondrial proteins or by direct interaction
with the organelle and modulation of its metabolic activity and trafficking.
Abnormal interaction between mHTT and the transcriptional regulator p53
results in p53 increased levels in the nucleus and increased transcriptional
activity, leading to the upregulation of pro-apoptotic targets as well as
mitochondrial membrane depolarization (Bae et al., 2005); mHTT also
represses the transcription of genes involved in mitochondria biogenesis and
respiration (Cui et al., 2006). Altered mitocondrial morphology and dynamics
are also reported in HD (Costa and Scorrano, 2012). Abnormal interaction
between mHTT and molecular motors or physical blockade exerted by mHTT
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inclusions along the axons causes reduction in mitochondrial motility (Orr et
al., 2008, Trushina et al., 2004, Reddy and Shirendeb, 2012); mHTT elicits an
imbalance in mitochondrial fission and fusion that initiates neurodegeneration
(Reddy and Shirendeb, 2012, Labbadia and Morimoto, 2013, Guo et al., 2013).
Given the multiple roles of HTT and mHTT in controlling biological processes,
therapeutic intervention needs to focus on multiple targets in order to alleviate disease.
Fig. 5
General scheme of the proposed pathologic pathways involved in HD. From (Zuccato et al., 2010).
(A) mHTT causes a conformational change of the protein that leads to partial unfolding or abnormal
folding of the protein, which can be corrected by molecular chaperones. Full-length mHTT is cleaved
by proteases in the cytoplasm. In an attempt to eliminate the toxic HTT, fragments are ubiquitinated
and targeted to the proteasome for degradation. However, the proteasome becomes less efficient in
HD. Induction of the proteasome activity as well as of autophagy protects against the toxic insults of
mHTT proteins by enhancing its clearance. B: NH2-terminal fragments containing the polyQ strech
accumulate in the cell cytoplasm and interact with several proteins causing impairment of calcium
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signaling and homeostasis (C) and mitochondrial dysfunction (D). E: NH2-terminal mutant huntingtin
fragments translocate to the nucleus where they impair gene transcription or form intranuclear
inclusions. F: the mutation in huntingtin alters vesicular transport and recycling. muHtt, mutant
huntingtin.
1.6 Current therapies and targets for therapeutic intervention
Currently no effective therapies for preventing or delaying the onset of HD are
available. Therapies are symptomatic and include the use of antichoreic drugs to
control the involuntary movements and the use of psychotropic medications to address
depression, obsessive compulsive symptoms, or psychosis. Medications often have
side effects and do not repair damage or stop the disease from progressing. Speech
therapy and physical therapy are useful in addressing the swallowing and walking
difficulties that many HD patients experience (Bilney et al., 2003).
Genetic animal models provide an opportunity to test potential treatments to translate
to human patients, and therapies successful in mice represent good candidates for
clinical trials. So far, therapeutic strategies in animal models of HD have been
focusing on the following targets:
? Reducing aggregate formation through pharmacological targeting of toxic
conformational changes of mHTT. A polyphenol (epigallocatechin gallate
(EGCG)) was found to decrease toxic forms of mHTT (Ehrnhoefer et al.,
2008) while an aggregation inhibitor (a sulfobenzoic acid derivative termed
C2-8) showed a beneficial effect on behavioural phenotypes and striatal
neuronal volume in the R6/2 mouse model of HD although it had no effect on
survival (Chopra et al., 2007). Intracellular antibodies developed against an
epitope of human HTT specifically bind to mHTT and reduce its toxicity in
cellular and animal models (Colby et al., 2004, Khoshnan et al., 2002, Wang et
al., 2010, Wolfgang et al., 2005);
? Enhancing clearance of aggregates through autophagy. Treatment with
rapamycin or its analog CCI-779, inhibitors of mTOR, stimulated mHTT
clearance in cells (Ravikumar et al., 2004, Ravikumar et al., 2002) and
improved phenotype in fly and mouse models of HD (Ravikumar et al., 2004);
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? Reducing proteolitic cleavage of HTT. Studies in transgenic YAC mice
expressing mutant HTT with alterations at the position 586, cleavage site for
caspase 6, showed reduced pathological effects (Graham et al., 2006).
Inhibition of caspases 1 and 3 has been proved to be beneficial in mouse
models of HD (Chen et al., 2000, Ona et al., 1999) and in patients, treatment
with the caspase inhibitor minocycline resulted in slight improvements in both
neuropsychological performance and motor function (Bonelli et al., 2003,
Thomas et al., 2004);
? Targeting abnormal gene expression due to transcription dysregulation.
Administration of inhibitors of histone deacetylases (HDACs), enzymes which
cause transcriptional repression, were found to ameliorate the HD phenotype
in mouse and invertebrate models (Steffan et al., 2001, Hockly et al., 2003,
Pallos et al., 2008, Bates et al., 2006), and are now ready to be used in clinical
trials phase I;
? Targeting excitotoxicity blocking the excessive release of glutamate or its
action at the postsynaptic receptors. Glutamate receptor blockers have been
used on HD patients with disappointing results: a clinical trial of lamotrigine, a
glutamate antagonist, showed no significant effect on slowing disease
progression despite a reduction in chorea (Kremer et al., 1999); other
glutamate antagonist under trial such as riluzole (Landwehrmeyer et al., 2007)
and remacemide (Huntington Study, 2001) had same negative results. Studies
in HD mice revealed that therapeutic treatments aimed at blocking NMDA
receptors should be designed to target extrasynaptic receptors. In YAC mice,
treatment with low but not high dosages of memantine ameliorated adverse
neuropathological and behavioural effects (Okamoto et al., 2009). Indeed,
memantine at low dosages, more selectively targets the extrasynaptic receptors
(Hardingham and Bading, 2010). A pilot study on human patients showed
promising results of the use of memantine (Ondo et al., 2007);
? Targeting reduced mitochondrial activity and energy impairment. Treatments
aimed at amelioration of the cellular energy deficit and improvement of
mitochondrial function in HD through the use of metabolic antioxidants
??????????? ????????? ?????? ??????????????????? ???? ????????? ?????? ?????? ????
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involved in cellular energy production and act as cofactors of several
metabolic enzymes, could be beneficial (Moreira et al., 2010). In transgenic
mice, treatment with Q10 was found to promote survival, attenuate striatal
lesions and reduce weight loss and motor deficits (Matthews et al., 1998) and
in patients, two major phase III trials (2CARE and CREST-E) are testing
coenzyme Q10 and creatine, respectively. Treatments with inhibitors of the
enzyme kynurenine 3-monooxygenase (KMO), key enzyme of the kynurenine
pathway which is disrupted in HD, also ameliorates behavioural and
neuropathological deficits in HD models (Thevandavakkam et al., 2010);
? Reducing the amount of pathogenic protein by genetic manipulation such as
conditional knock-out or siRNA, aiming at decreasing mHTT production
(Yamamoto et al., 2000, DiFiglia et al., 2007, Boudreau et al., 2009) or by
enhancing clearance through autophagy and lysosome system (Renna et al.,
2010) or molecular chaperones (Perrin et al., 2007, Vacher et al., 2005).
Yamamoto and collaborators showed for the first time that blockade of
expression of mHTT in a conditional transgenic mouse model of HD at
symptomatic stage, leads to the disappearance of inclusions and to the
amelioration of the behavioural phenotype (Yamamoto et al., 2000). In a more
recent study performing selective reduction of mHTT expression in cortex,
striatum or both brain areas, in a conditional transgenic HD mouse model,
demonstrates distinct but interacting roles of cortical and striatal mHTT in HD
pathogenesis and suggests that optimal HD therapeutics may require targeting
mHTT in both cortical and striatal neurons (Wang et al., 2014). Another
approach based on allele-specific silencing of mHTT targeting single
nucleotide polymorphisms (SNP), proved to be successful in a BACH mouse
model of HD and in HD human stem cells resulted in functional recovery of
the vesicular transport of BDNF along microtubules (Drouet et al., 2014). In
patients, gene therapy using siRNA and shRNA to silence CAG repeats have
also shown promising results (Brett et al., 2014);
? Reducing loss of BDNF, crucial for striatal neuronal survival. In vitro,
administration of BDNF to cultured mammalian neurons or to primary neurons
expressing mHTT was found protective against the toxicity induced by the
mutant protein (Saudou et al., 1998, Zala et al., 2005). Other in vivo studies in
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R6/1 and R6/2 mice treated intrathecally via a mini-pump confirmed the
neuroprotective effect of BDNF delivery (Canals et al., 2004, Giampa et al.,
2013). Limitations to this approach include the difficulty to determine the
actual amount of BDNF reaching the affected neurons as BDNF is quite
unstable and only a small quantity crosses the blood brain barrier; and clinical
trials based on subcutaneous or intrathecal administration had little success
(Zuccato and Cattaneo, 2007). More recently, other methods of administration
such as in vivo and ex vivo gene transfer aimed at stimulating the synthesis of
endogenous BDNF, or the use of BDNF mimetic drugs have been investigated
(Nagahara and Tuszynski, 2011).
? Targeting cell loss through striatal and stem cell transplantation. Preclinical
studies on mouse excitotoxic HD models showed that foetal striatal grafts
transplanted into the lesioned area can survive and improve motor and
cognitive impairment (Dunnett et al., 1998, van Dellen et al., 2001) suggesting
that grafts restore functional circuits with the cortex (Dunnett, 1995). Clinical
trials on HD patients using human striatal foetal tissue from spontaneously
aborted foetuses were carried out with contrasting results. A successful
transplant where increases in motor and cognitive function were seen 2 years
after implant of intrastriatal grafts was described by Bachoud-Levi and
colleagues (Bachoud-Levi et al., 2000) but 6 years after graft implant the same
group reported that the initial beneficial effects were largely lost (Bachoud-
Levi et al., 2006). Transplant of embryonic stem cells (Aubry et al., 2008) or
induced pluripotent stem cells extracted from adult somatic cells into rodents
showed that these did form clusters of medium spiny neurons but they also
induced the formation of tumours (Roy et al., 2006). Further studies are
needed to improve the quality and quantity of the neurons obtained and to
establish whether this approach could be one day safely and effectively
transferred to human patients.
1.7 Axon degeneration in neurodegenerative diseases
The axon is the most extensive part of a neuron accounting for up to 99.8% of the total
volume of the cell. In adult humans it can stretch up to 1 m in length in motoneurons
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and collateral branches can further increase the total volume. Such a long structure is
required to connect functionally distant regions and deliver electric impulses, newly
synthesized molecules and other axonally-transported molecules and organelles from
the cell body to the axon terminal, but at the same time represents a vulnerable
structure that can be affected in many pathological conditions (Perlson et al., 2010).
Not surprisingly, several types of insults such as mechanical lesions, chemical toxins,
metabolic or neurodegenerative disorders can affect the axon and trigger a similar
degenerative process.
The first to describe the process of degeneration of an axon was Augustus Waller in
1850. After lesioning of the glossopharyngeal and the hypoglossal nerves of a frog,
Waller observed that the distal stump of nerves from the site of injury, which were
separated from their cell bodies, became disorganized by 5-6 days after the cut and by
12-15 days all structures were completely degenerated (Stoll et al., 2002). This
process was named after him “Wallerian degeneration (WD)” and became an
important experimental tool to study the mechanisms underlying these events in both
peripheral and central nervous system. In mammals, WD normally occurs over a time
course of around 24-48 h following mechanical (transection, crush and blunt trauma),
chemical (acrylamide), or metabolic (ischemia) injury (Neukomm and Freeman,
2014). Early morphological changes during WD are focal swelling and beading of the
axons (Waller, 1850) followed by disintegration and degeneration of the axoplasma
and axolemma which is completed within 24-48 h (George et al., 1995). Subsequently,
breakdown of myelin sheath occurs, macrophage infiltration and Schwann cell
proliferation (LeBlanc and Poduslo, 1990) to clear axonal remains and to promote
regenerative attempts at the proximal stump (Fig. 6). Cytoskeleton breakdown is
mediated by extracellular calcium influx and involves activation of axonal proteases
(Schlaepfer and Bunge, 1973, George et al., 1995). During this process, molecular
changes such as upregulation of neurotrophins, cytokines and neural cell-adhesion
molecules produced by Schwann cells occur in the degenerating distal stump of the
nerve (Stoll and Muller, 1999, Kury et al., 2001).
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Fig. 6
Schematic representation of Wallerian degeneration. From Weiqian Mi PhD dissertation, 2003. (a)
Intact axon with its surrounding myelin sheath, (b) fragmentation of axon and myelin following cut, (c)
phagocytosis of axon and myelin fragments by macrophages, (d) Schwann cells guide regeneration of
nerve, (e) Regenerated fibers.
WD shares morphological features with axonal pathology in some disease states such
as toxic or genetic neuropaties, inflammation and neurodegenerative disorders such as
Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS) or
amyotrophic lateral sclerosis (ALS), which for this reason is known as “Wallerian
like” degeneration (Coleman and Freeman, 2010). Increasing evidence suggests that
axonal degeneration occurs early in neurodegenerative diseases often determining the
course of pathology (Conforti et al., 2007a). For example, in MS, magnetic resonance
(MR) studies have detected early loss of axons, suggesting that axon pathology may
precede degeneration of other neuronal compartments (Narayanan et al., 1997, van
Waesberghe et al., 1999). In AD, live imaging using transgenic or virally-encoded
fluorescent proteins revealed highly dystrophic axons close to amyloid plaques and
dendrites losing spines before breaking (Tsai et al., 2004, Spires et al., 2005); and in
vitro and in vivo imaging of fluorescent neurons in AD mice crossed with yellow
fluorescent protein mice (YFP-H) revealed dystrophic axons close to the amyloid
plaques in the absence of cell-body death (Adalbert et al., 2009, Crowe and Ellis-
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inflammation and demyelination (Sherriff et al., 1994, Ferguson et al., 1997). In ALS
considerable axonal loss is found both in human and in animal models. Studies on
transgenic mice expressing mutant Cu/Zn superoxide dismutase (SOD1) showed that
axon degeneration parallels symptom onset (Fischer et al., 2004, Pun et al., 2006).
??????????????????????????????????????????????????????????????????????????????????
Lewy with axonal swellings (Martin et al., 2006). Although the axonal damage in each
of these disorders may be the result of a variety of different triggers, the similarity in
pathology suggests the existence of an underlying common mechanism in axon
degeneration. The study of the molecular mechanisms underlying WD is therefore
useful to elucidate pathology in these diseases and the axon could be a promising
target for therapeutic intervention (Conforti et al., 2014).
Axon degeneration in HD
Much is still unknown about axon degeneration in HD. Morphological alterations in
dendritic arbors and spines of MSSNs, as well as in axons, have been reported in early
studies on post-mortem material from HD patients using Golgi impregnation
(Graveland et al., 1985) and immunostaining with calbindin D28K (Ferrante et al.,
1991) and with SMI32 and SMI31 (Nihei and Kowall, 1992). More recently, the use
of in vivo neuroimaging has revealed reduction of fractional anisotropy, measure of
white matter integrity, in presymptomatic HD subjects indicating early white matter
disorganization (Reading et al., 2005, Weaver et al., 2009); and several studies have
related white matter abnormalities in early patients to deficits in behaviour (Dumas et
al., 2012, Beglinger et al., 2005). In animal models, behavioural abnormalities
resemble those seen in HD patients and often appear at a stage of the disease where no
overt signs of neuropathology are present, suggesting that neurological dysfunction
more than cell loss is responsible for the behavioural phenotype (Crook and Housman,
2011). Morphological and functional dendritic abnormalities have been reported in
several HD mice (Guidetti et al., 2001, Laforet et al., 2001, Milnerwood et al., 2010,
Lerner et al., 2012) as well as alterations in synaptic activity (Cepeda et al., 2003,
Milnerwood et al., 2006, Cummings et al., 2007) and abnormalities in the expression
and release of neurotransmitter receptors (Cha et al., 1999, Klapstein et al., 2001, Li et
al., 2003, Andre et al., 2006) and synaptic vesicle proteins at early stage (Smith et al.,
45
2005). Impaired axonal trafficking of synaptic vesicles and mitochondria, by increased
stalling of transported vesicles, was detected at early stage in C. elegans and
Drosophila models of HD (Gunawardena et al., 2003, Parker et al., 2001, Sinadinos et
al., 2009) as well as in mammalian neurons (Trushina et al., 2004, Chang et al., 2006).
Abnormalities have also been detected in axons of transgenic HD mice but whether
these precede or parallel symptom onset and cell body degeneration remains unclear
(Li et al., 2001). Thus, further investigations are needed to assess whether axon
degeneration occurs before death of other neuronal compartments and can be a target
for future therapeutic strategies.
1.8 Axon degeneration as a therapeutic target
Historically research on neurodegenerative diseases has focused on the cell body as it
was commonly believed that axon degeneration occurred as a secondary event
following cell body death. For long time, axon degeneration has been considered a
passive breakdown of the axon due to lack of cell body-derived trophic factors
(Lubinska, 1977, Lubinska, 1982) or activation of Ca2+-dependent proteases
(Schlaepfer and Hasler, 1979) and not surprisingly therapeutic approaches aiming at
protecting the cell body compartment only had not been successful in long-term trials.
The discovery of the spontaneous mutant mouse WldS (Wallerian degeneration slow)
(Perry et al., 1990) drastically changed this assumption and highlighted that axon
degeneration is an active self-destructing process involving a determined molecular
cascade which is different and independent from apoptosis (Raff et al., 2002,
Whitmore et al., 2003, Deckwerth and Johnson, 1994). In the WldS mouse, axon
degeneration after acute injury is delayed by 10-fold and a stable synaptic activity is
recorded for more than 2 weeks after separation from the cell body (Lunn et al., 1989).
The spontaneous mutation responsible for this phenotype has been identified as an 85
kb tandem triplication mapping to mouse chromosome 4 (Coleman et al., 1998). This
unusual rearrangement brings two endogenous genes together forming a chimeric
gene that encodes an in-frame fusion protein that is absent in wild-type mice
(Coleman et al., 1998, Conforti et al., 2000). The protein contains the amino (N)-
terminal 70 amino acids (N70) fragment of the ubiquitination factor E4B (UBE4B),
the complete sequence of the enzyme nicotinamide adenylyltransferase 1 (NMNAT1)
and a linking portion of 18 AA originally belonging to the 5’ untranslated region of
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the Nmnat1 gene (Conforti et al., 2000) (Fig. 7). NMNAT is the central enzyme of
NAD synthesis and it catalyses the reaction NMN + ATP => NAD+ PPi, the last step
in all NAD biosynthetic pathways. NMNAT1 is one of the three mammalian NMNAT
isoforms (1, 2 and 3) which have different subcellular localization. NMNAT1 is a
nuclear protein while NMNAT2 and 3 are mainly associated with Golgi and
mitochondria, respectively (Berger et al., 2005). N70 contains, in its N-terminal 16
amino acids (N16) region, a binding site for the valosin containing protein (VCP), a
ubiquitous cytoplasmic AAA-ATPase with several roles including one in the ubiquitin
proteasome system (UPS) (Laser et al., 2006). The direct binding of WLDs to VCP is
responsible for the distribution of WLDs in nuclear foci (Wilbrey et al., 2008). It has
been demonstrated that both N70 and NMNAT1 are required for the protecting
phenotype in vivo (Conforti et al., 2009, Conforti et al., 2007b).
Fig. 7
Schematic representation of WldS gene. An 85Kb tandem triplication results in a chimeric gene that
encodes for a chimeric protein, a fusion of the N-terminal seventy amino acids of the ubiquitination
factor E4b (UBE4B), the full sequence of the enzyme nicotinamide mononucleotide adenylyltransferase
1(NMNAT1) and a linking portion of 18 AA originally belonging to the 5’ untranslated region of the
Nmnat1 gene.
Introducing the WldS gene in the genome of different species replicates the protecting
phenotype. For example, it was found to protect physically injured axons in transgenic
rats (Adalbert et al., 2005), injured olfactory receptor neurons (ORN) in Drosophila
(Hoopfer et al., 2006, MacDonald et al., 2006) and axotomised trigeminal neurons in
zebrafish (Martin et al., 2010), suggesting a similar conserved mechanism trough
evolution. Importantly, WldS neuroprotective efficacy extends to a variety of disease
models suggesting that similar mechanisms regulate axon degeneration in both acute
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injuries and chronic diseases. For example it was found to extend life span and
alleviate symptoms in the progressive motor neuronopathy (pmn) mouse model of
motoneuron disease (Ferri et al., 2003), in Parkinson’s disease mouse models (Sajadi
et al., 2004, Hasbani and O'Malley, 2006), in a rat glaucoma model (Beirowski et al.,
2008) and in a gracile axonal dystrophy mouse model (Mi et al., 2005). However,
WldS failed to protect in some model of neurodegenerative diseases including a mutant
SOD1 mouse model of ALS (Vande Velde et al., 2004, Fischer et al., 2005), in mouse
models of spinal muscular atrophy (SMA) (Kariya et al., 2009) and in prion infected
mice (Gultner et al., 2009), suggesting that there are distinct pathways to axon
degeneration that can be distinguished by their sensitivity to WldS (Conforti et al.,
2014).
The molecular mechanisms of WldS-mediated protection are still not fully understood
but progresses have been made in understanding since its first discovery (Coleman
and Freeman, 2010, Wang et al., 2012, Conforti et al., 2014). WLDs is predominantly
nuclear (Mack et al., 2001) but recent studies reported a cytoplasmic and potentially
axonal site of action (Beirowski et al., 2009, Sasaki et al., 2009a, Yahata et al., 2009,
Babetto et al., 2010, Cohen et al., 2012). The binding of VCP protein to the N16
region of N70 allows the relocation of nuclear NMNAT1 to the axon where it acts to
??????? ???? ??????????? ??????????? ??? ????WldS transgenic mice, lacking the N16
region, no protection was detected (Conforti et al., 2009, Avery et al., 2009). Thus, for
axon protection, both NMNAT enzyme activity and its localization in the axon are
necessary to confer protection (Conforti et al., 2009, Babetto et al., 2010). An
interesting model to explain WLDSs axonal protection has been recently proposed
(Gilley and Coleman, 2010). According to this study endogenous NMNAT2, which is
the most labile NMNAT isoform with a half-life of less than an hour, is an essential
survival factor for maintenance of healthy axons. Its depletion by transection of mouse
superior cervical ganglia (SCG) neurites or by specific RNAi in the absence of acute
cut is sufficient to induce spontaneous axon degeneration. In normal conditions,
NMNAT2 is continuously transported along the axons (Milde et al., 2013c, Gilley and
Coleman, 2010) but after injury, NMNAT2 present in the distal stump of the axon is
rapidly depleted before signs of degeneration. When in the injured axon is present
WLDs, capable of enzymatic NAD synthesis by its NMNAT1 activity and much more
stable compared to NMNAT2, this substitutes for loss of endogenous NMNAT2
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maintaining its activity for a prolonged period (Gilley and Coleman, 2010, Gilley et
al., 2013) (Fig. 8). WldS mice, rats and Drosophila crossed with disease models are a
unique experimental tool to explore axon degeneration, investigate novel biochemical
pathways and determine how axon degeneration contributes to neurodegenerative
pathology and symptoms, ultimately leading the way to new therapeutic approaches.
Fig. 8
A molecular model of WldS-mediated axon protection. From (Di Stefano and Conforti, 2013). NAD
metabolism controls axon degeneration. In neurons, NMNAT2 is transported along the axon, and its
catalytic activity maintains axon viability. However, in degenerating axons after an injury, NMNAT2 is
rapidly degraded, leading to a decrease in NAD levels and other not yet elucidated events which may
lead to degeneration, which may not be the critical event promoting axon degeneration (see text). The
neuronal compartments are not shown to scale.
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1.9 Aims and Objectives
The present thesis intends to expand our understanding of the role of axon
degeneration in HD mouse models; to characterise its development and to address
whether this precedes the death of other neuronal compartments and therefore can
represent an early target for therapeutic intervention. Indeed, while axon pathology
has been reported previously in patients and animal models, an accurate
characterisation of its spatio-temporal development in relation to neuronal loss and to
the deposition of mHTT aggregates is lacking.
Thus, the present thesis aims to:
1. Clarify the involvement of axon degeneration in HD.
To this aim:
? Using as models R6/2 transgenic and HdhQ140 knock-in mice crossed with
YFP-H mice, I studied axon and cell body morphology at various time-points
by imaging of fluorescent neurons. The YFP-H mouse, which expresses the
marker protein YFP in a subset of neurons affected in HD, allows visualising
neurons and axons over hundreds of microns and has recently been used
successfully to dissect neuronal pathology in neurodegeneration models. Using
this powerful tool in HD mouse models, I tested the hypothesis that axon
fragmentation or swelling, signs of axon degeneration, precede or at least
parallel the onset of synapse loss and dysfunction and neuronal loss;
? I investigated how axon degeneration relates to mHTT aggregate formation
through immunofluorescent labelling and imaging. This part of my study
addresses a long lasting and topical question in the HD field of whether or not
mHTT nuclear and extranuclear aggregates have a toxic role;
? I performed a longitudinal behavioural characterisation of the HdhQ140 mouse
behaviour, using a battery of motor and cognitive trials, testing the hypothesis
that axon pathology develops in parallel to symptom onset and progression.
Indeed, although severe motor symptoms have been generally associated with
neuronal loss mainly in the striatum and cortex, more subtle axonal defects
could account for behavioural changes and cognitive abnormalities observed in
the early phase of the disease.
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2. Study potential changes in NAD metabolism as a possible mechanism leading
to axonal dysfunction in HD.
To this aim:
? I checked for alteration in the activity of key enzymes in the NAD biosynthesis
(NMNAT and NAMPT), in their expression levels and in the levels of the
substrates and products of these enzymes, the nucleotides NAD and NMN,
testing the hypothesis that pathology in these mice correlates with alterations
in the NAD biosynthetic pathway, recently linked to axon survival and axon
and synapse degeneration in many neurodegenerative disorders;
? I looked at possible interactions between wild-type and mHTT and NMNATs
enzymes, including the WLDs protein, in a cellular model of HD by
transfection and imaging techniques, testing the hypothesis that mHTT can
interfere/impair the normal function of this enzyme by direct interaction,
contributing to neuropathology.
51
CHAPTER 2
Material & Methods
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Note: Some sections are reported in a manuscript produced as a result of this work,
Marangoni et al., 2014. Age-related axonal swellings precede other
neuropathological hallmarks in a knock-in mouse model of Huntington's disease,
Neurobiol Aging, 35, 2382-93.
2.1 Mouse origins and breeding
Hemizygous R6/2 and homozygous HdhQ140 (HdhQ140/Q140) males (Mangiarini et al.,
1996, Menalled et al., 2003) were bred to female Thy1.2-YFP-H homozygotes on a
C57BL/6 background (Feng et al., 2000) to produce R6/2/YFP-H and heterozygous
HdhQ140/YFP-H (HdhQ140/+/YFP-H) in the F1 generation. The latter were then
intercrossed to produce mice homozygous for the Q140 mutation and hemizygous for
YFP (HdhQ140/Q140/YFP-H). 4 and 12 week old R6/2/YFP-H mice and YFP-H
littermate controls were used whereas HdhQ140/YFP-H and YFP-H littermates were
used at 4 and 12 months for heterozygous and at 6 and 12 months for homozygous
mice. All mice were obtained from The Jackson’s laboratories (USA) and kept at the
Babraham Institute in Cambridge and at the University of Nottingham. All breeding
and procedures were performed as authorised under the Animals (Scientific
Procedures) Act 1986, under project licences 80/2254, 40/3576 and 40/3482.
2.2 Genotyping
Tail tips or ear biopsies of 10-day old mice were collected under isoflurane
anaesthesia. DNA was extracted from biopsies and genotyping was performed by PCR
using the following forward (for) and reverse (rev) primers according to The
Jackson’s Lab Protocols (http://www.jax.org/):
R6/2
for: 5’- CCGCTCAGGTTCTGCTTTTA-3’
rev1: 5’-TGGAAGGACTTGAGGGACTC-3’
rev2: 5’-GGCTGAGGAAGCTGAGGAG-3’
HdhQ140
for1: 5’-CATTCATTGCCTTGCTGCTAAG-3’
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rev1: 5’-CTGAAACGACTTGAGCGACTC-3’
for2: 5’-GATCGGCCATTGAACAAGATG-3’
rev2: 5’-AGAGCAGCCGATTGTCTGTTG-3’
For YFP genotyping, primers used were as follows:
for: 5’-CGAACTCCAGCAGGACCATGTGA-3’
rev: 5’-CTTCTTCAAGGACGACGGCAACT-3’
R6/2 and HdhQ140 DNA samples were sent to Laragen Inc. (USA) for CAG repeat
sizing.
2.3 Methods for chapter 3
2.3.1 Histology and Immunohistochemistry
Tissue processing
R6/2/YFP-H and HdhQ140/YFP-H mice, together with the corresponding YFP-H
littermate controls, were perfused transcardially with 4% phosphate-buffered
paraformaldehyde (PFA) and brains dissected and processed as previously described
(Adalbert et al., 2009). Brains were post-fixed by overnight immersion in the same
fixative and then cryoprotected in 30% sucrose at 4°C for at least 48 h before
processing. On the day of sectioning, brains were split into two halves and from each
half free-floating 50 μm sagittal and 20 μm coronal brain sections, respectively, were
obtained using a Leica CM1850 cryostat.
H&E staining
For evaluation of gross brain morphology, 20 μm coronal sections were mounted onto
Superfrost slides (BDH), air dried and stained with Haematoxylin and Eosin (H&E)
(Lillie, 1965).
Hoechst staining
For morphological analysis of YFP expressing (YFP+) neurons, 50 μm sagittal
sections were incubated for 10 min with nuclear staining Hoechst 33258 (Invitrogen,
1:500) in PBS with 1% Triton, washed 3 times in PBS and then mounted onto
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Superfrost slides in Vectashield mounting medium (Vector Laboratories) (Adalbert et
al., 2009) .
Nissl staining
?????????????????????????????????????????????????????????????????????????????????????
fluorescent Nissl stain in PBS (Invitrogen-Molecular Probes, 1:300) for 20 min and
then washed in PBS for 2 h at room temperature before being mounted onto slides in
Vectashield containing DAPI.
Immunohistochemistry
For immunohistochemistry, 20 μm coronal sections were incubated in PBS with 1%
Triton for 10 min, washed 3 times in PBS and then blocked for 1 h at room
temperature with 3% BSA in PBS, before overnight incubation at 4°C with mouse
anti-human Huntingtin (Chemicon clone EM48, 1:100). Goat anti-mouse Alexa Fluor
568 (Invitrogen, 1:200) was used as secondary antibody (Adalbert et al., 2009). After
incubation in secondary antibody, sections were washed 3 times in PBS and then
mounted onto Superfrost slides in Vectashield mounting medium containing DAPI
(Vector Laboratories).
2.3.2 DiI staining
A separate set of WT/YFP-H mouse fixed brains were used to mark corticostriatal
??????????? ???????? ????? ???????????????????????????????????????????????????????
perchlorate (DiI) fluorescent neurotracer (Sigma), a lipophilic membrane stain
(Godement et al., 1987). Crystals of DiI were inserted into perfused brains and were
kept for at least 2 weeks in 4% PFA, at 37°C to speed up the uptake process which is
slower in fixed tissues (Holmqvist et al., 1992). In some brains, DiI crystals were
inserted into the cortex while in some others into the striatum. Crystal insertion was
carried out using the tip of a fine gauge needle and under a dissection microscope to
guide it. After 2 weeks, 50 μm sagittal brain slices were obtained using a Vibratome
(Leica vt1000s) and mounted onto Superfrost slides.
2.3.3 Golgi staining
A separate set of HdhQ140/YFP-H mouse brains were used to visualise striatal
neurons with Golgi staining. For this technique, brains were perfused with PBS and
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4% PFA. After fixation they were immediately immersed in the impregnation solution
(solutions A + B in equal parts) from FD Rapid GolgiStain Kit (FD Neuro
Technologies, USA) (Gao et al., 2011, Milatovic et al., 2010) for about two weeks,
according to manufacturer’s instructions. After this time, brains were transferred to
another solution (solution C) from the kit and kept in the dark at 4°C for 24 h for up to
1 week. Later, brains were rapidly frozen by immersion in iso-pentane pre-cooled (-
70°C) in dry ice and sliced with a cryostat to obtain 50 μm sagittal sections. Brain
slices were mounted onto gelatine-coated microscope slides and stained according to
manufacturer’s instructions.
2.3.4 Western blot
Western blot was carried out as previously described (Conforti et al., 2007b). Fresh
frozen striata and cortices from R6/2, HdhQ140 and wild-type littermate mice were
homogenised in RIPA lysis buffer containing protease inhibitors (Complete mini,
Roche), protein samples loaded on a 10% SDS polyacrylamide gel and then
transferred to nitrocellulose membrane using a semi-dry blotting apparatus (BioRad).
Membranes were then blocked for 1h in 5% BSA in PBS plus 0.2% Tween-20
(PBST), incubated overnight with primary antibody in 5% BSA in PBST at 4°C and
subsequently washed in PBST and incubated for 1h at RT with HPRT-linked
secondary antibody in 2% BSA in PBST. Finally membranes were washed, treated
with ECL (Enhanced Chemiluminescence detection kit; GE Healthcare) and exposed
to film for an appropriate time. The following primary antibodies were used: mouse
anti-synaptophysin (Dako clone Y38, 1:10000) and mouse anti-PSD-95 (Abcam,
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2.3.5 Imaging and quantitative analysis
Fluorescently labelled section
Z-stack images were acquired by confocal microscopy (Zeiss LSM 710 Laser
Scanning Microscope) at 1 Airy Unit (AU) with the following excitation/emission
filters: DAPI/Hoechst 405nm/420–480nm, YFP 488nm/505–550nm, AlexaFluor 568
and NeuroTrace 561nm/575–615nm. All quantitative analyses on confocal images
were performed manually using ImageJ software, on maximum projection images
resulting from the superimposition of the single z-stacks. In particular:
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? For morphological characterisation of YFP+ neurons and axons, confocal
images were acquired with a 20X air-objective (Plan-Apochromat 20X/0.8)
and axonal swellings quantified in 3 images per section, corresponding to
cortex, striatum dorsal and striatum ventral, in 3 sections per animal (n = 3-6,
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quantification and the analysis was carried out independently by two different
persons, at least one of whom blinded to the mouse genotype (Bridge et al.,
2009);
? For visualisation and colocalisation analysis of mHTT aggregates, confocal
images were acquired using a 63X oil-immersion objective (Plan-Apochromat
63X/1.40). Colocalisation studies were performed using Volocity 6.1 software
which allows 3D reconstruction of maximum projection images;
? For analysis of nuclear size of Hoechst stained 50 μm sagittal sections in
cortex and amygdala, a 40X oil-immersion objective (Plan-Apochromat
40X/1.3) was used and quantification was performed in three different brain
sections per animal (n = 4-6). In the amygdala, a 0.035 mm2 box was randomly
placed within the imaged section and size of Hoechst stained nuclei of YFP+
cell bodies was measured within it (Adalbert et al., 2009);
? Nissl stained sections were imaged at 40X and the number of Nissl positive
neurons was quantified in three different striatal fields per section, in three
sections per animal (n = 4-6, see Fig. 2 A);
? DiI stained slices were imaged at 63X and reconstruction images of
superimposing YFP+ and DiI+ neurons used to show colocalisation between
the two colours.
H&E stained sections
Sections were imaged by low power (Plan-NEOFLUOAR 1.25X/0,035) light
microscopy (Zeiss Axioplan) and the area of the lateral ventricle was measured using
Volocity 6.1 software. Sections representative of 4 different antero-posterior brain
areas were matched between control and HD mice and used for the analysis (n = 4).
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Golgi stained sections
Sections were imaged under bright field microscopy (DMIRB, Leica), using a 63X
oil-immersion objective and with z-stack acquisition (n = 2).
Western blots
WB bands were analysed using imageJ gel analysis software. For each band, the
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tubulin III loading control for each sample, was calculated (n = 7-8).
2.3.6 Statistical analysis
Data are presented as mean ± SEM. Student’s t-test or One-way ANOVA followed by
Bonferroni post hoc test for multiple comparison was performed for statistical
analysis: group comparison was considered statistically significant when p-value was
< 0.05. Analysis and graphs were obtained using Prism GraphPad 5.0 software.
2.4 Methods for chapter 4
2.4.1 Behavioural assays
In order to evaluate a range of motor and cognitive behavioral functions in the KI
homozygous model, mice were subjected to a battery of behavioral tests that were
adapted from previous validated studies (Rising et al., 2011). 14 HdhQ140/Q140 mice (7
males and 7 females) and 12 WT controls (6 males and 6 females) were used for the
study. A longitudinal study was carried out and mice were tested at age 1, 3, 6, 9 and
12 months. For each time-point, mice performed in the following tests over a period of
two weeks (Fig. 9):
Fig. 9
Schematic representation of the behavioural assessment. Behavioural tests were performed over a
period of two weeks at each time-point. Rotarod, overnight running wheel and open field tests are
measure of locomotor activity, pre-pulse inhibition of sensorymotor gating, spontaneous alternation
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and novel object recognition tests of cognitive function and open field and elevated plus maze tests of
anxiety-related behaviour.
Rotarod: mice were placed on a rotating rod of a Rotarod apparatus (Letica Scientific
Instruments), facing the direction of movement. The latency to fall was recorded over
a period of 10 min during which speed was set to
increase from 5 to 35 RPM, as a measure of motor
coordination with natural fear of falling response. The
test was carried out over 3 consecutive days (day 1-3),
with an extra 2-day training phase preceding it, at 1
month only. For each day, three trials were performed
with a 1 to 2 h inter-trial time and each trial was
repeated twice with a 5 minute interval. Motor skill learning, related to cognitive
impairment, was also evaluated in the 3 trials per day over the 3 days of testing;
Overnight running wheel: between day 4 and 5 mice were placed in single cages fitted
with a running wheel connected to a sensor recording the
number of rotations and the average speed per hour
completed by the mouse as measure of the locomotor
activity during nocturnal hours in which rodents are more
active. All mice tested were singly housed at 6 pm on day
4. Data were collected at 9:30 am on the following day
and mice placed back in the homecage. Food and water were provided at all times.
Spontaneous alternation task: a Y-shaped maze comprised of three transparent
Plexiglas® arms at a 120°
angle from each other was used
for this test. The start point was
located in the centre of the
maze and the animal was
allowed to freely explore the three arms over 5 min. Alternation rate of arm choice
and total number of arm entries were measured as parameter of spatial working
memory and locomotor activity, respectively. This test was conducted on day 8 before
the open-field test;
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Open-field: on day 8, following the spontaneous alternation task, mice were placed in
the open-field arena (30 cm x 35 cm x 30 cm) and
allowed to move freely for 30 min. Their behavior was
recorded using Ethovision Software (Noldus,
Wageningen, Netherlands). The total distance moved
and the percentage of time spent in the centre of the
arena was considered as index of locomotor activity and
anxiety-related behaviour, respectively;
Novel object recognition task (NO): on day 9, mice were placed in the same arena
used for the open-field test in which two objects were placed. The task consisted of
three trials of 6 min each separated by a 10 min interval
between the first and second trial and a 20 min one
between the second and the third in which mice were
placed back into the home cage. In the first trial
(Habituation) two objects (object 1 and 2) of the same
shape were placed into the arena and the animal was
allowed to freely explore them over 6 min. In the second
trial (Location) the object 2 was moved to a different location in the arena while in
third trial (Discrimination) the object 2 was replaced by an object of different shape.
The total distance moved and the time spent exploring the objects were recorded using
Ethovision Software. Data from location and recognition trials were used as a measure
of spatial and recognition memory respectively, based on the spontaneous tendency of
normal rodents to spend more time exploring a novel object (object 2) rather than a
familiar one (object 1);
Prepulse inhibition (PPI): on day 10, mice were placed into a Plexiglas cylinder
inside a chamber (SR-LAB San Diego Instruments, USA), equipped with fan and
light, that prevents external noise or vibrations from interfering with the experiment.
A speaker was producing acoustic stimuli and mouse movements were detected and
recorded as measure of sensory gating. The test session was adapted from Brody et al.,
2004 (Brody et al., 2004) and consisted of 72 trials of different trial types: 40 ms-long
120 dB stimuli (pulse alone trial); 20 ms-long of either 68, 72, 80 or 90 dB stimuli
preceding the 120 dB (prepulse + pulse trial) and 65 dB background white noise (no
60
stimulus trial). Trial types were presented in an
irregular, counter-balanced order with around 15
sec inter-trial time and proceeded by 5 min
acclimation period during which the background
noise was presented alone. Startle magnitude was
calculated as the average response to the pulse
alone trials and % of PPI was calculated as follows:
[1?????????????????????????????????????????????????????????????????????????????
Elevated plus maze (EPM): on the last day of testing, animals were placed in a plus-
shaped apparatus with two open and two enclosed arms constructed from white
opaque acrylic, each with an open roof and elevated
around 80 cm from the floor. Mice were placed at the
junction of the four arms of the maze and allowed to
explore freely over 5 min. Their behaviour was
recorded with Ethovision. The preference for being in
open arms over closed arms (expressed as either as a
percentage of entries and/or a percentage of time spent
in the open arms) was calculated as measure of
anxiety-like behaviour. This test relies upon rodents’
tendency toward dark, enclosed spaces and an unconditioned fear of heights/open
spaces.
Mice were weighed monthly and on day 1 during testing phase.
2.4.2 Statistical analysis
Data are presented as mean±SEM. Two- or Three-way ANOVA was used for
statistical analysis: group comparison was considered statistically significant when p-
value was < 0.05. Weight was considered as a covariate in tests, such as rotarod,
running wheel and PPI, where it was shown to affect performance. Analysis was
performed using InVivoStat software.
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2.5 Methods for chapter 5
2.5.1 Determination of NMN and NAD levels and NMNAT enzyme activity
This analysis was carried out during my visit to the Università Politecnica delle
Marche in Ancona (Italy), in collaboration with Dr. Giuseppe Orsomando.
Nucleotide levels in HdhQ140/Q140 and corresponding wild-type littermates were
determined accordingly to previously described methods (Formentini et al., 2009,
Graeff and Lee, 2002). Frozen cortices (n = 6-8) and striata (n = 4-6), previously
dissected from 6 and 12 month old HdhQ140/Q140 and fresh frozen in liquid nitrogen,
were weighed and grinded with a pestle on liquid nitrogen. Samples were then
collected in a tube, acidified by addition of HClO4, sonicated and then neutralized by
addition of K2CO3 and kept at -80°C till use. On the day of use, samples were
defrosted, centrifuged and in each extract NMN and NAD levels were determined as
follows: NMN was measured upon derivatisation with acetophenone and
spectrofluorometric HPLC analysis (Formentini et al., 2009): each sample was
incubated with acetophenone (C8H8O) and potassium hydroxide (KOH) for 15 min at
4°C, then formic acid (HCOOH) was added and the solution incubated at 100°C for 5
min and finally centrifuged. Derivatization allowed NMN to be converted into a
highly fluorescent compound (Fig. 10). A duplicate sample containing NMN spike of
a known amount was analysed in parallel. Pure NMN standard (Sigma) was dissolved
in water and solution analysed by HPLC with fluorimetric detection.
Fig. 10
Derivatisation of NMN. NMN is converted into a fluorescent compound upon reaction with acetophenone and
formic acid.
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NAD content was instead measured by a fluorescence cyclic assay (Graeff and Lee,
2002) carried out onto a 96-well plate reader (Bio-Tek). Each well was loaded with
appropriate volumes of the sample homogenates (5, 10 and 20 μl, plus or minus NAD
spikes at known amounts) diluted to 150 μl with water, further added with 100 μl of
fresh cycling reagent containing 96% ethanol, 0.3 M TFNa pH8, 1 mg/ml alcohol
dehydrogenase/1.5 mg/ml BSA_gelfit, 0.1 mM resazurin in 0.1M TFK pH8,
diaphorase, l mM FMN. The increase in the resorufin fluorescence was measured
using the fluorescence plate reader.
Total NMNAT enzymatic activity was measured as previously described (Balducci et
al., 1995, Conforti et al., 2011). Grinded cortical and striatal samples (n = 2) were
homogenised in a buffer containing protease inhibitors and sonicated. For each
sample, a reaction mix containing 50 mM HEPES/KOH pH 7.5, 1 mM ATP, 20 mM
NaF (Sodium fluoride), 25 mM MgCl2, 1 mM DTT (DLDithiotreitol), BSA 0.6 mg/ml
and appropriate aliquot of the brain homogenate was prepared. 1 mM NMN was
added at the end to start the reaction and incubated at 37°C. 4 sets of reactions were
prepared and stopped at time 0, 3, 6 and 9 min, respectively, by addition of ice-cold
HClO4. Samples were then neutralised and run on HPLC for determination of the
product (NAD).
2.5.2 Western blot
Fresh frozen striata and cortices from 6 and 12 month old HdhQ140/Q140 and wild-type
littermate mice were collected and processed as described for samples in chapter
2.3.2. Mouse anti-NAMPT (Enzo Life Sciences, 1:2000) (Laiguillon et al., 2014) and
anti-mouse HRP-conjugated (GE Healthcare, 1:2000) were used as primary and
secondary antibodies respectively. Membranes were incubated overnight at 4°C with
????????????????????????? ????????????????????????????????????????????????????
in PBST was used as loading control. WB bands were analysed as in 2.3.5 and data
??????????????????????????????
2.5.3 Cell culture
PC12 and HEK293 cells
For WLDs studies, an inducible line of rat pheochromocytoma (PC12) cells expressing
a GFP-tagged exon1 fragment of the human HD gene containing a 21 (PC12 Q21) and
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72 (PC12 Q72) CAG repeat driven by a doxycycline-dependent Tet-ON promoter
(Wyttenbach et al., 2000, Gossen et al., 1995) was used. Cells were cultured on
collagen-coated flasks (collagen from rat-tail, Sigma) in high glucose Dulbecco’s
Modified Eagle’s medium (DMEM, Sigma D6546) supplemented with 5% fetal
bovine serum (FBS tetracycline free, PAA), 10% heat inactivated horse serum
(GIBCO), 2 mM L-glutamine and 100 μg/ml penicillin/streptomycin (Invitrogen), 100
??????????? ?????????????????????????????????????????????????? ???????????????????
were seeded onto treated ibidi μ-dishes (Thistle Scientific) coated with collagen from
rat tail (Sigma) and allowed to reach 60-80% of confluence. On the same day of
transfection, cells were treated with differentiating medium containing DMEM
supplemented with 2% B27, 1:1000 gentamycin and 100 ng/ml 7S NGF and treated
with 1 μg/ml doxycycline to induce aggregate formation.
For cotransfection and colocalisation studies between full-length human wild-type and
mutant Huntingtin and NMNATs proteins, wild-type PC12 and Human embryonic
kidney (HEK) 293 cells were used. Wild-type PC12 cells were cultured on collagen
coated flasks as for the Tet-ON PC12 in the same medium without G418 and
Hygromycin B. HEK293 cells were cultured in high-glucose DMEM supplemented
with 10% FBS, 110 mg/L sodium pyruvate, 2mM glutamine, and 1X
penicillin/streptomycin (10,000 u/mL).
Primary cultures
For studies of colocalisation and live axonal transport, superior cervical ganglia (SCG)
explants were dissected from 2 day old C57/BL6 mouse pups and dissociated as
previously described (Buckmaster et al., 1995). Dissected SCG ganglia were
incubated in 0.025% trypsin (Sigma) in PBS (without CaCl2 and MgCl2) for 30 min
followed by 0.2% collagenase type II (Gibco) in PBS for 30 min. Ganglia were then
gently triturated using a pipette and then plated onto ibidi μ-dishes pretreated with 20
μg/ml Laminin (Invitrogen) in DMEM, and cultured in DMEM (Sigma D6546)
medium supplemented with 10% FBS, 2 mM L-glutamine, 100 μg/ml
Penicillin/Streptomycin, and 100 ng/ml 7S NGF (Invitrogen) and 4 μM aphidicolin
(Calbiochem) to reduce the number of dividing cells. Medium was changed every 2-3
days.
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2.5.4 Plasmids
To study the effect of WLDs on Tet-ON PC12 expressing wild-type or mHTT, cells
were transfected with WldS in DsRed vector. To study colocalisation between mHTT
aggregates and WLDs or NMNAT1 in Tet-ON PC12, cells were transfected with
WldS-mCherry in pCDNA3 vector or NMNAT1-DsRed in pDsRed2-N1 vector. HEK
293 cells were instead cotransfected with a synthetic vector termed pARIS-htt
(Adaptable, RNAi Insensitive&Synthetic) encoding the full-length wild-type (pARIS-
httQ23) or mutant (pARIS-httQ100) human HTT fused to mCherry, kindly donated by
Prof. Frederic Saudou in Paris (Pardo et al., 2010); and NMNAT2-EGFP in pEGFP-
N1 vector to study colocalisation. Shorter vector encoding only the N-terminal part of
wild-type (pARIS htt 1-586-Q23 in pENTRY vector) and mutan Huntingtin (pARIS
htt 1-586-Q100 in pCDNA vector) were also used (kind gift of Dr. Diana Zala and
Prof. Frederic Saudou). Primary neurons were contransfected with these shorter
versions of pARIS-htt vector and NMNAT2-EGFP to study colocalisation and
transport along the axons.
2.5.5 Transfection
Lipofectamine
Transfection of Tet-ON and wild-type PC12 cells was performed using Lipofectamine
2000 (Invitrogen) in Opti-MEM (GIBCO), using plasmids purified by EndoFree
Plasmid Maxi-kit (Qiagen). For transfection in 35 mm ibidi μ-dishes, 0.8 μg DNA and
2 μl of Lipofectamine 2000 were used, according to the manufacturer’s instructions.
Microinjection
Dissociated SCGs were transfected by microinjection as previously described (Gilley
and Coleman, 2010). 3-4 days after plating, when neurites were sufficiently extended,
cells were microinjected using a Zeiss Axiovert S100 microscope with an Eppendorf
FemtoJet transjector and 5171 micromanipulator system and Eppendorf Femtotips.
Plasmids were diluted in 0.5×PBS to the desired concentration and passed through a
Spin-X filter (Costar). The mix was injected directly into the nuclei of SCG neurons in
???????????? ?????????????? ???????????????? ????? ??? ?? ????????????????????? ????????????
DsRed was used at 20 ng/μl to avoid cytotoxicity (Zhou et al., 2011).
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2.5.7 Imaging and quantitative analysis
For colocalisation studies and quantitative analysis cells were fixed in 4% PFA, nuclei
stained with Hoechst dye (as for 2.3.1) and confocal images acquired as for 2.3.3.
Hoechst stained healthy nuclei were counted manually with imageJ software.
For live axonal transport studies on dissociated SCGs, time-lapse imaging was
conducted using a Total Internal Reflection Fluorescence (TIRF) microscope (Axio
ObserverZ1, Zeiss) with a 100X oil-immersion objective (Alpha Plan-Apochromat
100X/1.46) and single image frames were acquired every second for 3 minutes.
Neurons were imaged within 24 h after microinjection. Videos were then analysed
using Difference tracker ImageJ plugin (Andrews et al., 2010) to measure the average
number of moving particles and their average speed.
2.5.8 Statistical analysis
Data are presented as mean ± SEM. Student’s t-test or One-way ANOVA followed by
Bonferroni post hoc test for multiple comparisons were performed for statistical
analysis: group comparison was considered statistically significant when p-value was
< 0.05. Analysis and graphs were obtained using Prism GraphPad 5.0 software.
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CHAPTER 3
Characterisation of axon pathology in
R6/2 and HdhQ140 mice
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3.1 Introduction
3.1.1 Choice of the model
The present study focuses on two mouse models of HD: R6/2 transgenic and
HdhQ140 knock-in.
R6/2 mice were the first to be analysed. The choice of this particular model was
driven by the fact that R6/2 (Mangiarini et al., 1996) is the best characterised mouse
model and the most widely used in preclinical trials. These mice were the first to be
made available in the literature and to be rapidly placed into a commercial breeding
facility becoming accessible to scientists. Moreover, their rapid disease progression
including behavioural changes, brain pathology and premature death, make them
suitable for preclinical drug testing. Extensive atrophy of the striatum, cortex and
other brain areas was shown in these mice with histopathological techniques (Stack et
al., 2005) and MRI imaging (Sawiak et al., 2009) accompanied by little or no neuronal
loss (Li and Li, 2004). Thinner dendrites and reduced dendritic spines were also
described (Klapstein et al., 2001) as well as synapse dysfunction and loss in the
striatum at early stages of the disease, which may be the structural correlates to the
development of cognitive dysfunction in the asymptomatic phase (Murphy et al.,
2000, Cepeda et al., 2003). And in axon terminals, where mHTT aggregates are
present, reduction in normal level of synaptic vesicles was shown by electron
microscopy (EM), suggesting abnormal association between aggregates and vesicles
which could be responsible for synaptic impairment (Li et al., 2003).
While several pathological aspects of the disease are modelled in R6/2, the relevance
to the human pathology is still to be fully clarified. First, Tg mice are genetically not
representative of the disease as it appears in humans. HD patients have only one
normal copy of the HTT gene and one mutated copy while Tg mice usually contain
multiple copies of the mutant HTT gene. Moreover, the random insertion of the human
HTT gene in the mouse genome may interfere with the normal function of other genes
not related to HD. Furthermore, the expression of HTT in these mice is driven by an
artificial promoter, whose spatial and temporal control of expression is different from
that of the endogenous mouse Hdh promoter. In addition to the different genetics, the
extremely short lifespan of these mice, which die prematurely around 15 weeks,
represents a limitation to the study of an age-related disease which in humans appears
68
late and takes decades to progress. Not surprisingly, successful therapeutic trials on
R6/2 often failed to succeed in clinical trials on patients. For instance, treatment with
the glutamate antagonists riluzole and remacemide, and with the metabolic antoxidant
coenzyme Q10 successfully ameliorated the disease phenotype in R6/2 mice
(Schilling et al., 2001, Ferrante et al., 2002, Schiefer et al., 2002) but were not
beneficial for patients (Huntington Study, 2001, Landwehrmeyer et al., 2007).
KI mice are a genetically more precise model of HD. Here, mHTT is inserted in the
appropriate genomic context, which is in the endogenous mouse Hdh locus and under
the endogenous promoter. Although these mice show milder phenotype and slower
disease progression compared to the transgenic, pathological changes have also been
described. In particular in HdhQ140 mice (Menalled et al., 2003), object of this study,
several neuronal abnormalities are reported making them a good candidate model to
study axon pathology in HD. Reduction in striatal volume is documented, together
with dendritic complexity and spine density alterations in Golgi stained striatal
neurons (Lerner et al., 2012) accompanied by limited neuronal loss (Hickey et al.,
2008). Alterations in striatal synaptic activity is also reported (Cummings et al., 2007)
as well as degenerative processes at the level of the axon (Li et al., 2001). In axon
terminals, an EM study detected at an early stage of the disease the presence of
degenerated organelles including mitochondria in the proximity of mHTT aggregates
suggesting that aggregates block the transport of organelles or vesicles along the axon
(Li et al., 2001).
3.1.2 YFP-H mice: a tool to dissect neuropathology in models of disease
For the study of axon pathology in R6/2 and HdhQ140 mice, both models were
crossed to YFP-H mice which express the YFP protein in restricted subsets of neurons
thus allowing longitudinal imaging of neuronal structures including axons.
YFP-H mice were first generated in 2000 by Feng and collaborators (Feng et al.,
2000), together with other transgenic mouse lines constitutively expressing different
fluorescent proteins (XFPs, X = red, yellow, green or cyan) in subsets of neurons
under the control of the modified neuron-specific promoter Thy-1.2. All XFPs
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labelled neurons in their entirety, including axons, nerve terminals, dendrites, and
dendritic spines (Fig 11).
The generation of XFP mice helped the study of neurodegeneration and brought
advantages over previously available techniques of visualization of neurons and their
compartments. Most of the above mentioned studies describing neuritic pathology in
R6/2 and HdhQ140 mice utilise techniques such as immunohistochemistry and
electron microscopy which limit the analysis to restricted areas of individual neuronal
compartments, or use selective stainings such as Golgi staining which are
unpredictable, require fixed tissue and if neurons have already degenerated, stain only
contiguous segments. To understand the progression of a disease and to optimize
effective treatments to prevent or block neuronal death, it is very important to identify
the neuronal compartment where degeneration first occurs (axon, dendrites, synapses,
or cell body) and how it progresses with time. Thus, imaging neurons in their full
length is important to investigate their structure and correlate it to pathology and
genetic approaches, based on the expression of fluorescent proteins restricted to few
neurons, represent a useful tool to do so.
Fig. 11
XFP staining in transgenic mice. From (Feng et al., 2000). (A) Four distinct XFPs as Vital Stains in
Transgenic Mice. Neuromuscular junctions from thy1-YFP line H (a), thy1-GFP line H (b), thy1-CFP
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line D (c), and thy1-RFP line 8 (d) transgenic mice. (B) Multiple Neuronal Subsets in thy1-XFP Double
Transgenic mice. (a) Dorsal root ganglion from a GFP/RFP double transgenic (thy1)-GFP line M and
thy1-RFP line 8); (b) Dorsal root ganglion from a CFP/YFP double transgenic (thy1- distinct patterns
of expression. Together, these features CFP line S and thy1-YFP line H). Many neurons are YFP
positive, and subsets are also YFP or YFP/CFP positive; (c) Section from the cortex of the mouse
shown in (a).
The Thy1.2 cassette was previously modified from the gene of the Thy1 glycoprotein,
expressed in a variety of tissues and cell types including thymus, nervous system, and
connective tissue fibroblasts, by partial deletions of genomic regions required for the
expression in non-neural cells but not in neurons (Vidal et al., 1990, Caroni, 1997)
(Fig. 12). Transgene expression begins at P6–10 and some variations in the number of
fluorescently labelled neurons exist between different XFP transgenic mouse lines.
Fig. 12
Schematic representation of the Thy-1.2 expression cassette. Modified from (Caroni, 1997). The
mouse Thy1 glycoprotein gene (top) is deleted to develop the modified Thy1.2 cassette, for expression
of transgenes in a random subset of neurons. Part of exons II, the whole exon III and part of exon IV,
together with the introns in between, are deleted and substituted with an XhoI site, for cloning
purposes. The deleted regions contain portions essential for the expression of the Thy glycoprotein in
the thymus. EcoRI site and PvuI site are at the extremities of the cassette. The deletions disrupt the
expression of the Thy1 glycoprotein.
A comprehensive mapping of the specific neurons labelled in adult and postnatal
YFP-H mice has been provided (Porrero et al., 2010) (Fig. 13). The YFP transgene is
selectively expressed in projection neurons and limited to a few neuronal
subpopulations among them. Most of YFP+ neurons are located in the cortex,
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hippocampus and amygdala but smaller, additional projection neurons are also present
in some brainstem nuclei (Porrero et al., 2010).
Fig. 13
Fluorescent neurons in YFP-H mouse brain sagittal section. From (Porrero et al., 2010).
Photomontage made from serial sagittal section images shows a panoramic view of corticofugal cell
somata in the cerebral hemisphere as well as the path followed by their axons through the internal
capsule (ic), cerebral peduncle (cp), pyramidal tract (py) and pyramidal decussation (pyx) towards the
dorsal corticospinal tract of the spinal cord (dcs). A fiber bundle emerging perpendicularly from the
CP towards the pretectum (Pt), deep superior collicular layers (SC) and mesencephalic tegmentum is
labeled “LF” (“lenticular fasciculus”) following Valverde (1998). Additional terminal fields are
distinguishable in the zona incerta (ZI), subthalamic nucleus (STh), and pontine nuclei (Pn). In
addition to corticofugal cells, a subpopulation of eYFP+ reticular formation neurons and their axons
(black arrows) are also visible in the photomontage. Labeling in hippocampus (CA), nucleus
accumbens (Acb), olfactory turbercle (Tu) and stria terminalis (st) reflects additional eYFP+
expression in other pathways.
The YFP-H line has been extensively characterized and successfully used to assess
neurodegeneration both in CNS and PNS. Crossing of these mice with WldS
transgenic mice have been successfully used to follow, in vivo, the rate of Wallerian
degeneration over a distance of up to 2–3 cm in peripheral nerves (Beirowski et al.,
2004) and in the CNS, to study axonal and dendritic damage induced by ischemic
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damage (Zhang et al., 2005, Enright et al., 2007). Crossing with a mouse model of
???? ????????????????????????? ?????????????????????????????? ??? ??????????????????
amyloid (Brendza et al., 2003); and crossing with a 3xTg-AD model showed loss of
dendritic spines of individual dendrites (Bittner et al., 2010). In another AD model,
the TgCRND8 mouse, YFP-H expression allowed visualization of severe proximal
axonal dystrophy in the vicinity of amyloid plaques (Adalbert et al., 2009) (Fig.14).
This last study is particularly relevant to the present thesis as I conducted a similar
analysis to detect axon pathology in HD mouse models. Adalbert and collaborators,
viewing axonal, somatic and dendritic compartments of individual cortical neurons
simultaneously through longitudinal imaging, showed that cell bodies and dendrites
remain normal up to 1 year after appearance of axonal dystrophy (Fig. 14 B), raising
the prospect of a therapeutic window for functional rescue of individual neurons after
their axons become highly dystrophic (Adalbert et al., 2009).
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Fig. 14
Axonal dystrophy in TgCRND8/YFP-H mice leaves other parts of the same neuron morphologically
unaltered. From (Adalbert et al., 2009). (A) Cortical neuron from a control YFP-H mouse; (B) cortical
neuron from a 5-month-old TgCRND8/YFP-H mouse with severe proximal axonal dystrophy but
normal cell body and nuclear size (arrow, bottom) and abundant dendritic spines on apical dendrite
(arrow, top); (C) another neuron with severe, proximal axonal dystrophy from a 5-month-old
TgCRND8/YFP-H mouse also retains axon continuity and basal dendrites. (D) Quantification of cross
sectional nuclear area reveals no significant difference between TgCRND8/YFP-H neurons with severe
axonal dystrophy within 250 mm of the cell body and control YFP-H neurons. (E) Axonal dystrophy at
a plaque in a 14-month-old TgCRND8 mouse. The majority of axons emerging from the dystrophic
region are continuous and unswollen (arrows), cell bodies retain normal morphology and nuclear size
and location. Green = YFP; Red = Ab deposits; Blue (where present) = Hoechst 33258 dye. Scale bar:
A, B, C and E: 20mm (insets, 10 mm).
3.1.3 Hypothesis and aim of the chapter
Based on the evidence discussed above, here I tested the hypothesis that axon
pathology in HD mice occurs as an early degenerative process that precedes death of
other neuronal compartments. To this purpose, this work aims to characterise axon
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pathology, as previously described in models of different neurodegenerative diseases,
by detecting morphological abnormalities along YFP positive axons of HD/YFP-H
mice. By means of fluorescence imaging and immuno- and dye-staining I looked at
axon integrity as well as at the status of the cell body and correlated them to the
formation of neuropil and nuclear mHTT aggregates.
3.2 Results
Some sections are reported in a manuscript produced as a result of this work,
Marangoni et al., 2014. Age-related axonal swellings precede other
neuropathological hallmarks in a knock-in mouse model of Huntington's disease,
Neurobiol Aging, 35, 2382-93.
3.2.1 R6/2 and HdhQ140/Q140 mouse brains show an age-dependent enlargement of
the lateral ventricle but no striatal neuronal loss
To assess neuropathology in our HD mice I first looked at gross alterations in brain
morphology in H&E stained sections. I compared matching sagittal sections (20 μm)
representative of four different antero-posterior brain levels. In YFP-H control mice,
the area of the lateral ventricle in sections representative of all four levels increased
during aging, becoming significantly larger at 12 months of age compared to 3 and 6
months. Instead, there was no difference between 3 and 6 month of age (Fig. 15 and
Table 2). Consistent with previous studies describing brain atrophy in R6/2 (Sawiak et
al., 2009, Aggarwal et al., 2012) and HdhQ140/Q140 mice (Lerner et al., 2012), our
results showed a significant enlargement of the lateral ventricle in 3 month old R6/2
and 6 and 12 month old HdhQ140/Q140 mice compared to control littermates (Fig. 15 and
Table 2).
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Fig. 15
HD mice show enlargement of the lateral ventricle. H&E stained coronal brain sections (20 μm) of 3
month old R6/2/YFP-H and 6 and 12 month old HdhQ140/Q140/YFP-H mice and corresponding YFP-H
control littermates. Sections from four different antero-posterior brain levels were matched between
HD and control mice and imaged (1.25X) for analysis of gross brain morphology (see Methods). The
area of the lateral ventricle was then measured for each section as described in the Methods.
Representative sections from each genotype, brain level and age are shown. Scale bar, 330 μm.
76
Table 2
Quantification of the area of the lateral ventricle shows significant enlargement in HD mice. Lateral
ventricle areas (μm2) were measured using Volocity 6.1 software in coronal brain sections of four
different brain levels (I-IV) of 3 month old R6/2 and 6 and 12 month old HdhQ140/Q140 and corresponding
control littermates. A significant increase was found in all the four brain areas considered in R6/2 and
HdhQ140/Q140 compared to control mice, at all time-points (n = 3, mean±SEM, unpaired Student’s t-test,
*, P<0.05, **, P<0.01, ***P<0.001). A significant enlargement was also found within control mice at
12 months compared to 3 months (n = 3, mean±SEM, one-way ANOVA followed by Bonferroni post
hoc test, ^^, P<0.01, ^^^, P<0.001) and to 6 months (n = 3, mean±SEM, one-way ANOVA followed by
????????????????????????????????????????????????????
To investigate whether this was due to neurodegeneration, I determined the number of
neurons in coronal sections (20 μm) of R6/2 and HdhQ140 mouse brain striatum
stained with Nissl dye (Fig. 16). Although with differences to the human phenotype,
the striatum of HD mouse models remains the brain area where the majority of
neuropathological hallmarks, such as deposition of mHTT aggregates, has been
described (Davies et al., 1997, Hickey et al., 2008) and where any potential
neurodegeneration is most likely to be detected. I counted the number of Nissl stained
neurons in striatal sections of 12 week old R6/2 (Fig. 16 B), 12 month old HdhQ140/+
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(Fig. 16 C) and 6 and 12 month old HdhQ140/Q140 (Fig. 16 D) mice and found no
significant reduction compared to their control littermates. These results are consistent
with previous evidence that HD mouse models show little or no neuronal loss at least
until very late time-points (Davies et al., 1997, Hickey et al., 2008) and suggest that
more subtle changes preceding cell death might account for brain atrophy. Altered
dendritic morphology such as reduced branching and spine density described in both
HD patients and mouse models (Nithianantharajah and Hannan, 2013) could explain
the brain atrophy found in these mice.
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Fig. 16
The number of striatal neurons in HD mice is unaltered compared to controls. (A) The number of
Nissl positive neurons was evaluated in coronal brain sections (20 μm) of HD/YFP-H mice and
corresponding YFP-H control littermates. (a) Representative fluorescent image (2.5X) of a coronal
brain section showing the 3 striatal fields (red boxes) acquired per each section for quantification of
neuronal number (see Methods). Scale bar, 100 μm. (b) Representative confocal image (40X) of a Nissl
????????????????????????????????????????????????????????????????????????????????????????????????????????
blue: DAPI. (B-D) Quantitative analysis shows no significant cell loss in 3 month old R6/2/YFP-H (B),
12 month old HdhQ140/+/YFP-H (C) and 6 and 12 month old HdhQ140/Q140/YFP-H (D) compared to the
relative controls (n = 3-6, mean±SEM, unpaired Student’s t-test and one-way ANOVA followed by
Bonferroni post hoc test).
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3.2.2 Axon swelling is an early feature of HdhQ140/Q140 mice
I then analysed the morphology of corticostriatal neurons and axons of R6/2 and
HdhQ140 mice crossed with YFP-H mice. Because of the restricted expression of the
fluorescent protein, the YFP-H mouse line allows longitudinal tracing of individual
neurons running from the cortical layer V towards the striatum passing through the
corpus callosum and therefore enables visualisation of all structures of these neurons,
from dendrites to cell bodies to the long projection axons (Adalbert et al., 2009).
I first analysed brain sections of 4 and 12 week old R6/2/YFP-H mice corresponding
to early and late stages of the disease in this mouse model (Mangiarini et al., 1996). At
both time-points, the majority of fluorescent axons of R6/2/YFP-H mice looked
morphologically normal and did not show signs of degeneration such as swellings or
spheroids, typical features of the central nervous system (CNS) axonal dysfunction
during normal aging and in many disorders (Ferguson et al., 1997, Galvin et al., 1999,
Tsai et al., 2004, Bridge et al., 2009) (Fig. 17 A). I found a limited number of
swellings in both R6/2 and control mice with a non-significant trend to an increase in
the R6/2 mice (Fig. 17 B-C). Moreover, no significant reduction in nuclear size of
YFP+ cortical neurons stained with Hoechst was detected in these mice suggesting
that the health status of the cell bodies was good (Adalbert et al., 2009) (Fig. 17 D-E).
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Fig. 17
R6/2 mice have normal cell bodies and no obvious axon abnormality. Sagittal brain sections (50 μm)
of R6/2/YFP-H mice and corresponding YFP-H control littermates were imaged with confocal
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microscopy (20X) for analysis of axon morphology. (A) 4 week (a-b) and 12 week (c-d) old mice show
morphologically intact YFP+ neurons and projections both in cortex (a-c) and striatum (b-d). Arrows
????????????????????????????????????????????????????????????????????????????????????????????????????????
occasional swellings in cortex (red box), dorsal (white continuous box) and ventral (white dashed box)
striatum shows a tendency to an increase in R6/2/YFP-H mice compared to controls albeit with no
significant difference (n = 4, mean±SEM, one-way ANOVA followed by Bonferroni post hoc test). Scale
????????????????????????????????????????????????????????????????????????????????????????????????
mice in sagittal brain sections stained with Hoechst show no gross morphological changes in cell body
morphology and (E) quantification of their nuclear size reveals no difference between the two
?????????????????????????????????????????????????????????????????????????????????????????????????????
In order to have an additional confirmation that the YFP+ axons labelled in the
striatum of the YFP-H mouse belong to either intratelencephalic (IT) or pyramidal
tract (PT)-type terminals of cortical layer 5 neurons, I performed DiI staining of a
WT/YFP-H mouse brain. A single DiI crystal was placed either into the cortex (Fig.
18 A), for diffusion from the cell body towards axon terminals in the striatum, or in
the striatum (Fig. 18 B) for diffusion back to the cortex. Confocal imaging of brain
sections were acquired two weeks after crystal placement and showed extensive
colocalisation of DiI and YFP fluorescence in the fibres projecting from the cortex
supporting the idea that the majority of YFP+ neurons were part of corticostriatal
projection neurons. YFP/DiI co-labelled axons, part of IT and PT projections, are
described to send excitatory inputs to striatal D1 or D2 neurons, respectively (Reiner
et al., 2010, Li and Conforti, 2013).
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Fig. 18
YFP positive fibers in YFP-H mice are part of the corticostriatal pathway. Photomontage made from
serial confocal images (20X) of sagittal brain sections (50 μm) of WT/YFP-H transgenic mice two
weeks after a single DiI crystal was placed in cortex (A) and striatum (B). Both images show
colocalisation (arrows) between YFP positive fibers and DiI labeled fibers. Green=YFP; red=DiI,
scale bar, 100 μm.
Next, I analysed brain sections of 4 and 12 month old HdhQ140/+ mice corresponding to
early and advanced stage in this model which carries the mutation in the appropriate
genomic and protein context and at a heterozygous, physiological concentration. At 4
months I could not find any abnormalities in the KI model compared to control mice
(not shown). However, interestingly I found an increase in the number of axonal
swellings of HdhQ140/+/YFP-H mice compared to YFP-H wild-type mice at 12 months
(Fig. 19 A) albeit this increase did not reach a statistically significant value (Fig. 19
D).
Therefore, to test whether increasing mutant Hdh gene dosage accentuates the axonal
morphological abnormalities I detected in the heterozygous HdhQ140 mice, I
analysed HdhQ140/Q140 mice at 6 and 12 months of age. Importantly, homozygotes
retain the advantages of normal gene expression pattern, physiological expression
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level, and normal RNA splicing despite differing from human patients in having two
mutant copies of the gene. At 6 months the number of swellings in corticostriatal
axons was not significantly different from that of the controls and generally lower
than that found in 12 month old heterozygotes (Fig. 19 B-D). However, I observed a
striking, highly significant increase in the number of axonal swellings in 12 month old
HdhQ140/Q140/YFP-H compared to that in YFP-H wild-type controls (Fig. 19 C-D).
Morphological alterations appeared to be limited to the axonal compartment as the
nuclear size of the YFP+ neurons remained unaltered (Fig. 19 E-F) as well as their
gross dendritic morphology (Fig. 19 G-H).
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Fig. 19
Axonal swellings are detected in HdhQ140/Q140 mice before changes in cell bodies and dendrites.
Confocal images (20X) of sagittal brain sections (50 μm) from (A) 12 month old WT/YFP-H (a-b-c) and
HdhQ140/+/YFP-H (d-e-f) mice, from (B) 6 month old WT/YFP-H (a-b-c) and HdhQ140/Q140/YFP-H (d-e-f)
mice and (C) 12 month old WT/YFP-H (a-b-c) and HdhQ140/Q140/YFP-H (d-e-f) mice, show increased
???????????????????????????????????????????????????????????????????????????????????????????????????????
number of swellings in cortex and striatum dorsal and ventral reveals a significant increase in the
striatum of HdhQ140/Q140 mice compared to controls at 12 months of age. No difference could be detected
in HdhQ140/Q140 at 6 months, while in HdhQ140/+ mice at 12 months we could detect a trend to an increase
although it was not statistically significant (n = 3-6, mean±SEM, one-way ANOVA followed by
Bonferroni post hoc test, *, P<0.05, **, P<0.01, compared to the corresponding WT). (E) Confocal
images (40X) of YFP+ neurons with nuclei stained with Hoechst in the cortex of (a) 12 month old
HdhQ140/Q140 ??????????????????????????????????????????????????????????????????????????????????????
Quantification of their nuclear areas did not show gross difference between the genotypes. (G)
Dendrite morphology appears normal in 12 month old HdhQ140/Q140 (a) compared to YFP-H control
mice (b). (H) Quantification of (a) dendrite diameter and (b) spine density over 50 μm (red bar in (G)
a, b) shows no significant difference in HdhQ140/Q140 mice compared to YFP-H (n = 4, mean±SEM,
????????????????????????????????????????????????????????????????
A big increase in axonal swellings in HdhQ140/Q140/YFP-H mice was detected in axons
running through the stria terminalis, a limbic forebrain structure located in the
proximity of the striatum and the lateral ventricle. Neurons whose axons form this
structure are also YFP+ in the HD/YFP-H mice (Porrero et al., 2010) (Fig. 20 A).
Upon quantification, the number of axonal swellings in this area in HdhQ140/Q140 mice
resulted to be significantly increased compared to the control mice already at 6
months and was even greater at 12 months (Fig. 20 B). The morphology of YFP+ cell
bodies located in the amygdala, an area that contains the cell bodies of the axons
running in stria terminalis (Fig. 20 C), appeared generally normal and their nuclear
size was not altered in HdhQ140 compared to wild-type mice (Fig. 20 D); only
occasionally I could detect some dysmorphic cell bodies in a few of the mice,
irrespective of the genotype (data not shown).
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Fig. 20
Increased number of axonal swellings is detected in stria terminalis of HdHQ140/Q140 mice. (A) Sagittal
brain sections (50 μm) of HdhQ140/Q140/YFP-H and WT/YFP-H mice. (a) Representative fluorescent
image (2.5X) of a sagittal brain section; the red box indicates the brain area of stria terminalis where a
???????????????????????????????????????????????????????????????????????????????????????????????????????
month old HdhQ140/Q140 and (c) control mice show increased swellings in the KI model compared to WT.
??????????????????????????????????????????? ?????????????? ????????????????????? ??????????????????????
?????? ?????????????????? ????????????????????????????????????????????????????????????????????????????????
terminalis of HdhQ140/Q140 at 6 and 12 months of age shows significant increase compared to control
mice. (B) Confocal reconstruction images of sagittal sections show a big number of axonal swellings in
12 month old HdhQ140/Q140 mice (a) compared to control littermates (b) in axons running in the stria
terminalis (white arrowheads). Their corresponding cell bodies are located in the amygdala (white
????????? ?????? ????? ???? ???? ???? ??????????????? ??? ???? ???????? ???????? ???????? ????? ??? ????? ?????
bodies in the amygdala reveals no significant difference between the genotypes (n = 4-5, mean±SEM;
one-way ANOVA, *, P<0.05, **, P<0.01).
Taken together, these results suggest that axon dystrophy precedes cell body and
dendrite abnormalities in the HdhQ140 HD model. In addition, they suggest that the
corticostriatal pathway may not be the first site of degeneration which can instead
originate in other brain areas. On the other hand, a different sequence of
neuropathological events characterises the R6/2 model in which significant axonal
degeneration could not be detected.
In addition, in HdhQ140/Q140 mouse brains at 6 months, I performed Golgi staining to
look at alterations in MSSNs, which are reported to be affected first in HD. Using this
technique; I aimed to see whether morphological alterations were present in these
neurons which are not YFP labelled in the YFP-H model. No gross morphological
changes were found in KI mice compared to the ones of control mice as similar cell
bodies and abundant dendritic spines were observed in both genotypes (Fig. 21).
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Fig. 21
Golgi staining shows normal morphology of MSSNs in HdhQ140/Q140 mice. Bright field images (63X) of
Golgi stained sagittal brain sections (50 μm) of 6 month old WT (A) and HdhQ140/Q140 mice (B) show no
gross alteration in dendritic spines (arrows) and cell body of striatal neurons in HD mice compared to
controls (n = 2). Scale bar, 20 μm.
3.2.3 mHTT inclusions do not correlate with axon pathology
Next, I asked whether axon abnormalities correlate with the deposition of mHTT
aggregates in HD mouse models. As aggregates are mostly believed to have a toxic
function, a possibility was that degenerating axons were those containing inclusions.
Thus I wanted to test whether this was the case in my HD/YFP+ mouse models.
First, I analysed by confocal microscopy brain sections of R6/2 mice at 4 weeks of age
stained with EM48, an antibody widely used to detect human mHTT in mouse models
(Gutekunst et al., 1999). I confirmed the presence of widespread small NIIs and
neuropil aggregates in cortex and striatum at this time-point, in addition to nuclear
diffused fluorescence (Fig. 22 A a-b-e). At 12 weeks, NIIs appeared as one single
larger inclusion per nucleus (Fig. 22 A c-d-f). These findings are in agreement with an
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earlier study which described the age-dependent deposition of NIIs in the cortex and
the striatum of R6/2 mice (Davies et al., 1997). 3D reconstruction of confocal images
confirmed colocalisation between mHTT aggregates and some YFP+ neurons in our
models (Fig. 23 A, suppl. video 1A); however I was unable to detect any
colocalisation between the small neuropil aggregates and the YFP+ axons with this
imaging approach (Fig. 23 B, suppl. video 1B). Thus, neurons of R6/2 mice develop
big mHTT intranuclear aggregates and yet maintain normal axon morphology.
In agreement with previous characterisations (Menalled et al., 2003), the deposition of
mHTT aggregates follows a slower time course in HdhQ140 mice. In the striatum of
HdhQ140/+ mice at 4 months of age only small NIIs were detected, whereas no
immunostaining was visible in the cortex (Fig. 21 B a-b-g). At this time-point, in
contrast to the earlier description from Menalled and collaborators (Menalled et al.,
2003), I could not clearly detect neuropil inclusions in striatum and cortex. At 12
months, striatal NIIs increased in size but still no immunoreactivity could be detected
in the cortex (Fig. 22 B c-d-h).
In HdhQ140/Q140 mice at 6 months, large NIIs were detected in the striatum, while no
immunoreactivity was present in the cortex, similar to heterozygotes at 12 months
(Fig. 22 C a-b-i). In addition to the large NIIs in the striatum, small extranuclear
aggregates appeared in the cortex of HdhQ140/Q140 mice at 12 months (Fig. 22 C c-d-l).
Neither in the amygdala nor in the stria terminalis, could mHTT immunoreactivity be
detected in homozygous KI mice (data not shown).
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Fig. 22
Spatio-temporal characterisation of mHTT aggregate formation in HD models. Coronal sections (20
μm) of R6/2/YFP-H and HdhQ140/YFP-H mice. Sections were immunostained with anti-HTT antibody
(EM48) and imaged under high resolution (63X) confocal microscopy to characterise mHTT
inclusions. (A) 4 week old R6/2 mice show small intranuclear (arrowhead) and extranuclear (arrow)
mHTT aggregates both in (a) cortex and (b) striatum. 12 week old R6/2/YFP-H mice show small
intranuclear (arrowhead) and large exanuclear (arrow) mHTT aggregates both in (c) cortex and (d)
striatum. Strong diffused nuclear staining is also visible. (B) 4 month old HdhQ140/+/YFP-H mice show
small intranuclear (arrowhead) mHTT aggregates in the (b) striatum while no immunostaining is
detected in (a) the cortex. 12 month old HdhQ140/+/YFP-H mice show a large intranuclear aggregate
(arrowhead) in the (d) striatum and no aggregates in (c) the cortex. (C) HdhQ140/Q140/YFP-H mice at 6
months of age show large intranuclear aggregates (arrowhead) in (b) the striatum and no staining in
(a) the cortex. In 12 month old HdhQ140/Q140/YFP-H mice small extranuclear aggregates appear in the
cortex (c, arrow) in addition to the large NIIs detectable in striatum (d, l). (e, f, g, h, i, l) enlarged
images from the corresponding boxed areas show mHTT aggregates in the nucleus (arrowheads). Scale
bar, 20 μm. Green: YFP, red: mHTT, blue: DAPI.
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Fig. 23
Neuropil mHTT inclusions do not colocalise with YFP+ axons in R6/2 mice. (A) YFP+ neurons of
R6/2 mice accumulate mHTT nuclear aggregates. Confocal images (63X) of coronal sections (20 μm)
of 3 month old R6/2/YFP-H mice immunostained with anti-HTT antibody (EM48). In the cortex, mHTT
aggregates colocalise with the nucleus of YFP+ neurons (arrow) and this is confirmed by 3D
reconstruction (Suppl. video 1A). (B) Neuropil mHTT aggregates do not colocalise with YFP+ axons in
R6/2 mice. In the striatum, colocalisation between mHTT neuropil aggregates and YFP+ axons is not
?????????????????????????????????????????????????????????????????????????????????????????????????
DAPI.
While these data confirm the subtle and progressive onset of mHTT deposition in our
mouse models, they argue against a correlation between mHTT aggregates and the
formation of axonal swellings. However, the presence and detrimental role of soluble
mHTT in the abnormal axons cannot be excluded (Arrasate et al., 2004).
3.2.4 Synaptic abnormalities in HD mouse models
Synaptic transmission is altered in HD and abnormalities have been described at early
time-points in HD models (Smith et al., 2005). To investigate potential synaptic
defects in our R6/2 and HdHQ140 mice and evaluate their temporal pattern of onset in
relation to the axonal abnormalities, I looked at the expression levels of the pre- and
post- synaptic marker proteins synaptophysin and PSD-95 by Western blotting.
In R6/2 mice at 12 weeks of age, a late time-point in this mouse model but when
axons still look intact (Fig. 24), the levels of both these synaptic markers appeared
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significantly reduced in the striatum, while no significant difference was found in the
cortex (Fig. 24 A-B).
Alterations in the level of neither synaptophysin nor PSD-95 were detected in cortex
and striatum of HdhQ140/Q140 mice both at 6 and 12 months of age (Fig. 24 C-D). The
same result was found at 12 months in the hypothalamus, one of the main areas where
the axons running in stria terminalis project their synapses (Fig. 24 E).
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Fig. 24
Levels of synaptic markers in HD mouse brains. Western Blots of mouse brain homogenates probed
???????????????????????? ??????????????????????????????? ???????????????????????????????????? ????????
used as a loading control in all blots (KDa 50). Blots for (A) synaptophysin (KDa 38) and (B) PSD-95
(KDa 95) of cortical and striatal homogenates of 12 weeks old R6/2 and WT mice and corresponding
quantification (right) show no significant reduction of both markers in the cortex of 3 month old R6/2
compared to WT mice. In striatum, the level of synaptophysin (A) and PSD-95 (B) are significantly
reduced compared to WT mice (n = 8, mean±SEM, unpaired Student’s t-test, *, P<0.05). In
HdhQ140/Q140 mice at 6 and 12 months of age we found no significant difference in the levels of (C)
synaptophysin and (D) PSD-95 (n = 7-8, mean±SEM, one-way ANOVA followed by Bonferroni post
hoc test). (E) The levels of synaptic markers in the hypothalamus of 12 months old HdhQ140/Q140 mice do
not differ from those of control littermates (n = 7-8, mean±SEM, one-way ANOVA followed by
Bonferroni post hoc test).
Taken together, these results suggest synaptic dysfunction is a prominent feature of
disease in R6/2 transgenic mice and this precedes degeneration of other neuronal
compartments. However, in HdhQ140 KI mice, the level of synaptic markers are not
altered at a time when axonal abnormalities are evident, suggesting that the sequence
of neuropathological events can vary depending on the genetic model and that axonal
abnormalities are the first signs of pathology in this mouse.
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3.3 Discussion
These data show that in HdhQ140 homozygous mice, axon pathology precedes death
of other neuronal compartments. In HdhQ140/Q140/YFP-H mice at 6 months of age, a
striking increase in the number of axonal swellings compared to wild-type mice is
found and this precedes signs of degeneration in cell bodies, dendrites and synapses.
Data also demonstrate that increase in swellings is detected first in the stria terminalis,
a brain area which is part of the limbic system and plays a role in fear and anxiety-
related behaviour. In support of these results, recent studies have reported the
involvement of the limbic system in early behavioural symptoms in HD patients
(Petersen and Gabery, 2012) and mice (Van Raamsdonk et al., 2005b). Furthermore, a
recent study describes early onset anxiety-related behaviour in HdhQ140 mice
(Hickey et al., 2008), which is consistent with the findings that degenerative processes
in axons are on-going in this area. At the later time-point of 12 months, significant
axon pathology extends also to the corticostriatal axons of HdhQ140/Q140 mice. These
findings highlight the importance of studying on multiple brain areas also in human
patients in order to detect early axon degeneration in HD.
Axonal swellings are morphologically similar to those seen during normal aging but
appear earlier and their number is significantly higher. Importantly, morphological
abnormalities in HdhQ140 axons seem to be independent from mHTT inclusion
formation since no aggregate could be detected in YFP+ neurons in the cortex and in
the amygdala, two areas where the cell bodies of corticostriatal axons and of stria
terminalis axons are located. However, other factors such as the presence of the toxic
undetectable fraction of mHTT could play a critical role in this process.
HdhQ140 mice represent a more accurate model to investigate axon degeneration
during HD progression. KI mice are genetically more similar to human HD patients
than transgenic mice; they have normal life-span and milder phenotype resembling the
presymptomatic stage of the disease in human patients. And here I show that the
sequence of pathological events more closely resembles findings in human patients
(Li and Conforti, 2013). Possibly, the combination of full-length mHTT expression at
a physiological level, rather than just mutant N-terminal fragments expressed at high
levels as in transgenic models like the R6/2 mouse, and the slower progression of the
disease which allows normal aging in these mice in parallel with disease onset,
explain the appearance of morphological signs of axon pathology. Moreover, these
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results suggest that a certain level of mHTT is required to induce axonal pathology as
only homozygous HdhQ140 mice, and not heterozygotes, exhibit a significantly
higher number of swellings compared to control mice at 1 year of age. In
HdhQ140/+/YFP-H mice at 12 months, the increase in number of axonal swellings may
be in part related to normal aging and potentially to YFP accumulation in aging
animals rather than to HD pathology, as an increase with ageing was observed both in
KI mice and in control littermates with no statistically significant difference between
the genotypes. This is consistent with previous observations suggesting that long term
expression of the YFP transgene itself increases age-related swellings in some axons
(Bridge et al., 2009). In heterozygotes, possibly the number of swellings would
increase and become significantly higher than that in control mice at time-points later
than 12 months.
Results in R6/2 mice confirm previous observations of synaptic abnormalities in the
striatum of these mice (Klapstein et al., 2001, Cepeda et al., 2003) and these are found
to occur before cell body or axonal death. These abnormalities could result either by
synaptic degeneration or by synaptic remodeling (Torres-Peraza et al., 2008).
Conversely, axonal swellings and spheroid formation is not a prominent feature in
these mice, nor is striatal neuronal death. These findings point out the limitations of
the transgenic model which partially recapitulate the human pathology. The
aggressive phenotype with early death around 12-15 weeks of age makes the R6/2
mice particularly convenient for preclinical testing and therapy screening but less
suitable for the investigation of the early mechanisms of an age-related disease that in
human patients has late onset and slow progression. Considerations should be made
on the role of mHTT aggregates in R6/2. Here, immunostaining with an anti-mHTT
antibody reveals the presence of both intranuclear and neuropil mHTT aggregates but
only the first is found to colocalise with YFP+ neurons. However a colocalisation and
a toxic effect of neuropil aggregates on axons of non YFP+ neurons cannot be
excluded.
Finally, this study reveals how the YFP-H mouse is a powerful tool to detect
morphological changes when crossed with neurodegenerative disease models and to
assess axon pathology both in CNS and peripheral nerves. In a similar study on a
mouse model of Alzheimer’s disease (Adalbert et al., 2009), axonal swellings in the
absence of any morphological sign of cell body dysfunction is also observed. The
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similarities between this and the present study suggest analogies in the sequence of
events leading to degeneration in these two different disease models. However, due to
the limited expression of the fluorescent protein to subsets of neurons, in both HD
models, we cannot exclude that axon degeneration occurs in non YFP+ neurons.
Striatal D2 neurons, which are affected very early in HD progression, are not
fluorescently labelled in the YFP-H mouse line (Reiner et al., 1988, Albin et al., 1992)
and we cannot rule out degeneration occurring in these neurons. Indeed, Golgi
staining revealed no gross alteration in dendritic spines of individual neurons but
technical problems and the unpredictability of the technique itself made it difficult to
draw a final conclusion on these neurons.
In summary, axon pathology was found in the HdhQ140 mouse as a primary event
which may initiate in brain areas other than those considered most susceptible to
mHTT toxicity, while corticostriatal axons are affected at a later stage. Results also
underline important differences in the site where the first abnormalities are observed
depending on the HD mouse model under study. Understanding the mechanism at the
basis of axon pathology is likely to be crucial to alleviate symptom onset and delay
progression in HD.
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CHAPTER 4
Longitudinal behavioural assessment of
HdhQ140 homozygous mice
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4.1 Introduction
4.1.1 Behavioural profile of HD
As mentioned in the first introductory chapter, HD patients suffer from a triad of
symptoms which include motor, cognitive and behavioural abnormalities. These
reflect the pathological changes affecting a number of brain areas including the
striatum, which suffers the greatest damage, the cortex and subcortical regions such as
the substantia nigra (SN), globus pallidus (GP), subthalamic nucleus (STN),
amygdala, thalamus and hypothalamus, all affected at varying degrees and all tightly
inter-connected by neural circuits.
The uncontrollable movements (chorea) that characterize HD and originally gave the
name to the disease are now accepted to be only one part of the behavioural profile.
Initially basal ganglia, which striatum is one of the main components, were thought to
be purely a motor structure but later observations that striatal damage was leading to
cognitive and emotional dysfunction as well as motor symptoms, suggested a more
complex system of connections, ultimately controlling a variety of functions (Divac et
al., 1967). The pioneer work of Alexander and collaborators led to the concept of the
“functional loop” which proposed the existence of 5 structurally and functionally
distinct circuits (motor, oculomotor, dorsolateral, ventral/orbital and anterior
cingulate) connecting cortex, basal ganglia and thalamus (Fig. 25), 3 of which connect
to non-motor areas of the frontal lobes, involved in planning, working memory, rule-
based learning attention and other functions (Alexander et al., 1990, Alexander et al.,
1986).
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Fig. 25
Parallel organization of functionally segregated circuits linking basal ganglia and cortex. From
(Grahn et al., 2009). The dorsal and ventral striatum are differentially connected to discrete prefrontal
cortical regions in segregated corticostriatal circuits. The putamen plays a critical role within the so-
called ‘motor circuit’ while the caudate forms part of the oculomotor, dorsolateral and ventral/orbital
circuits. SMA= supplementary motor area, vl-GPi = ventrolateral globus pallidus (internal segment),
cl-SNr = caudolateral substantia nigra pars reticulata, VLo = ventrolateral nucleus of thalamus pars
oralis, Vlm = ventrolateral nucleus of thalamus pars medialis, FEF = frontal eye fields, cdm-GPi =
caudodorsomedial globus pallidus (internal segment), vl-SNr = ventrolateral substantia nigra pars
reticulata, l-VAmc= lateral ventral anterior nucleus of thalamus pars magnocellularis,MDpl =
parvocellular subnucleus ofmediodorsal nucleus of the thalamus, DLPFC = dorsolateral prefrontal
cortex, Caudate (DL) = dorsolateral caudate, Caudate (VM) = ventromedial caudate, mdm-GPi =
dorsomedial globus pallidus (internal segment), rm-SNr = rostromedial substantia nigra pars
reticulata, m-VAmc=medial ventral anterior nucleus of thalamus pars magnocellularis,
MDmc=magnocellular subnucleus of mediodorsal nucleus of the thalamus, ACA= anterior cingulate
area, VS = ventral striatum, rl-GPi = rostrolateral globus pallidus (internal segment), VP = ventral
posterior nucleus of the thalamus, rd-SNr = rostrodorsal substantia nigra pars reticulata, pm-MD=
posteromedial mediodorsal nucleus of the thalamus.
Cognitive and behavioral symptoms in HD can appear up to 15 years prior to the time
of motor diagnosis, in the preclinical phase (Paulsen, 2011, Brooks and Dunnett,
2013) and have strong impact on patients quality of life. Early disturbances include
personality and psychiatric symptoms, such as lack of concentration, changes of
mood, aggressive behaviour, depression, apathy and anxiety (Paulsen et al., 2001,
Dewhurst et al., 1970, Caine and Shoulson, 1983); and mild cognitive impairment
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such as deficits in learning (Knopman and Nissen, 1991, Lawrence et al., 1998), in
working memory and in executive memory (Paulsen, 2011, Lawrence and AD, 1998,
Lawrence et al., 1996). These early symptoms reflect pathological changes both at
striatal and cortical level and dysfunctions of neural circuits. In particular, defects in
executive functions such as in the ability to solve complex problems like learning new
information, planning ahead, regulating actions according to the environmental
stimuli, are associated with alterations in the dorsolateral circuit; irritability,
emotional instability, and lack of empathy are instead associated with damage to the
ventral/orbital circuit. Damage to the anterior cingulate circuit that projects to the
ventral striatum, which also receives limbic input from the hippocampus, amygdala,
and entorhinal cortex, is instead associated with decreased motivation such as akinetic
mutism, apathy, indifference to pain, thirst or hunger and lack of spontaneous
movements, verbalization and response to commands (Tekin and Cummings, 2002).
Early symptoms include also alterations in sexual behaviour, in the wake-sleep cycle
and symptoms not directly associated to brain changes such as progressive weight
loss, skeletal-muscle wasting and testicular atrophy (Politis et al., 2008, van der Burg
et al., 2009). Recent studies have highlighted the important contribution of
hypothalamic dysfunction and changes in the limbic system in the early non-motor
features of the disease (Petersen and Gabery, 2012). Indeed, the limbic system
regulates emotion, sleep, circadian rhythm, temperature and body weight, all functions
disrupted in HD. As pathology progresses, personality changes become more
accentuate and cognitive impairments worsen leading to dementia often accompanied
by psychotic symptoms.
In line with the observations of an early contribution of limbic system dysfunction to
symptoms in HD patients, are results from chapter 3. The early pathological changes
found in axons of stria terminalis in HdhQ140/Q140 mice indicated possible alterations in
the limbic system and hinted further investigation of the behavioural phenotype in
these mice.
Motor symptoms occur later in the disease progression and develop over a period of
10-15 years. Typically, the earliest motor signs are eye movement abnormalities
(Avanzini et al., 1979), followed by the progressive appearance of orofacial
dyskinesias, involving the head, neck, trunk and arms, before becoming chorea
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(Brouillet et al., 1999). Dysarthria, speech difficulties, is present at early stages and
becomes more pronounced with disease progression and dysphagia, difficulties in
swallowing, develops in advanced stages and may lead to choking. Hyperkinesia,
linked to the choreic involuntary movements, is the main feature of HD but together
with this, impairment in voluntary movements such as bradykinesia (Thompson et al.,
1988), the slow execution of movement, akinesia (Albin et al., 1990a), the inability to
initiate movement and hypokinesia (van Vugt et al., 1996), the reduction of
movement, have also been reported to coexist in patients. These manifestations reflect
the pathological changes in the normal function of the motor circuits of the basal
ganglia (see chapter 1.2). In particular, the preferential loss of striatal neurons
projecting to the external segment of the Globus Pallidus (GPe) (indirect pathway)
results in chorea and at a more advanced stage, the additional loss of striatal neurons
projecting to the internal segment of the Globus Pallidus (GPi) (direct pathway)
results in a rigid-akinesia. Alterations in sensorimotor gating of the startle reflex,
measured by prepulse inhibition (PPI), are also well documented in HD patients
(Swerdlow et al., 1995, Swerdlow et al., 2001). These are regulated by circuitry within
the limbic system and frontal cortex, basal ganglia, and pons which seem to be
affected in HD.
At a late stage, severe dementia and progressive motor dysfunction make patients
unable to walk, talk, eat and ultimately to care for themselves. As the disease
progresses, abnormal involuntary movements and dementia occur (Anderson and
Marder, 2001, Rosenblatt, 2007, Politis et al., 2008) (Fig. 26).
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Fig. 26
Schematic representation of HD symptoms and progression with time.
4.1.2 Behavior of HD mouse models and its assessment
The characteristic late onset of HD pathology makes any attempt to reproduce the
human phenotype within the life span of a mouse particularly challenging. Despite the
limitations, genetic mouse models are the most common HD models used in
behavioural studies since motor, cognitive and psychiatric symptoms, resembling
those seen in patients, are observed in these animals (see Table 1) and a number of
standardized batteries of tests are now available to assess them. A certain grade of
variability exists depending on the type of tests used and also on the characteristics of
the genetic model (CAG repeat number, expression of fragment or full length HTT
and type of insertion of the mutant gene) as well as the specific background strain
(Pouladi et al., 2013). In general, mHTT fragment transgenic models exhibit early
onset and robust behavioral phenotype associated with significant weight loss and
premature death. Although these mice display many of the behavioral and
neuropathological features observed in HD patients, they do not mimic the genetic
disease-initiating mechanism of HD, moreover, the rapid disease progression and the
broad extra-striatal profile of the pathology make detailed analysis of behavior more
difficult (Hickey and Chesselet, 2003). By contrast, knock-in mice which are the most
precise genetic model of HD, show slower, more progressive impairment, allowing a
detailed analysis of behavioural changes (Menalled et al., 2002, Kirkwood et al.,
2001).
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Motor function is found altered in HD mice. This can be assessed in mice by tests of
general locomotor activity such as open-field and running wheel; coordination and
balance such as rotarod, balance beams, swimming, climbing and grip strength; and
sensorimotor gating such as prepulse inhibition (Brooks and Dunnett, 2009). N-
terminal transgenic models generally display an early onset of severe motor
symptoms: R6/2 mice, the most extensively studied and best characterized, show
resting tremor, chorea-like movements, stereotypic involuntary grooming movements,
and dystonia of the limbs (Mangiarini et al., 1996, Stack et al., 2005) which is also
found in patients (Myers et al., 1988, Pratley et al., 2000). Alterations are also
observed in grip strength measurements and in rotarod test starting as early as 40 days
of age (Luesse et al., 2001). Full-length transgenic models such as YAC mice display
more delayed motor symptoms compared to fragment models: in YAC72 mice a
significant impairment in rotarod test is detected not earlier than 16 months (Seo et al.,
2008) and in YAC128 mice around 6–7 months of age (Slow et al., 2003, Van
Raamsdonk et al., 2005b). Knock-in mice often do not display the overt motor
symptoms seen in transgenic models: in HdhQ92, HdhQ111 mice rotarod and gait
deficits are not described until 2 years of age (Trueman et al., 2009, Menalled et al.,
2009, Heng et al., 2007) and in HdhQ140 early mild gait abnormalities are seen at 1
year (Menalled et al., 2003) and subtle rotarod impairment at 4 months (Hickey et al.,
2008). Abnormal sensorimotor gating is also found in HD mice as in human patients.
Reduced PPI is found in R6/2 transgenic mice and this appear as early in disease
progression (Carter et al., 1999).
Cognitive deficits which resemble those in patients are also found in HD mice and
often, as in patients, precede the appearance of overt motor symptoms. Tests such as
Morris water maze, T maze and Y maze (swimming or elevated) as well as operant
chambers, can assess learning and memory dysfunctions in mice. Transgenic fragment
mice such as the R6/2 mice show early cognitive defects by 3.5 weeks of age (Lione
et al., 1999) while in full-length models such as YAC128 mice impairments appear
later at around 8 months (Van Raamsdonk et al., 2005b). Among the knock-in HD
mouse models, HdhQ92 mice show deficits around 10 months while HdhQ150
displayed no learning abnormalities (Heng et al., 2007).
Finally, psychiatric disturbances such as depression and anxiety are also modelled in
HD mice and measured by a number of tests such as forced swim test (FST), tail
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suspension test (TST), open-field test, elevated plus maze (EPM), and others
(Tarantino and Bucan, 2000). Depression-like behaviour is found in female R6/1, in
female HdhQ111 and in YAC128 mice (Pang et al., 2009, Orvoen et al., 2012, Pouladi
et al., 2009). Increase in anxiety-like behaviour is reported in R6/2 transgenic mice
(Menalled et al., 2009); in YAC128 mice (Menalled et al., 2009) and in HdhQ140
mice (Hickey et al., 2008).
In addition to motor, cognitive, and behavioural symptoms, HD mice display also
some of the additional symptoms found in patients such as sleep abnormalities (Fisher
et al., 2013, Kantor et al., 2013); circadian disturbances (Kudo et al., 2011, Davies et
al., 1997) and changes in body weight (Menalled et al., 2009, Phan et al., 2009).
4.2 Hypothesis and aim of the chapter
This chapter aims to detect the onset and progression of potential behavioural
abnormalities in HdhQ140 homozygous mice and correlate them to the
neuropathological changes observed in these mice and described in chapter 3. I
hypothesized that the increased formation of axonal swellings from 6 months of age in
brain areas such as the limbic system particularly relevant for behavior parallels onset
and progression of behavioural symptoms. To this aim, mice were subjected to a
battery of tests specific to assess behavioural dysfunctions linked to alterations in
cortex, striatum or limbic system; in a longitudinal follow-up in order to improve
detection of early changes in these mice. Tests of sensorimotor function included
rotarod, running wheel, open-field and prepulse inhibition; while tests of cognitive
and behavioural included spontaneous alternation, novel object recognition, elevated
plus maze and open-field.
4.3 Results
4.3.1 Locomotor activity is decreased in HdhQ140/Q140 mice but motor balance and
coordination remain normal
First I used the rotarod test accelerated paradigm (see methods) to assess motor
coordination and balance, and motor learning in HdhQ140 homozygous mice. Rotarod
is one of the most commonly used assay to measure motor function in rodents
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(Dunham and Miya, 1957). In addition, overnight running wheel test was used to
measure voluntary locomotor activity during dark phase when mice are most active
(93% of total activity is in dark phase) (Hickey et al., 2008, Hickey et al., 2005, Van
Raamsdonk et al., 2007); and open-field test to assess general locomotor activity in
light phase (Christmas and Maxwell, 1970) (see methods). Mice were tested at 1, 3, 6,
9 and 12 months of age.
Performance in rotarod test was not impaired in HdhQ140 mice compared to C57BL/6
control mice and both genotypes showed an age-dependent worsening of the
performance (Fig. 27). Motor function at day 3 showed no overall genotype effect,
suggesting no alterations in coordination and balance in the KI mice (Fig. 27 A). A
significant effect of genotype was found on motor learning only at 1 month of age
when the latency to fall during the three days of testing (learning curve) was
significantly reduced in HdhQ140 mice compared to control mice (Fig. 27 B). At all
other time-points a non-significant trend to increase was found in the KI mice (Fig. 27
C, D, E, F) compared to control mice, suggesting motor learning function is not
impaired in this mice up to 12 months of age. A significant effect of gender was found
only at 3 months (Fig. 27 C).
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Fig. 27
Rotarod performance is not impaired in HdhQ140/Q140 mice. Latency to fall (min) was measured in three
trials per day over three days of testing. Graphs report the latency to fall at day 3 only with time (A)
and the learning curves at 1 (B), 3 (C), 6 (D), 9 (E) and 12 (F) months. The effect of
gender/genotype/age interactions is reported in the tables for each time-point. (A) Motor function has
no overall genotype effect although at 1 month of age KI perform significantly worse, with no gender
effect. Learning curves reveal a genotype effect at 1 month of age (B) when KI mice perform
significantly worse than WT mice at day 2 and 3 (n = 12-14, mean±SEM, two-way ANOVA with Tuckey
post-hoc test, compared to wild-type, *, P<0.05, ***, P<0.001); while at 3 (C), 6 (D), 9 (E) and 12
months of age (F) no difference is found between genotypes. Only at 3 months of age (C) a significant
effect of sex is found (n = 6-7, mean±SEM, 3-way ANOVA with Bonferroni post-hoc test, compared to
wild-type, *, P<0.05) while at all other time-points data are pulled together (two-way ANOVA). Body
weight was used as covariate in all statistical analyses.
Voluntary wheel running performance showed instead significant difference between
HdhQ140 and relative control mice from 9 months of age with a general trend to
decrease from 3 months. The distance run (km) was significantly reduced in the KI
mouse model compared to WT mice (Fig. 28 A), with a significant effect of gender
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(Fig. 28 A-b), but the speed of run (km/h) was not altered at all the time-points tested
(Fig. 28 B).
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Fig. 28
Running wheel test performance is impaired in HdhQ140/Q140 mice. Mice were singly housed during
dark phase and the distance and the average speed run on a wheel were automatically recorded. The
effect of gender/genotype/age interactions is reported in the tables. A significant genotype effect is
found in the distance run (Km) (A) as KI mice run less than WT mice with a significant difference at 9
and 12 months of age (A-a) (n = 12-14, mean±SEM, two-way ANOVA followed by Bonferroni post-hoc
test, compared to wild-type, **, P<0.01). A gender effect is also found and HdhQ140 females perform
significantly worse than WT females at 9 months (A-b) (n = 6-7, mean±SEM, 3-way ANOVA with
bonferroni post-hoc test, compared to wild-type, *, P<0.5). Average speed (B) is instead unaltered at
all time-points and no effect of genotype is detected (B a). Body weight was used as a covariate in all
statistical analyses.
Weight was considered as a covariate in statistical analysis of rotarod and running
wheel data as it is believed to affect performance. Strain differences in rotarod
performance had been previously correlated with variations in body weight
(McFadyen et al., 2003). Mice were weighed monthly and at the beginning of each
experimental time-point and a significant loss was found at 12 months of age in
HdhQ140 mice compared to controls (Fig. 29 a), with a significant gender effect (Fig.
29 b).
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Fig. 29
Weight loss is significantly higher in HdhQ140/Q140 compared to WT mice. Significant weight loss is
recorded in HdhQ140 mice at 12 months of age (a) (n = 12-14, mean±SEM, two way ANOVA followed
by Bonferroni post-hoc test, compared to wild-type, **, P<0.01, mean±SEM) with a significant gender
effect as both KI females and males weigh significantly less than the corresponding WT (b) (n = 6-7,
mean±SEM, 3-way ANOVA with Bonferroni post-hoc test, compared to wild-type *, P<0.05, ***,
P<0.001). The effect of gender/genotype/age interactions is reported in the tables.
Open-field test confirmed reduced locomotor activity in HdhQ140 mice and this was
detected already at 3 months of age and later (Fig. 30 A-a), with a significant gender
effect (Fig. 30 A-b). Thus, defects in motor activity develop early in these mice, prior
to any detectable sign of pathology and deposition of mHTT aggregates in
corticostriatal neurons (see Fig. 22 C).
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Fig. 30
Locomotor activity is reduced in HdhQ140/Q140 mice on open-field test. Mice were allowed to move
freely in an open-field arena for 30 min and the total distance moved was measured. The effect of
gender/genotype/age interactions is reported in the tables. A significant effect of genotype, gender and
age was found (table). Significant reduction in general locomotor activity is recorded early by 3 months
of age (a) (n = 12-14, mean±SEM, two-way ANOVA followed by Bonferroni post-hoc test, compared to
wild-type **, P<0.01, ***, P<0.001) with difference found both in the KI males and females compared
to the corresponding controls (b) (n = 6-7, mean±SEM, 3-way ANOVA with Bonferroni post-hoc test,
compared to wild-type **, P<0.01, ***, P<0.001). Body weight was used as covariate in all statistical
analyses.
4.3.2 The prepulse inhibition of startle test shows sensory-gating deficits in
HdhQ140/Q140 mice
To assess sensorimotor processes in HdhQ140 mice, I tested animals in the prepulse
inhibition of startle test (PPI) (see methods), measure of sensorimotor gating (Davis,
1980) which is reported to be impaired in several psychiatric disorders and also in HD
patients and mouse models, where disruption of corticostriatal circuits and limbic
system occur (Swerdlow et al., 1995, Geyer et al., 2002).
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Data showed altered peak startle response and latency in HdhQ140 mice compared to
WT controls (Fig. 31). At 3 and 12 months of age startle response was significantly
lower (Fig. 31 A-a) and startle latency was significantly higher (Fig. 31 B-a) in the
HD mice compared to control mice, with a significant gender effect (Fig. 31 A-b, B-
b). PPI results (Fig. 32) showed a significant impairment in HdhQ140 mice compared
to WT controls at 12 months of age (Fig. 32 E), while at all other time-points, an
overall non-significant difference was detected (Fig. 32 A-B-C-D), although
HdhQ140 males performed worse than WT males at 3 and 9 months of age (Fig. 32 B-
b, D-b). These results suggest the presence of abnormal sensorimotor gating in this
HD mouse model which reaches its peak at 12 months of age although some changes
are observed already by 3 months.
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Fig. 31
Acoustic startle response and latency are altered in HdhQ140/Q140 mice. (A-a) Measure of startle
magnitude in response to the 120 dB acoustic peak reveals HD mice have tendency to startle less
compared to the WT and the difference reaches statistical significance at 3 and 12 months of age (n =
12-14, mean±SEM, two-way ANOVA followed by Bonferroni post-hoc test, compared to wild-type, **,
P<0.01, ***, P<0.001). (A-b) A significant gender effect is also found and HdhQ140 males perform
significantly worse than WT males at almost all time-points, while HdhQ140 females are worse only at
12 months of age (n = 6-7, mean±SEM, 3-way ANOVA with Bonferroni post-hoc test, compared to
wild-type, *, P<0.05, ***, P<0.001). (B-a) Average latency to peak startle is increased in HD mice
compared to the WT and this is also significant at 3 and 12 months. (B-b) analysis as a function of sex
shows significant increase in latency in HD males versus WT males at 3 and 12 months and of HD
females at 12 months only. Body weight was used as covariate in all statistical analyses. The effect of
gender/genotype/age interactions is reported in the tables.
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Fig. 32
Prepulse inhibition is altered in HdhQ140/Q140 mice at 12 months of age. At 1 (A), 3 (B), 6 (C) and 9
(D) months of age, no significant impairment in PPI is found in HdhQ140 mice compared to controls (n
= 12-14, mean±SEM, two-way repeated measures). (B-b, D-b) Significant lower % of PPI is found in
HD males compared to WT males (n = 6-7, mean±SEM, 3-way ANOVA with Bonferroni post-hoc test,
compared to wild-type,*, P<0.05). (E-a) at 12 months of age a significant genotype effect is found, with
% of PPI significantly lower in the HD mice compared to the WT for all prepulses, together with a
significant gender effect (E-b). The effect of gender/genotype/age interactions is reported in the table.
Body weight was used as covariate in all statistical analyses.
4.3.3 No impairment in learning and memory is detected in HdhQ140/Q140 mice
with Spontaneous alternation and Novel object recognition tests
Among the cognitive tests which allow assessment of learning and memory, I chose
the Spontaneous Alternation (SA) test and the Novel Object recognition (NOR) task to
detect potential abnormalities in the HdhQ140 mice. These tests provide information
about impairments in cognitive functions mainly controlled by hippocampus and
perirhinal cortex (Wan et al., 1999, Lalonde, 2002).
Results from SA task revealed that all mice alternated arms higher than chance and
that no genotype nor gender effects were found in the percentage of alternation (Fig.
33 a-b), suggesting no deficits in spatial working memory (Deacon and Rawlins,
2006) in the KI mice. However, not surprisingly, the measured number of arm entries
of the HdhQ140 was significantly lower than the one of WT mice from 3 months of
age (Fig. 33 c). These observations suggest reduced locomotor activity and motivation
in these mice which are in agreement with data from the open-field test and overnight
running wheel.
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Fig. 33
Spontaneous alternation in Y-maze shows no impairments in HdhQ140/Q140 mice. Mice were allowed to
freely explore the maze over a period of 5 min and the number of arm entries and the percentage of
alternation were measured. The spontaneous alternation rate was calculated as the ratio of
alternations performed, out of the maximum number of alternations possible, by the total number of
arm entries minus one. The effect of gender/genotype/age interactions is reported in the table. (a)
Alternation performance is not impaired in HdhQ140 mice which do even better than WT mice at 3 and
9 months of age (n = 12-14, mean±SEM, two-way ANOVA followed by Bonferroni post-hoc test,
compared to wild-type, *, P<0.05). (b) KI males overall alternate significantly more than WT males
with a highly significant difference at 3 months (n = 6-7, mean±SEM, 3-way ANOVA with Bonferroni
post-hoc test, compared to wild-type, **, P<0.01). (c) The number of arm entries is significantly lower
in HdhQ140 mice from 3 months onwards (n = 12-14, mean±SEM, two-way ANOVA, *, P<0.05, ***,
P<0.001).
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Data from NOR task also showed that mice performed higher than chance and that
neither spatial memory (Fig. 34 A) nor recognition memory (Fig. 34 B) were impaired
in HdhQ140 mice compared to WT controls at any time-point. No gender effect was
also detected in both trials (tables).
Fig. 34
Novel object recognition task reveals no alterations in spatial or recognition memory in HdhQ140/Q140
mice. Mice were tested in Location and Discrimination tasks where one of the two objects in the arena
was switched location and switched with a different object, respectively. The effect of
gender/genotype/age interactions is reported in the tables. The preference index (preference in
exploring the novel object) showed no significant difference at all time-points between the two
genotypes (A, B) (n = 12-14, mean±SEM, 3-way ANOVA followed by Bonferroni post-hoc test,
compared to wild-type).
4.3.4 HdhQ140/Q140 mice show no anxiety-related behaviour in Open-field and
Elevated plus maze tests
In order to assess behavioural symptoms in our HdhQ140 model, I tested mice in
Open-field and Elevated Plus Maze (EPM) assays. EPM is a well-established
paradigm successfully used to assess anxiety in mice (Holmes et al., 2003, Bailey et
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al., 2007, Pellow and File, 1986) and also open-field test, in addition to general
locomotor activity, can provide information regarding anxiety in rodents (Prut and
Belzung, 2003).
Open field data revealed no overall significant difference in the distance run and in the
time spent in the centre of the arena by the KI mice compared to the controls,
suggesting a non-anxious behavior in HD mice (Fig. 35 A-a, B-a). No overall
genotype or gender effects were found although multiple comparison analysis showed
that at 9 months the distance and time in the centre were significantly lower for
HdhQ140 mice with KI males performing worse than WT males (Fig. 35 A-b, B-b).
However, this difference was not confirmed at 12 months of age.
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Fig. 35
Open-field test reveals no anxiety-like behavior in HdhQ140/Q140 mice. The distance moved (A-a) and
time spent (B-a) by the KI mice in the centre of the open-field arena is not significantly lower than that
spent by the WT controls if not at 9 months (n = 12-14, mean±SEM, two-way ANOVA followed by
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Bonferroni post-hoc test, compared to wild-type, ***, P<0.001) when the KI males do significantly
worse than male WT for both parameters (A-b, B-b) (n = 6-7, mean±SEM, 3-way ANOVA with
Bonferroni post-hoc test, compared to wild-type, *, P<0.05, ***, P<0.001 ). The effect of
gender/genotype/age interactions is reported in the tables. Overall genotype and gender effects are not
detected in this test, suggesting a non-anxious behaviour of the HD mice.
Results from EPM test showed that the time spent in the open unprotected maze arms
and the frequency of entry in those arms are progressively reduced in both genotypes.
At 1 month of age, the time/frequency of HdhQ140 mice was s significantly lower
than that spent of WT controls, suggesting an anxious behavior of KI mice at this
time-point. Overall significant effects of genotype and gender were found. At all other
time-points though, no significant difference between the two genotypes was
appreciated (Fig. 36 C-D). General exploratory behavior, measured by the total
distance moved, and the frequency of entries in all maze arms, were significantly
reduced in the HD mice compared to the WT (Fig. 36 A-B), in agreement with the
above mentioned results from locomotory tests (fig. 28 and 30). These observations
taken together suggest a lack of motivation in initiating an action in the HdhQ140
mice.
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Fig. 36
Elevated Plus Maze test shows anxiety-related behaviour in HdhQ140/Q140 mice at 1 month of age. Mice
were allowed to freely explore the maze over a time of 5 min. The distance moved and the exploratory
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behaviour were recorded. The effect of gender/genotype/age interactions is reported in the tables. The
total distance moved in all arms of the maze is significantly reduced in the KI mice compared to the WT
by 3 months of age (A-a) (n = 12-14, mean±SEM, two-way ANOVA followed by Bonferroni post-hoc
test, compared to wild-type, **, P<0.01) with a significant decrease in HdhQ140 males compared to
WT males (A-b) (n = 6-7, 3-way ANOVA with Bonferroni post-hoc test, compared to wild-type, *,
P<0.05). Same result is found for the frequency of entry in all arms (B-a) with significant decrease
observed also in HdhQ140 females versus WT females at 12 months (B-b), overall suggesting a
reduction in locomotor activity in the HD mice. Time spent and frequency of entry in the open arms is
significantly lower in the KI mice only at 1 month of age suggesting and anxious behaviour in these
mice, while at all other time-points no difference between the genotypes is appreciated (C-a, D-a).
Analysis as a function of sex shows significant lower time spent in the open arms by the HdhQ140
males compared to WT males (C-b) while no differences is found between the females (C-b) as well as
no difference in the frequency of entry in open arms (D-b).
Discussion
In this part of the study I investigated the behavioural phenotype of HdhQ140
homozygous mice. Arguably, analysis of both neuropathological and behavioural
changes is important to fully characterise pathology in mice and to provide a platform
for preclinical assessment of potential therapeutic strategies.
Overall, my results indicate an altered sensorimotor function in HdhQ140 mice, no
abnormalities in cognition with the tests chosen for this study; and an obvious
reduction in general locomotor activity. This seems to be explained by increased
apathy and lack of motivation in starting action more than to motor impairment.
Indeed, coordination and balance, assessed by rotarod test, were unaltered, in
agreement with a previous study reporting no alteration in rotarod performance using
the accelerated paradigm (Hickey et al., 2008). These results are in line with findings
in human HD patients were apathy and lack of motivation are extensively described
(Paulsen et al., 2001, Rosas et al., 2008). Possibly, the reduced latency to fall detected
in these mice at 1 month of age only could be explained by the well documented
hyperactivity of these mice at early age (Menalled et al., 2003). Despite hyperactivity
was not confirmed by the open field tests at this time-point, I noticed a tendency of
HdhQ140 mice to quickly jump off the rod.
Reduced exploratory behaviour found in these mice with the open-field and elevated
plus maze tests seem also be explained by increased apathy more than by increased
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anxiety. An increase in activity in the open arms of the elevated plus maze (duration
and/or entries) or in the central part of the open field arena (distance run and/or time
spent), reflects a non-anxious behavior. Both HdhQ140 and control mice showed no
significant differences in these parameters, suggesting a normal behaviour of KI mice.
This result was unexpected in light of the high number of axonal swellings detected in
HdhQ140 mice at 6 months of age in stria terminalis, a brain area involved in fear and
anxiety. However, we cannot exclude that other specific tests might detect alterations;
and indeed, in the CAG140 mouse model, a previous study reported evidence of
anxiety using light-dark choice (LDC) and fear-conditioning tests (Hickey et al.,
2008).
Sensorimotor abnormalities were also detected in HdhQ140 mice by PPI test, one of
the few paradigms in which humans and rodents are assessed in similar fashion. This
test models pathology in HD patients who also show reduced PPI (Swerdlow et al.,
1995), and in mouse models (Carter et al., 1999) although little or no alterations were
previously described in knock-in HD models (Brooks et al., 2012a, Brooks et al.,
2012b, Menalled et al., 2009). Altered PPI was found at the last time-point of this
longitudinal study, 12 months, together with alterations in peak startle response and
peak latency which were significantly decreased and increased, respectively. These
findings parallel the increase in axonal swellings in corticostriatal projection neurons
described in chapter 3, and may suggest a contributory role of axon degeneration in
these neurons to symptom onset. In support of this, dysfunctions in the corticostriatal
circuitry and limbic system are addressed as possible cause of PPI abnormalities in
HD (Swerdlow et al., 1995).
Finally, cognitive function tests used in this study did not detect impairments in spatial
learning and recognition in HdhQ140 mice at any time-point. This suggests no
functional alterations at the level of hippocampus and perirhinal cortex in these mice
at the time-points considered.
Behavioural abnormalities detected in HdhQ140 homozygous mice in this study were
subtle and occurring late, in agreement with previous studies (Menalled and Chesselet,
2002). Indeed, knock-in models show a slower, more progressive impairment of
behavioral phenotype (Menalled, 2005), in contrast to transgenic mice, particularly
those transgenic mice which overexpress N-terminal fragments of mHTT such as the
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R6/2 line, which show robust motor and cognitive symptoms and rapid disease
progression (Carter et al., 1999, Lione et al., 1999, Stack et al., 2005). In this respect
KI mice often represent a more suitable model to study behavioural symptoms which
in patients progress over a long period of time. In R6/2 mice, possibly due to the high
toxicity of mHTT fragments compared with the full-length protein (Goldberg et al.,
1996, Cooper et al., 1998), death occurs prematurely around 12-15 months. This
makes detailed analysis of behavioural phenotype, as well as that of pathology
progression, more difficult. I have previously shown that little or no morphological
abnormalities in corticostriatal projection neurons or other YFP+ neurons were
detected in R6/2 mice at 3 months of age, final stage of the disease in these mice. This
does not reflect the human condition where axon degeneration is well documented,
together with the minimal loss of striatal neurons which is not representative of the
robust loss observed in patients. The absence of axonal pathology (Fig. 17) and the
little or no neuronal loss reported here (Fig. 16) and in other studies (Mangiarini et al.,
1996, Davies et al., 1997), together with the acute behavioral phenotype of the R6/2
mice, seem to suggest that this is not a faithful model of HD and question the
extensive use of this mice in preclinical testing which often fail in the clinical phase.
HdhQ140/Q140 mice instead showed progressive axon degeneration and the present
behavioral analysis, together with reported studies (Rising et al., 2011, Hickey et al.,
2008), suggests a more progressive onset and course of pathology, which can be of
help in understanding the relationships between neurodegenerative changes in
particular brain areas and symptom onset and progression.
In conclusion, these data suggest sensorimotor defects occur in HdhQ140
homozygous mice before cognitive and behavioural abnormalities. They also reveal
that major impairments occur at late time-point, at 12 months of age, time when also
axon pathology is most striking in these mice. At this time-point, high number of
axonal swellings in corticostriatal projection neurons could contribute to apathy
(Grillner et al., 2008) and abnormalities in PPI (Larrauri and Schmajuk, 2006) as
dysfunctions in frontal-subcortical circuits seem to play a role in both processes
(Bonelli and Cummings, 2007). At 6 months of age, swellings in stria terminalis
could not be related to anxiety-like behaviour which was not detected in the KI mice
with EPM and open-field tests. However, other tests such as PPI suggested possible
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alterations in the limbic system in HD mice and leaves open the possibility that other
tests could detect it.
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CHAPTER 5
Axon pathology and NAD biosynthetic pathway
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5.1 Introduction
5.1.1 NAD biosynthetic pathway and role in neuroprotection
Nicotinamide adenine dinucleotide (NAD) has been known for its important role in
energy metabolism as a co-enzyme for oxidation/reduction reactions for over a
century (Berger et al., 2004). NAD and its phosphorylated (NADP) and reduced
(NADH, NADPH) forms are hydride-accepting and hydride-donating coenzymes and
numerous hydride transfer enzymes or oxidoreductases interconvert either NAD and
NADH or NADP and NADPH to reduce or oxidize small-molecule metabolites
(Berger et al., 2004) (Fig. 37).
Fig. 37
NAD as a coenzyme for reversible hydride transfer. From (Belenky et al., 2007). In a typical NAD-
dependent oxidation, an alcohol is converted to the corresponding aldehyde with the production of
NADH plus a proton. In the NADH-dependent direction, an aldehyde is reduced to an alcohol, which
regenerates NAD.
However, more recent studies have revealed that NAD has also a key role as
signalling molecule in a variety of non-redox reactions. Other than being a cofactor
for oxidoreductases, NAD is also substrate for protein post-translational modifications
such as deacetylation and mono- and poly(ADP-ribosyl)ation and participates in Ca2+
signalling through its derivative nicotinic acid adenine dinucleotide phosphate
(NAADP) and its degradation products ADP-ribose (ADPR) and cyclic ADP-ribose
(cADPR) (Belenky et al., 2007, Berger et al., 2004) (Fig. 38). These reactions regulate
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fundamental cellular processes such as gene expression, cell differentiation, apoptosis,
aging, circadian rhythm, inflammation and neurodegeneration, thus a strong interest in
the enzymes involved in NAD biosynthesis and the signalling mechanisms
downstream NAD synthesis has been growing in the past few years.
NAD synthesising enzymes and role in neuroprotection
NAD synthesis takes place through the “de novo pathway”, which produces NAD
from quinolinic acid (QA), and through the “salvage pathways” which produce the
dinucleotide starting either from nicotinic acid (NA), nicotinamide (NAM) or
nicotinamide riboside (NR) (Fig. 38).
Alterations in the de novo pathway are reported in HD. In post-mortem HD human
brains, the levels of the kynurenic acid, precursor of QA, are found decreased (Beal et
al., 1990, Beal et al., 1992) while the levels of 3-hydroxykynurenine (3-HK) and QA
increased (Pearson and Reynolds, 1992, Guidetti et al., 2004). QA is an excitotoxic
NMDAR agonist and in vivo injections cause selective degeneration of MSSNs that
can partially model HD (Beal et al., 1991, Beal et al., 1986). In R6/2 mice, also
elevated 3-HK and increased activity of the biosynthetic enzyme of 3-HK, Kynurenine
3-monooxygenase (KMO) are detected (Guidetti et al., 2006, Sathyasaikumar et al.,
2010). Altered levels of these metabolites seem to play a role in neurodegeneration in
HD; For example, pharmacological or genetic inhibition of the KMO increases levels
of the neuroprotective metabolite kynurenic acid relative to the neurotoxic metabolite
3-HK and ameliorates neurodegeneration in a Drosophila (Campesan et al., 2011) and
a mouse model (Giorgini et al., 2013). However, the consequences of blocking KMO
on NAD metabolism have not been investigated.
133
Fig. 38
Mammalian NAD metabolic pathways. From (Hassa et al., 2006).
For most cells in mammals the salvage pathway from NAM is the most relevant (Di
Stefano and Conforti, 2013). The enzyme nicotinamide phosphoribosyltransferase
(NAMPT), which catalyses a rate-limiting step in this pathway (Revollo et al., 2004),
is involved in several physiological functions (Imai and Kiess, 2009, Yang et al.,
2006). NAMPT is found in both nucleus and cytoplasm where NAMPT-mediated
NAD biosynthesis plays a critical role in the regulation of the NAD consuming
enzymes Sirtuin1 (SIRT1) and mitochondrial Sirtuin3 (SIRT3) and Sirtuin4 (SIRT4)
(Imai, 2009, Donmez and Outeiro, 2013). In a model of stroke NAMPT was shown to
protect against neuronal death through activation of SIRT1-dependent adenosine
monophosphate-activated kinase pathway (AMPK), suggesting NAMPT as a new
therapeutic target for stroke. NAMPT levels decline with age (Liu et al., 2012) and
this could lead to neurodegeneration.
All salvage pathways share the common final step catalysed by the enzyme NMNAT.
In humans, three different NMNAT isoforms (NMNAT1, 2 and 3), differing in their
oligomeric state, subcellular localization and catalytic properties, have been identified
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and characterized (Berger et al., 2005). NMNAT1 is mainly localised in the nucleus
while NMNAT2 and 3 are associated with Golgi apparatus and mitochondria,
respectively.
NMNAT1 and WldS
Studies on WldS mouse, a spontaneous mutant mouse with delayed axonal
degeneration of transected nerves (see chapters 1.7 and 1.8) have elucidated some of
the mechanisms responsible for its protective phenotype. The WLDs protein contains
the amino (N)-terminal 70 amino acids (N70) fragment of the ubiquitination factor
E4B (UBE4B), the complete sequence of the enzyme nicotinamide
adenylyltransferase 1 (NMNAT1); and a linking portion of 18 AA originally
belonging to the 5’ untranslated region of the Nmnat1 gene (Fig. 7). Studies of
structure-activity relationship have demonstrated that the enzymatic activity of
NMNAT1 is required for axon survival (Conforti et al., 2009). Moreover, they showed
that this activity needs to be present in axons to confer protection as shown that
nuclear NMNAT1 does not affect axon degeneration even when over-expressed
(Conforti et al., 2007b, Conforti et al., 2011, Cohen et al., 2012). Following
redistribution of WLDs to the axon, through the binding of VCP protein to the N16
region of the protein, the nuclear NMNAT1 can function in the axon and confer the
protective phenotype (Conforti et al., 2009, Avery et al., 2009). How NMNAT activity
exerts its protection is still not fully clarified. While initially an increase in NAD
levels was believed to be responsible for neuroprotection (Araki et al., 2004, Wang et
al., 2005), more recent studies have demonstrated its independence from NAD
production, suggesting an alternative role for NMNAT enzymatic activity in the axon
(Conforti et al., 2007b, Sasaki et al., 2009b). Moreover, neuroprotective effects could
be mediated by different mechanisms of action not related to enzyme activity. In a
Drosophila model of spinocerebellar ataxia 1 (SCA1), Zhai and collaborators showed
that NMNAT functions as a chaperone in protecting neuronal degeneration
independently from its NAD-synthesis activity (Zhai et al., 2008, Zhai et al., 2006);
and in a Drosophila model of frontotemporal dementia with parkinsonism linked to
chromosome 17 (FTDP-17), overexpression of NMNAT significantly ameliorated
behavioural deficits and morphological neurodegenerative changes associated with
tauopathy. In this fly model, NMNAT reduces the level of hyperphosphorylated tau
and promotes ubiquitylation and clearance of the toxic tau oligomeric species (Ali et
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al., 2012). In a mouse model, overexpression of NMNAT1 and NMNAT2 promotes
clearance of hyperphosphorylated tau and reduces neurodegeneration (Ljungberg et
al., 2012).
NMNAT2
The role of WLDs in the axon is emerged from a recent study in which
downregulation of NMNAT2, the endogenous isoform of NMNAT in the axon,
caused spontaneous degeneration of not injured-axons, indicating that NMNAT2 acts
as an endogenous survival factor (Gilley and Coleman, 2010). NMNAT2 is
synthesised in the cell bodies and constantly delivered to the axon and axon terminal
by fast axonal transport. However, it has a short half-life and when axons are injured
or axonal transport is impeded, its axonal levels quickly decrease triggering
degeneration and neither NMNAT1 nor NMNAT3 can compensate for the loss of
NMNAT2 (Milde et al., 2013c, Gilley and Coleman, 2010, Gilley et al., 2013). In
addition, NMNAT2 is required for normal axon growth in embryos (Gilley et al.,
2013, Hicks et al., 2012). NMNAT2 is also neuroprotective in models of
neurodegeneration; in mouse models of human tauopathies, NMNAT2 gene
transcription is decreased while its over-expression ameliorates the pathology
(Ljungberg et al., 2012). In WldS mice, the NMNAT1enzymatic activity of the WLDs
protein, when relocated to the axon, may compensate for loss of NMNAT2
maintaining axonal integrity (Conforti et al., 2009, Beirowski et al., 2009, Babetto et
al., 2010, Gilley and Coleman, 2010, Gilley et al., 2013, Conforti et al., 2014).
NMNAT1 is a more stable isoform and its action could explain the protective
phenotype in these mice.
The role of NMNAT1 and 2 in neurodegeneration/protection in HD is not clear. HTT
and the WLDs protein, which contains the entire NMNAT1 sequence (see above),
share a common binding partner, the abundant cellular protein VCP/p97 (Hirabayashi
et al., 2001); and WLDs preferentially distributes to nuclear foci resembling the
localisation of mHTT aggregates. Moreover, VCP/p97 has been shown to be involved
in clearance of polyubiquitylated aggregates and to reduce aggregate toxicity
(Kobayashi et al., 2007). In addition, both HTT and NMNAT2 are palmitoylated.
Palmitoylation of NMNAT2 at cysteine 164 and 165 is responsible for its association
to Golgi vesicles, which is required for its axonal transport. In the absent of the
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cysteine residues, NMNAT2 adopts a more diffuse cytosolic localisation (Milde et al.,
2013c). HTT is palmitoylated at cystein 214 by HIP14 (see chapter 1.4) and this is
essential for its trafficking and function (Yanai et al., 2006). Thus, the possibility
raises that HTT and NMNAT2 are transported with the same vesicles and that mHTT
could alter this normal process.
NAD consuming enzymes
In non-redox reactions, breakdown of NAD molecule is carried out by three classes of
enzymes which cleave NAD to produce NAM and an ADP-ribosyl product (Fig. 38
and 39): ADP-ribosyl cyclases, that use NAD as a substrate to generate ADP-ribose
and cyclic ADP-ribose (cADPR) (Lee, 2001); mono(ADP-ribose) transferases (ARTs)
and poly(ADP-ribose) polymerases (PARPs) that use NAD to add one or more ADP-
ribosyl groups to target proteins (Lautier et al., 1993); and Sirtuins (SIRTs) that have
both mono-ribosyl transferase and deacetylase activity consuming one NAD for every
ADP-ribosyl group they transfer to or every acetyl group they remove from a protein
substrate (Tanner et al., 2000).
cADPR produced by the cyclases acts as a second messenger and participates in
cytosolic Ca2+ regulation by binding to specific receptors on the surface of the
endoplasmic reticulum. This results in Ca2+release from intracellular stores (Galione,
1993). The activity of these enzymes is regulated by nitric oxide or glutamate
activation and hyperactivation of these enzymes in diseases such as neurodegenerative
disorders leads to rapid depletion of NAD (Balan et al., 2010) and increase in Ca2+
release that activates axonal proteases leading to axon degeneration in vitro (Stirling
and Stys, 2010).
PARPs are key enzymes involved in DNA repair in response to DNA breakage and
oxidative stress. Among the 17 PARP members, PARP1 is the first and best
characterised. It has been related to caspase-independent cell death as its hyper-
activation causes significant depletion of NAD and associated cell death (Hassa et al.,
2006, Chiarugi, 2002). Hyper-activation occurs in many pathophysiological situations
such as excitotoxicity, ischemia, and oxidative stress, when DNA damage is
extensive. Thus PARP1 inhibition or genetic inactivation has proved to be beneficial
in mouse models of ischemia (Chiarugi, 2002, Virag and Szabo, 2002) and
neurodegenerative disorders (Liberatore et al., 1999).
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In mammals, the NAD-dependent histone deacetylases (HDAC) Sirtuins are a group
of 7 enzymes (SIRT1–7) involved in major cellular processes, including
transcriptional silencing, DNA repair, DNA recombination and lifespan regulation
(Imai and Guarente, 2010). These enzymes have protective effects against age-related
diseases such as cancer, diabetes, cardiovascular and neurodegenerative diseases and
therefore promising targets for therapeutic interventions (Donmez and Outeiro, 2013).
In a C. elegans model of HD, up-regulation of the nuclear SIRT1 or treatment with
resveratrol, a natural SIRT1 activator (Tadolini et al., 2000, Belguendouz et al., 1997),
were found to rescue neurons from mHTT-induced toxicity and beneficial effects of
resveratrol were also found in a KI mouse model, the HdhQ111 (Parker et al., 2005).
In a study on N171?82Q mice, overexpression of SIRT1 improved motor function,
decreased brain atrophy, and attenuated the metabolic abnormalities and decline in
BDNF concentration induced by mHTT (Jiang et al., 2012). In the same study mHTT
was found to interact with SIRT1 and to inhibit its deacetylase activity, which
prevents its pro-survival function. In the R6/2 mouse model, brain-specific knock-out
of SIRT1 resulted in exacerbation of pathology whereas its overexpression improved
survival (Jeong et al., 2012). SIRT2 has also been implicated in neurodegeneration
and recent data have shown that its suppression ameliorates neurotoxicity in a variety
of neuronal disease models such as HD (Pallos et al., 2008) and PD (Outeiro et al.,
2007). SIRT2 is present mainly in the cytoplasm where it colocalises with
microtubules and deacetylates the major component of microtubules ?-tubulin (North
et al., 2003) and plays a role in microtubule stability. The role of SIRT2 has also been
investigated in HD and, in contrast to SIRT1, its inhibition is found to be beneficial.
Indeed, inhibition of HDAC is neuroprotective. In an in vitro study, inhibition of the
microtubule deacetylase 6 (HDCA6), enhanced MT-dependent transport through the
recruitment of the molecular motors dynein and kinesin-1 to microtubules and rescued
axonal transport defects in HD neurons (Dompierre et al., 2007). In a study on
cerebellar granule cells from WldS mice, microtubule acetylation was found increased
together with decreased cytoplasmic levels of NAD and SIRT2; and SIRT2
overexpression abolished the protection from axon degeneration induced by
colchicine, suggesting that SIRT2-mediated tubulin deacetylation is involved in both
microtubule hyperacetylation and resistance to axonal degeneration in WldS granule
cells (Suzuki and Koike, 2007). However, in this study the link between WldS and the
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decrease of NAD and SIRT2 remains unclear and would need further investigation. In
a fly model of HD, decreased levels of SIRT2 promoted the viability of photoreceptor
neurons (Pallos et al., 2008) and in cellular and invertebrate models its
pharmacological inhibition resulted in neuroprotection through a negative regulation
of sterol biosynthesis (Luthi-Carter et al., 2010).
Fig. 39
NAD consuming enzymes. From (Belenky et al., 2007). NAD as a substrate for ADP-ribose transfer,
cADP-ribose synthesis and protein lysine deacetylation. (a) ARTs and PARPs transfer ADP-ribose
from NAD as a protein modification with production of Nam. In the case of PARPs, the ADP-ribose
acceptor, X, can also be ADP-ribose, forming poly(ADP-ribose). (b) cADP-ribose synthases cyclize the
ADP-ribose moiety of NAD with production of Nam. These enzymes also hydrolyze cADP-ribose. (c)
Sirtuins use the ADP-ribose moiety of NAD to accept the acetyl modification of a protein lysine,
forming deacetylated protein plus Nam and, after acetyl-group rearrangement, a mixture of 20 and 30
O-acetylated ADP-ribose. Each NAD-consuming enzyme is inhibited by the Nam product.
All this evidence reveals the importance of NAD biosynthetic pathway in
physiological and pathological conditions and in particular its contribution to
139
neuroprotection. Thus, therapeutic strategies targeting the key enzymes in this
pathway could have useful effects in several neurodegenerative disorders.
5.2 Hypothesis and aim of the chapter
In this chapter, the involvement of NAD biosynthetic pathway and its correlation to
HD pathology is assessed in HdhQ140/Q140 mice. Alterations in NAD biosynthesis have
been recently linked to axon survival and axon and synapses degeneration in many
neurodegenerative disorders. In HD patients, altered levels of NAD precursors in the
de novo synthetic pathway are reported (Beal et al., 1990, Guidetti et al., 2004).
Moreover, HTT and NAD synthesizing enzymes share common binding partners.
Based on this evidence, I hypothesized dysregulations in NAD metabolism in my HD
mouse model as a consequence of the presence of mHTT which could aberrantly
interact with the NAD synthesizing enzymes and interfere with their normal function.
5.3 Results
5.3.1 Striatal levels of NMN significantly increase with age
To assess alterations in NAD biosynthesis in HdhQ140/Q140 mice, which showed axon
pathology by 6 months of age, I first analysed the levels of NAD and its precursor
nucleotide NMN in cortex and striatum of 6 and 12 month old animals (Fig. 40).
These levels were measured in brain homogenates by fluorimetric HPLC. Results
showed no difference in the levels of NMN between the two genotypes but,
interestingly, a significant increase was found in the striatum at 12 months, compared
to 6 months of age, in both KI mice and control littermates (Fig. 40 A). In the cortex
instead, a trend to decrease in NMN levels was detected in WT mice with time (Fig.
40A). In parallel, NAD decreased in both genotypes although this trend did not reach
significant difference with the n number available (Fig. 40 B). Consequently, the
calculated NAD/NMN ratio fell, reaching a significantly decreased value in HdhQ140
mice at 12 months of age (fig. 40 C).
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Fig. 40
NMN significantly increases in the striatum with age. The levels of NMN and NAD were measured in
cortical and striatal brain homogenates of 6 and 12 month old HdhQ140 and relative control mice. (A)
Significant increase is found in striatal NMN levels at 12 months of age in both genotype and (B) NAD
levels show a trend to decrease with age in both genotypes. (C) NAD/NMN ratio is significantly
reduced in HdhQ140 mice with age (n=5-8, mean±SEM, one-way ANOVA followed by Bonferroni post
hoc test, **, P<0.01, ***, P<0.001).
Next, I measured the enzymatic activity of NMNATs enzymes to assess whether
increased levels of NMN and reduced levels of NAD were due to reduced NMNAT
enzymatic activity with age and also if there were differences between HdhQ140 and
control mice. The low number of samples (n = 2) available for this analysis did not
allow statistical analysis however, a trend to decrease was observed in the cortex of
HdhQ140 mice at 12 months compared to 6 months of age. No gross difference
between KI and WT mice was instead appreciated (Fig. 41).
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Fig. 41
NMNAT enzymatic activity is unaltered in HdhQ140/Q140 mice. The total enzymatic activity of NMNATs
was measured in cortical and striatal brain homogenates of 6 and 12 month old HdhQ140 mice and
control littermates. No significant difference is found between the genotypes although a trend to
decrease is appreciated in the cortex of HdhQ140 mice at 12 months compared to 6 months of age. (n
= 2, mean±SD).
I also measured the levels of nicotinamide phosphoribosyltransferase (NAMPT), the
enzyme immediately upstream of NMNAT in the NAD salvage pathway, in cortex
and striatum of 6 and 12 months HdhQ140 mice and relative controls by Western blot
(Fig. 42). Despite NAMPT levels remained stable between genotypes, a trend to
decrease was observed with age in both cortex (Fig. 42 A) and striatum (Fig. 42 B)
and in the cortex of WT mice. In these mice, NAMPT decrease, consistent with
published observations (Liu et al., 2012), could explain the trend to a reduction in
cortical NMN levels observed with HPLC.
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Fig. 42
NAMPT levels are unaltered in HdhQ140/Q140 mice. Western Blots of mouse brain homogenates probed
??????????????????????????????????????????????????????????????????????????? was used as a loading
control in all blots (kDa 42). Quantitative analysis of blots from (A) cortical and (B) striatal brain
homogenates of 6 and 12 month old HdhQ140 mice and control littermates show no significant
difference of NAMPT levels in HdhQ140 mice compared to WT mice. Also the decrease in NAMPT
levels with age does not reach statistical significance with age (n = 4, mean±SEM, one-way ANOVA
followed by Bonferroni post hoc test).
5.3.2 mHTT and NAD biosynthetic enzymes: possible interaction and altered
axonal transport
In parallel to the study on HD mouse brains, I used cellular models of HD to
investigate whether HTT/mHTT interacts with the NAD synthesizing enzymes.
Despite the little differences found between HdhQ140 and control mice in the level of
nucleotides and enzymes involved in this pathway, interaction between these enzymes
and mHTT could contribute to axon degeneration. In addition, WLDs retains the
sequence of NMNAT1 and NAD biosynthetic activity.
mHTT colocalises with WLDs but not with NMNAT1 in the nucleus of PC12 cells
First, I looked at possible colocalisation between mHTT and WLDs protein in the
nucleus of Tet-ON PC12 cells. As mentioned in the introduction to the chapter, both
HTT and WLDs bind to VCP/p97 and WLDs preferentially distributes to nuclear foci
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resembling the localisation of mHTT aggregates, thus opening the possibility of an
interaction between the two proteins.
Tet-ON PC12 Q72 cells were transfected with WldS and, on the same day, treated with
doxycycline to induce mHTT expression and aggregate formation and imaged 3 days
after transfection. Confocal images confirmed a colocalisation between WLDs and the
nuclear mHTT aggregates (Fig. 43).
Fig. 43
WLDs colocalises with nuclear mHTT aggregates. Confocal images (63X) of PC12 Q72 cells
transfected with WldS in DsRed vector and treated with doxycycline to induce mHtt aggregates
formation. Some cells show colocalisation between mHtt aggregates and WLDs in the nucleus (arrows).
(a) red: WLDs? ??? ?????? ????? ??? ????? ???????? ??? ?????? ????????? ????? ???? ?????
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Then I checked whether colocalisation extended also to the NMNAT1 component of
WLDs underlying possible interaction. In the nuclei of Tet-ON PC12 Q72 cells, an
NMNAT1-DsRed vector fusion protein showed a discrete distribution in nuclear foci.
This could reflect an association of NMNAT1 with specific sub-nuclear domains,
although we cannot exclude mis-localisation due to the overexpression of the DsRed
fusion protein (Laser et al., 2006, Wilbrey et al., 2008). NMNAT1-DsRed did not
colocalise with mHTT aggregates (Fig. 44) which remained in different pools,
possibly suggesting that the full WLDs sequence is needed for the interaction and
further studies should address this.
Fig. 44
NMNAT1 does not colocalise with nuclear mHTT aggregates. Confocal images (63X) of Tet-ON
PC12 Q72 cells transfected with Nmnat1 in DsRed vector (arrows) show no colocalisation with mHTT
aggregates. ?????????????????????????????????????????????????????????
WLDs overexpression does not increase percentage of projections and healthy nuclei
in mHTT expressing cells
Previous studies have shown the toxic effect of mHTT aggregates on an inducible
model of PC12 cells (Wyttenbach et al., 2000, Wyttenbach et al., 2001). This has been
recently confirmed in a study from our laboratory which showed that mHTT
aggregates significantly reduce the number of neuritic projections and unhealthy
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nuclei (Othman, Pardon and Conforti, unpublished). An interaction between WLDs
and mHTT aggregates could play a role in aggregate formation and toxicity and
provide insights into the feasibility to investigate a potential protective effect of the
WLDs protein in HD.
I explored the possibility that expression of WLDs could rescue the toxic effect of
mHTT aggregates on Tet-ON PC12 cells and restore normal neuritic formation. To
this aim, Tet-ON PC12 with an expanded CAG repeat (PC12 Q72) treated with
doxycycline to express mHTT, were transfected with constructs encoding for a WLDs-
DsRed fusion protein and, 3 days after transfection, the number of projections (Fig. 45
A) and the number of Hoechst-stained healthy nuclei (Fig. 45 B), were counted over
the total number of transfected cells. Cells transfected with DsRed vector, for
expression of the red fluorescence protein only, were used as control. Unexpectedly,
overexpression of WLDs in PC12 cells revealed a toxic effect and caused a decrease in
cell viability (Fig 45 B). WLDs expression did not result in a higher percentage of
projections and healthy nuclei compared to the controls without WLDs.
Fig. 45
WLDs overexpression is toxic in PC12 cells. Tet-ON PC12 Q72 cells were transfected with WldS in
DsRed vector and after 3 days the number of cells with neurites was counted over the total of
transfected cells as well as the number of healthy DAPI-stained nuclei over the total transfected. Cells
transfected with DsRed only were used as control. WLDs does not increase the number of neuritic
projections neither the percentage of healthy nuclei in cells expressing mHTT. However, WLDs
overexpression reduces viability in Tet-ON PC12 cells Q72 (n = 3, mean±SEM, one-way ANOVA
followed by Bonferroni post hoc test,*, P<0.05, ***, P< 0.001).
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mHTT colocalises with NMNAT2
To study possible colocalisation between mHTT and NMNAT2, the endogenous
NMNAT isoform present in axons, I first looked at a possible colocalisation between
the two proteins in HEK293 cells, using the synthetic plasmid (pARIS-htt) expressing
full-length human HTT with either normal or expanded CAG repeat (Fig. 46) (Pardo
et al., 2010). Given the large size of the full-length HTT construct, we used HEK cells
where a high efficiency of transfection can be obtained. Cells were cotransfected with
plasmids encoding NMNAT2-EGFP and pARIS-htt(Q20/Q100)-mCherry and imaged
2 days after transfection. Confocal images suggested that both wild-type and mutant
HTT were enriched at a perinuclear location consistent with that of the Golgi
apparatus, where they colocalised with NMNAT2 (Fig. 46). Indeed, as reported in
(Pardo et al., 2010) pARIS-htt constructs conserve the region of HTT necessary for
Golgi association.
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Fig. 46
NMNAT2 colocalises with both wild-type and mHTT in HEK293 cells. Confocal images (63X) of
HEK293 cells, cotrasfected with NMNAT2-EGFP and (A) full-length pARIS-httQ23-mCherry and (B)
full-length pARIS-httQ100-mCherry, reveal proteins colocalise in a perinuclear formation, suggestive
of Golgi structure (arrows), independently from the CAG repeat length. (a) Red: pARIS, (b) green:
?????????????????????????????????????????????????????????????????
Next, I microinjected the same plasmids in dissociated SCGs to study colocalisation in
the axon. Dissociated SCGs have the advantage to extend long projections allowing
the study of axonal transport of fluorescent molecules. Red fluorescence was absent in
neurites and weak in cell bodies, possibly due to the lower efficiency of transfection
and expression of the large HTT expressing constructs in these cells. I then
microinjected SCGs with shorter versions of pARIS expressing only the N-terminal
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part of human HTT with normal or expanded CAG number (pARIS htt 1-586-
Q23/Q100). These fragment constructs still retained the palmitoylation site important
for vesicle association which is likely to contribute to the colocalisation with
NMNAT2 at the Golgi. Confocal images acquired on the day following the
microinjection, showed expression of the fragment HTT in both cell body and axons
(Fig. 47 and 48 A) and confirmed colocalisation with NMNAT2 in the cell body (Fig.
47).
Fig. 47
NMNAT2 colocalises with both wild-type and mHTT in the cell body of SCGs. Fluorescent images
(100X) of dissociated SCGs co-injected with NMNAT2-EGFP and (A) pARIS htt 1-586-Q23-mCherry
or (B) pARIS htt 1-586-Q23-mCherry reveal colocalisation between the two proteins (arrows),
independently from the CAG repeat length. (A) Red: pARIS, (B) green: NMNAT2, (C) merged channels.
Scale bar, 10 μm.
HTT is important for axonal transport and mHTT disrupts this process, therefore I
tested whether overexpression of HTT and mHTT could affect axonal transport of
NMNAT2, which is essential for axon maintenance.
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I studied the movement of NMNAT2 fluorescent molecules along the axons of
dissociated SCGs microinjected with N-terminal-httQ20/Q100 pARIS-mCherry and
NMNAT2-EGFP, to determine any potential change in NMNAT2 transport due to the
expression of these proteins. Time-lapse imaging and video analysis were carried out
as described in section 2.5.7. No significant difference neither in NMNAT2 particle
speed nor in the particle count and % of moving particles/frame, in the presence of
mHTT compared to wild-type HTT, was found upon analysis using Difference tracker
ImageJ plugin (Andrews et al., 2010) (Fig. 48 and suppl. video 2). However, a trend to
increase of all parameters was found in the presence of mHTT, possibly suggesting
abnormal axonal transport. Analysis of a larger number of axons is needed to confirm
these observations.
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Fig. 48
Axonal transport of NMNAT2 is not significantly altered in the presence of mHTT. (A) Fluorescent
image (100X) of dissociated SCGs co-injected with NMNAT2-EGFP and pARIS-htt 1-586-Q100-
mCherry. (a) green: NMNAT2-EGFP, (b) red: pARIS htt 1-586-NQ100-mCherry, (c) merged channels.
Scale bar, 10 μm. Analysis of time-lapse videos shows no significant changes neither in NMNAT2
particle speed (B) nor in number of particle and % of moving particles/frame (C, D), in the presence of
HTTQ100 compared to HTTQ23, however a trend to increase is found in the presence of mHTT (n = 4,
mean±SEM, unpaired Student’s t-test).
5.4 Discussion
Results from this part of the study revealed altered NAD metabolism in mice.
Genotype differences were not detected in brain samples but in HD cellular models
potential interaction of mHTT with NAD synthesizing enzymes, which could alter
normal enzyme trafficking and function, might contribute to axon pathology.
NAD role in axon protection has been questioned by several studies and unpublished
data from our lab suggest that an increase in NMN, rather than an increase in NAD,
underlines the protective effect of NMNAT and WLDs (Di Stefano et al.,
unpublished). Interestingly, NMN as well as quinolinic acid, both NAD precursors,
exert a toxic role. In this context, increased NMN levels detected in HD and control
mouse brain striata at 12 months of age could contribute to the pathological changes
observed in axons. Indeed, in many age-related neurodegenerative diseases or during
normal ageing, widespread axonal swellings are visible (Adalbert and Coleman,
2012). In analogy to injured axons, where loss of NMNAT2 initiates a pro-axon death
pathway, a decline in axonal transport during aging which could be exacerbated in
disease, could also lead to reduced delivery of NMNAT2 and consequent rise in NMN
levels in axons. Indeed a decrease in axonal transport of mitochondria and synaptic
vesicles during aging and in disease is described (Kimura et al., 2012, Gilley et al.,
2012, Adalbert and Coleman, 2012). NAD decrease between 6 and 12 months of age
in both genotypes, despite this does not reach statistical significance with this group
size, consistent with the idea that NMNAT2 may be in limited supply in older
animals.
Importantly, these results also reveal a regional alteration in nucleotide levels as the
increase in NMN was found significant only in the striatum and not in the cortex.
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Previous studies described a regional reduction in NAD synthesis in aged animals
(Mouchiroud et al., 2013, Massudi et al., 2012), confirming the importance of
analysing single brain areas to spot local deficiencies which could be missed in the
whole-brain due to the heterogeneity of cell types and structures. The alteration of
NAD metabolism in striatum could contribute to the increased susceptibility of this
brain area to degeneration in HD.
HD mutation seems not to contribute to alterations in the NAD biosynthetic pathway
at the age of analysis. However, as KI mice have a normal lifespan and slow onset and
progression of pathology, we cannot exclude that nucleotide levels at later stage of the
disease could be altered in these mice with respect to the controls.
The increase in NMN and decrease in NAD was accompanied by little reduction in
NMNAT total enzymatic activity with age but this analysis was carried out only in
few samples; thus, further investigation with larger number might detect a significant
reduction. Moreover, our analysis considered only the total NMNAT enzymatic
activity, while alterations in one specific isoform are difficult to detect and cannot be
excluded. Alternatively, we have to consider that the enzymatic activity in vitro might
not be the same as in vivo where a much higher reduction in NMNAT activity could
be observed.
qRT-PCR analysis of expression levels of NMNAT1, 2 and 3 and NAMPT, carried
out by other members of the laboratory (Othman et al., unpublished), found no
differences between HdhQ140 and control mice suggesting no transcriptional
dysregulation of this enzymatic pathway in HD, however post-translational regulation,
which is not taken into consideration by this technique, could be altered and affect
enzyme turnover or functionality.
I also detected a trend to a decrease in NAMPT in both genotypes and in both brain
areas, consistent with published observations (Imai, 2010). In WT mice, decrease in
NAMPT levels could explain the reduction in NMN in the cortex.
Interesting results also come from studies on cell models. In a Tet-ON PC12 cell
model of HD, mHTT aggregates colocalise with the UBE4B/NMNAT1 fusion protein
WLDs but not with NMNAT1, suggesting that the full-length sequence of WLDs is
required for the interaction. More experiments are required to assess if actual
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interaction is occurring between the two proteins and whether this is direct or indirect
via a common binding partner. Possibly, the N16 binding site for VCP/p97, protein
which also binds to expanded polyQ-containing proteins (Hirabayashi et al., 2001), is
necessary for the interaction. In Tet-ON PC12 cells, WLDs expression is toxic for the
cells at the concentration used for transfection. This is surprising in view of the
several reports of a beneficial effect of WLDs in axons and cell bodies in in vivo and
in vitro models of disease (Coleman and Freeman, 2010). Further studies are needed
to elucidate the mechanism of this toxicity.
Colocalisation between mHTT and NMNAT2 was instead studied in HEK293 cells
and disassociated SCGs. Since NMNAT2 is a cytoplasmic protein transported by fast
axonal transport, dissociated SCGs, which can extend long neurites, represented a
good preliminary model to study colocalisation in the axon and possible alterations in
its transport due to mutant HTT. Colocalisation was found in the cell body while in
the axon, a diffuse distribution of mHTT which possibly requires a longer time after
transfection to form aggregates, made it impossible to establish whether this was
present at the level of the well visible NMNAT2 vesicles. Despite these results, a co-
transport of mHTT and NMNAT2 on the same vesicles is likely to occur as both
proteins contain palmitoylation sites crucial for association to Golgi membranes
(Yanai et al., 2006). Moreover, it has been recently reported that the glycolytic
enzyme glyceraldehyde-3-phosphate dehydrogenase (GADPH) located on fast moving
vesicles provides local energy critical for fast axonal transport and that HTT is
important to scaffold GADPH on vesicles (Zala et al., 2013). NMNAT2 in these
vesicles could provide local NAD pool for the action of GADPH enzymes. In the
presence of mHTT, altered scaffolding function could play a detrimental role on FAT
axonal transport of NMNAT2, although further investigations are needed to assess
whether NMNAT2 is present in GADPH-containing vesicles.
Analysis of NMNAT2 axonal transport in these cells did not detect significant
difference in speed, particle count or percentage of moving particle, in the presence of
mHTT compared to wild-type HTT. However, a trend to increase was found in the
presence of the mutant protein. A reduced detachment of NMNAT2 from vesicles in
the presence of overexpressed mHTT; and a consequent alteration of NMNAT2 de-
palmitoylation and detachment could be hypothesised. Non-vesicular, cytosolic
NMNAT2 is more stable and more protective than the vesicle-associated form, thus its
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reduction could play a role in axon degeneration (Milde et al., 2013b, Milde et al.,
2013a). Further studies are needed to confirm this result and explore the mechanisms
of mHTT toxicity.
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CHAPTER 6
Conclusive remarks and future directions
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In this thesis I have explored several aspects of the HD pathology with a particular
focus on axon pathology during disease progression in relation to behavioural
abnormalities, using a variety of cell biology, biochemistry and
immunohistochemistry methodologies and behavioral analysis. I have demonstrated
that age-dependent axonal swellings are an early feature of HdhQ140 homozygous
mice crossed to YFP-H; that behavioural abnormalities also worsen with age and I
have given insights into the possible mechanisms underlying these neurodegenerative
changes. These findings initiate many avenues for further investigation, some of
which have been discussed in the previous chapters.
The data illustrated in chapter 3 strongly suggest that axonal pathology in HdhQ140/Q140
mice precedes dysfunction of other neuronal compartments and occurs in the form of
axonal swellings in otherwise continuous axons and healthy looking soma, supporting
the idea of still metabolically active cell bodies and continued axonal transport. This
raises the prospect of a therapeutic window for functional rescue of individual neurons
after formation of swellings and before cell body death, as suggested also for other
neurodegenerative disease models (Adalbert et al., 2009). Moreover, as early axonal
swellings in still continuous axons are shared by different models, therapeutic
intervention could be useful for the treatment of several neurodegenerative diseases.
Indeed ample evidence suggests that WLDs protects from axon degeneration in many
disease models (Conforti et al., 2014). Therefore, it would be of great interest to cross
HdhQ140/Q140/YFP-H mice with WldS mice to determine if the protective phenotype is
reproduced in these mice. A delayed onset of axonal swellings and behavioural
abnormalities would be hypothesized.
Data from this chapter also suggest that it would be interesting to cross the HdhQ140
mice to other lines of Tg mice expressing fluorescent markers in order to study
additional subsets of neurons and determine which ones are affected first and at what
age. Indeed, one of the main questions arising from our YFP-H model is that only
restricted subsets of neurons are fluorescently labelled and the D2 MSSNs, the most
affected in HD, are not among these. In this regard, crossing to Drd2-EGFP Tg mice,
which express YFP+ D2 striatal neurons, could be relevant to assess axon
degeneration in this neuronal population. As an alternative, in vivo Diffusion Tensor
Imaging (DTI) (Wu et al., 2013) could be used, as succesfully done in patients (Rosas
et al., 2006, Weaver et al., 2009), to identify axon degeneration and loss in HdhQ140
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mouse brain, although a limitation of this model is that little changes in specific
subsets of neurons could be difficult to detect.
Another part of the study worth further investigations is the behavioural phenotype of
HdhQ140 homozygous mice. This, similarly to the morphological changes in axons,
showed a progressive deterioration indicating that both morphological and
behavioural aspects of the disease, model well disease progression in humans. Thus,
behavioural assessment, together with in vitro analysis, could be an important readout
to evaluate future therapeutic strategies targeting protection of the axon.
As these mice have mild phenotype and normal life-span, it would be interesting to
test them also at later time-point, to see whether dysfunctions, other than the ones
detected at 12 months of age, are observed and if these parallel the progression of
axonal abnormalities. Additional tests of fear and anxiety-related behaviour such as
contextual fear conditioning or light/dark exploration tests would also be useful to
better determine the early contribution of axonal swellings found in stria terminalis.
Furthermore, additional cognitive tasks more specific for striatal dysfunction such as
delayed alternation or Serial Implicit Learning Task (SILT), together with histological
analysis of fluorescent neurons in HdhQ140/Drd2-EGFP mice, could reveal early
impairment of striatal neuron function.
Also, the data reported in chapter 5, contribute to the investigation of the mechanisms
of axon degeneration in HdhQ140/Q140 mice. Interesting preliminary analysis links
mHTT to NMNAT2, a NAD synthesizing enzyme and important axon survival factor,
in a cellular model of HD. Despite tissue-specific measurements of nucleotide and
enzyme levels did not show abnormal NAD metabolism in KI mice compared to the
control, defective processes local to individual neuronal compartments not detected
with these techniques could still contribute to degeneration in these mice. In support
of this, the increased number of axonal swellings which preceded cell body
degeneration, together with increased behavioural symptoms, suggests dysfunctions
are local to axons in these mice and contribute to pathology. Likely, impaired axonal
transport of vesicles containing important axon survival factors contributes to this
pathology as axonal transport defects are extensively described in HD patients and
mouse models. Despite the immunofluorescently labeled mHTT aggregates in mouse
brain were not found in YFP+ axons, a non-aggregated, soluble and possibly more
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toxic fraction of mHTT could play a role. Further experiments are needed to elucidate
if this is the case. However, the observation in SCG cellular model that HTT/mHTT
colocalises with NMNAT2; and the alterations found in NMNAT2 vesicular transport,
opens the possibility that mHTT interacts with NMNAT2 and interferes with its
transport and crucial activity in axons. An open question remains whether
colocalisation underlies interaction. Further experiments including pull-down and
immunoprecipitation, would be needed to assess binding. Attempts of pull-down
experiments were made using the full length human HTT (pARIS-htt) transiently
expressed in HEK cells, but proved unsuccessful due to the difficulties of expression
of this large protein which could not be detected in immunoblots. Future experiments
should be carried out using first the human HTT fragment (pARIS-htt 1-586) which
still retains the palmitoylation site responsible for association to vesicles and which
showed much higher transfection efficiency in SCGs.
Future additional experiments, in particular to increase the group size, are also needed
to confirm the changes observed in the measurement of the NMNAT enzyme activity
in mouse brain tissue and to establish whether alterations occur with age and in HD
compared to control mice. In addition, a discrimination assay, measuring the activity
of the individual NMNAT isoforms could be useful to understand the contribution of
the single enzymes and in particular of NMNAT2 in parallel to the in vitro results.
Moreover, if specific antibodies against NMNAT2 became available, future
experiments of Western blot could measure the levels of protein in brain
homogenates. A larger group size could also better clarify whether a significant NAD
decrease accompanies NMN increase in the striatum.
In conclusion, this work brings contribution to the understanding of the mechanisms
of axon degeneration in HD mouse models and of the role of axon pathology in the
development of disease. We have identified many questions that remain open and
addressing these questions should help us finding a therapeutic strategy to cure or at
least delay symptom onset and progression in HD and other neurodegenerative
disorders.
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Appendix
Movies on CD enclosed
Video 1A:
mHTT nuclear aggregates colocale with YFP+ cell bodies. 3D reconstruction of
confocal z-stack images (63X) constituting the projection of Fig. 23 A. Colocalisation
of the big NII aggregate with the cortical neuron nuclei indicated by the arrows is
documented in the 3D rotation of the image. Green: YFP, red: mHTT, blue: DAPI.
Video 1B:
mHTT neuropil aggregates do not colocalise with YFP+ axons. 3D reconstruction of
confocal z-stack images (63X) constituting the projection of Fig. 23 B. Lack of
colocalisation between neuropil aggregates and YFP+ axons projecting to the
striatum. Red neuropil aggregates are located in close proximity to green axons, but
the 3D reconstruction shows they never colocalise. Green: YFP, red: mHTT.
Video 2:
Axonal transport of NMNAT2-EGFP in the presence of mHTT. Time-lapse imaging
of axonal transport of NMNAT2 in dissociated SCGs. Cells were microinjected with
plasmid for expression of NMNAT2-EGFP and pARIS-htt 1-586-Q100-mCherry
fusion proteins and imaged (100X) with a TIRF microscope (Axio ObserverZ1, Zeiss)
24h after transfection. Green-fluorescent NMNAT2 moving vesicles are well visible
while mHTT red-fluorescence is diffused. Green: NMNAT2-EGFP, red: pARIS-htt 1-
586-Q100-mCherry.
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